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Tools to understand the mechanisms of protein binding to cell surface proteins are of 
interest to enable the manipulation of such proteins, such as for therapy and drug 
delivery. In particular, bioorthogonal techniques are of interest as they can be used to 
probe protein structure and function in their native environment with minimal 
structural perturbation, as described in Chapter 1. This work seeks to develop such 
bioorthogonally-designed materials (polymers and nanoparticles) in order to study 
adhesive proteins. 
In Chapter 2, using controlled radical polymerisation and “click”-like chemistries, 
doubly-functionalised glycopolymers with sequential variation in carbohydrate 
density, side chain length and secondary functionality were synthesized to probe the 
binding activity of an adhesive pathogenic toxin (Vibrio cholerae toxin subunit B). 
This revealed a new approach whereby sterically large secondary units enabled 
selectivity towards a toxin to be introduced.  
In chapter 3, a small (<5 nm diameter) gold nanoparticle (AuNP) scaffold was used as 
the basis for the development of a dendrimeric ice binding protein (antifreeze protein 
type III). Two different bioorthogonal immobilization strategies were developed to 
probe AFP capture to NP surfaces. Optimum AFP activity was observed only for 
covalent SNAP-tag conjugates. Furthermore, this was critically compared to a fully-
synthetic AFP mimic; poly(vinyl alcohol) coated gold nanoparticles. 
Chapter 4 reports a detailed investigation into the function of adhesive protein fibres 
from an insect pathogen, using the nanoparticle tools developed here. Recombinant 
his-tagged fibres were immobilized and evaluated for whole-cell binding to a range of 
cell lines, and also lipid and glycan arrays. Furthermore, proteomics used to identify 
insect and mammalian cell protein targets. This resulted in the first ever description of 
Pvc13 tail fibre protein function, which may help elucidate its pathogenicity and a 
potential application in drug delivery. 
In summary, novel nanomaterials were developed in order to probe adhesive protein 
structure and function. These materials must be delicately designed to avoid an impact 






1.1. Protein structure and function 
Biomacromolecules are responsible for a vast range of functions from intracellular 
processes to organism-wide signalling and providing physical structure. Proteins, 
involved in most cellular processes, are produced as a distinct sequence chosen from 
canonical amino acid residues as defined in the DNA or RNA of the productive 
organism. Proteins have a hierarchical structure, with four specific layers of structure 
adding up to a final quaternary structure (see Figure 1-1). It is this final, fully 
processed, quaternary structure that defines the function of the protein in vivo and its 
capacity to interact with other proteins, macromolecules and ligands.1,2 However, this 
quaternary structure is also in turn defined in the original primary structure produced 
by the ribosome. The primary amino acid sequence (with side chains) or post-
translational modifications, with different hydrophobicity, polarity and charge, 
determine the interactions that can occur with other amino acids both locally and 
further away in the primary sequence. The amino acids presented on the surface of the 
protein, and in its active or adhesion sites, are those residues that we can target to alter 





Figure 1-1. Hierarchical protein structures. *From Howard et al3. **From Merrit et 
al.4. 
Many proteins have an active site that binds to a selective ligand partner, including 
enzymes, which serve as catalysts for biochemical reactions, and antibodies (Abs), 
which bind specifically to antigens found on cell surfaces or in solution for 
immunological purposes. The 3-D structure of the active site is essential in the 
maintenance of these proteins’ function. 
Proteins engage in various forms of interactions with other molecules: hydrogen 
bonding, disulfide bridges, metal ion-conjugations, other electrostatic interactions or 
hydrophobic interactions (see Figure 1-2). Of particular interest to those in the drug 
design sphere is knowledge of the active site amino acid side chains with which the 
native ligand forms interactions, so that synthetic molecules may be designed to mimic 
these interactions or even out-compete the native ligand. 
Synthetic macromolecules (polymers, nanoparticles) have therefore been proposed to 
target biomacromolecules, with their capacity to tune both the overall size and surface 
properties of the materials (such as hydrophobicity, density of functionality and 3-D 
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organisation) as well as the specific functionalities installed to mimic the active site 
ligand binding. 
 
Figure 1-2. Different types of interactions in which proteins engage.  
 
1.1.1. The biological basis of bioorthogonal chemistry 
Bioorthogonal chemistry is a term coined by Bertozzi referring to chemical reactions 
which may occur in vivo without adversely affecting native processes.5–7 It is defined 
as follows: 
“The two components are non-interacting (orthogonal) to the functionality 
presented in biological systems. Further, the reaction must proceed in water 
at neutral or near-neutral pH at temperatures ranging from 25 to 37 °C 
without any cytotoxic reagents or byproducts.”8 
These bioorthogonal techniques are utilised to further the understanding of native 
biochemical processes such as the activity of proteins, glycans and lipids, with the 
introduction of a bioorthogonal probe allowing the researcher to monitor a target 
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macromolecule. Such chemistries must be extremely selective for their target, and 
must not alter other biochemical processes in order to allow effective study of the 
target macromolecule.5–7 They must also exhibit rapid kinetics on a timescale of 
minutes to reduce competition with native cellular reactions.8 
These chemistries often require two steps: the first being the introduction of a reactive 
functionality to the target, and the second being a reactive probe to couple with this 
functionality (such as a dye).9 In studying protein structure and function, the use of 
recombinant proteins can provide a different synthetic approach. 
 
Figure 1-3. Workflow for production of recombinant protein using E. coli plasmid 
vector.  
Recombinant proteins are necessary in biochemistry both to reduce costs and to 
produce a satisfactory yield of proteins for study. Escherichia coli is well-established 
as a prokaryotic factory for recombinant protein.10–13 This process involves selecting 
the gene for the protein of interest, cloning this gene into a plasmid, transforming this 
plasmid into E. coli and inducing this protein to be produced by the bacteria before 
purifying it (see Figure 1-3). Each of the steps in this workflow involves careful 
consideration of which reagents should be used. Of particular interest herein, to 
facilitate the purification step of soluble protein production, an affinity tag is often 
introduced into the gene cloned into the plasmid vector (at either the C- or N-terminus 
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of the protein, whichever is not buried in the protein’s final structure) to allow this 
protein to be selectively separated from E. coli’s other cellular components.10 
The expression of a peptide tag (a short amino acid sequence) or a fusion partner (a 
large polypeptide) allows the production of a chimeric protein that can be detected or 
isolated via its affinity tag and can even enhance solubility.10,14 Alternatively, 
unnatural amino acids can be used, though these methods can be laborious and 
expensive.15–17 For example, the amber stop codon (TAG in DNA, UAG in mRNA 
and CUA in tRNA) normally terminates translation by recruitment of release factor 1 
of 2 (RF1 or RF2).18 However, the suppression of this stop codon has allowed the use 
of modified UAG-tRNAs to incorporate unnatural amino acids into E. coli.  
Small peptide tags include the poly-His-, FLAG- and Strep II tags, and these tags 
generally have commercially-available antibodies to allow Western Blot detection.10,14 
The His-tag is ubiquitously included in many plasmids, and the facile technique of 
immobilised metal ion affinity chromatography (IMAC) is extensively used to capture 
His-tagged proteins.14,19–23 Cysteine is commonly a target for bioorthogonal labelling, 
but this is not possible if the amino acid is involved in the protein’s active site or if a 
newly-introduced cysteine becomes involved in intermolecular disulfide bonds or 
affects native disulfide bridges.9,24 It is still commonly used, however, due to the 
bioorthogonality of such chemistries, as well as the low frequency of cysteine in 




Figure 1-4. Amino acid frequency in protein structure. Amino acids are signified by 
their single letter (ie. C = cysteine). A) Mammalian non-membrane protein amino 
acid composition, from Gaur, 201425. B) Amino acid composition on protein surface 
of a nonredundant library of 3-D protein structure, from Lins et al.26 
Fusion partners can also enhance the solubility of purified proteins: examples include 
Maltose-binding protein27, thioredoxin28, glutathione S-transferase29, SNAP30 and 
SUMO31. Several of these tags have been proposed to possess intrinsic chaperone 
activity that accentuate this solubility enhancement.27,30 These tags also vary in their 
attachment to their substrates, with SNAP binding covalently to a benzylguanine 
group whilst maltose binding protein binds electrostatically.30,32–37 Alternatively, 
several fusion tags respond to stimuli such as temperature and calcium concentration, 
thus eliminating the need for purification by chromatography.10,38,39 
Bioorthogonal tags can be used to immobilise proteins to surfaces and materials such 
that their function can be probed. Site-specific protein labelling with such tags also 
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ensure that, if the structure is known, the active site can be made available for 
functional studies. Pull down assays are a well-established technique to assess the 
binding of a “bait” protein immobilised on beads (for example, his-tagged proteins 
attached to Ni-NTA groups on magnetic nanoparticles) to target proteins in solution.10 
Tags can also enable to use of specific dyes, meaning that the binding of protein to an 
array can be assessed by fluorescence measurements.  
The development of novel synthetic tools to exploit the presence of these affinity tags 
is of interest as these techniques are cheap, facile and well understood: these 




1.2. Synthetic bioorthogonal techniques 
Bioorthogonal chemistries are utilised to introduce a probe onto a protein that is then 
monitored to elucidate protein function in vivo or in vitro.9,40–42 Synthetic chemistries, 
rather than biological techniques, can afford a wide variety of functionalities 
interacting specifically in an affordable manner (see Figure 1-5 and Table 1-1). In 
particular, bioorthogonal techniques may be used to immobilise proteins onto a 
surface, such as a biochip, for further study, or specifically introduce a label.43 Labels 
can allow the tracking of protein localisation in cells, protein-protein interactions or 
protein binding to glycan or lipid arrays. 
A combination of biological and chemical conjugation can be achieved through 
enzyme chemistry, wherein a reactive functional group is introduced to the protein 
which can then “click” to a reactive chemical probe.24,44 As stated by Bertozzi: 
“A good click reaction satisfies many criteria: it should be high yielding, 
produce minimal byproducts, and be stereospecific when applicable. Further, 
it should involve readily available starting materials, take place in benign 
solvents (ideally water) or under solvent-free conditions, and allow simple 
isolation of products. In practice, click reactions tend to have large negative 
free energies and hence involve carbon-heteroatom bond-forming processes. 
Thus, unlike many conventional synthetic reactions, the power of click 
chemistry lies in its simplicity and ease of use.”8   
“Click” chemistries are those ‘spring-load’-like reactions between otherwise stable 
functionalities, and their power thus comes from its simplicity.45 For example, lipoic 
acid ligase can be used to acylate a specific lysine with lipoic acid or, more usefully, 
with modified lipoic acid analogues that may be chemically conjugated by “click”.24 
Herein, however, enzymatic techniques will not be considered, as their use can add 
another layer of complexity to an already-complex field. “Click” chemistries alone 





Figure 1-5. Schemes for proposed bioorthogonal chemistries and their non-
bioorthogonal precursors.  
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Table 1-1. Proposed bioorthogonal strategies. 









Takes place at ambient 
temperature, aqueous media 
at physiological pH. 
Specificity as native 
ketones and aldehydes are 




carbonyl (though not 
favoured). 
Competition with native 
aldehydes/ketones (eg. 
Glucose/pyruvate). 






Takes place at ambient 
temperature, aqueous media 
at physiological pH. 
Functionalities not present 
in biological systems.  
“Traceless” versions exist 
without phosphine oxide in 
product. 
No azide present in 
biological systems. 
Small azide does not hinder 
modified substrate. 
Azides may be reduced by 
thiols/disulfides, 
especially in basic 
conditions. 
Phosphines may reduce 
disulfides (though less at 
physiological conditions). 
Slow reaction kinetics (k 
= 10-3 M-1 s-1) require high 
triarylphosphine 









Takes place at ambient 
temperature, aqueous media 
at physiological pH. 
Functionalities not present 
in biological systems. 
First generation (without 
fluorine on cyclooctyne) 
exhibits slow kinetics (k = 





Various chemistries exist to non-specifically label proteins, such as EDC/NHS 
coupling, but the use of non-specific labelling has the potential to affect native protein 
function by blocking proteins’ active sites or affecting folding.9,46 Alternatively, 
specific tags on proteins can be used as a template for site-specific labelling. For 
example, terminally-introduced cysteine residues allow the introduction of 
maleimides of α-halo acids or the use of 2-cyanobenzothiazole condensation, the poly-
His tag conjugates to a nickel atom (or cobalt) bound to an NTA-group, and the larger 
Small azide does not hinder 
modified substrate. 
Does not require use of 
cytotoxic copper (I) 
catalyst. 
Gem-difluorinated 
cyclooctyne has similar 
kinetics to copper catalysed 








Takes place at ambient 
temperature, aqueous media 
at physiological pH. 
Functionalities not present 
in biological systems.  
High yield, rapid kinetics 
Competition via Michael 











Takes place at ambient 
temperature, aqueous media 
at physiological pH. 
Functionalities not present 
in biological systems.  
Rapid kinetics 
Competition via Michael 
additions from biological 
nucleophiles 
Possibility for non-




SNAP-tag can react specifically with a benzylguanine group.19,24,30,47 Bioorthogonal 
chemistries used to interact with proteins require delicate conditions to avoid affecting 
protein structure and function, and thus must proceed specifically, in high yields, 
rapidly and in aqueous solution.9 
The Staudinger ligation is a gold-standard bioorthogonal strategy developed by 
Bertozzi et al. from the Staudinger reaction, previously used for cell-surface 
engineering or bioconjugate preparation.5–7,48–51 This reaction involves the ligation of 
a phosphane reagent containing the chosen probe to the protein target via an aza-ylide 
intermediate moiety, forming a stable amide bond in aqueous media at high yields. 
These functionalities are not present in biological systems, thus affording perfect 
selectivity, though they proceed slowly and the phosphine-probes may oxidise in air. 
Bertozzi and Raines also developed the traceless Staudinger ligation, wherein the 
phosphine oxide moiety is no longer present in the final modified product, which may 
be preferable for preparation of protein microarrays.5,50  
Various other ligation mechanisms also exist, which typically involve a capture step 
to bring two specific reactive functionalities together in an unstable intermediate, 
followed by the ligation step.52,53 The oxime ligation, for example, involves the 
condensation of an oxyamine and an aldehyde/ketone, and occurs rapidly at high 
yields.52,54 However, the introduction of an aldehyde functionality (more common than 
the ketone) to a protein can be challenging.9,55 Other novel ligation strategies, such as 
using tetrazines or quandricyclanes, are also beginning to make the leap from synthetic 
to in vivo work.9,56–58 
Bertozzi et al. also developed the second landmark bioorthogonal chemistry: the 
copper-free click reaction (so called as the use of activated reagents negates the need 
for cytotoxic copper catalysts), as a more rapid alternative to the Staudinger ligation.59 
This reaction uses a strained cyclooctyne ring to interact with an azide, with the 17 ° 
deviation from the preferred geometry being sufficient to activate the reaction.5,35 
There are limitations to this method, including possible nucleophilic addition with 
cellular nucleophiles (for example, glutathione or oxidised cysteines), the 
hydrophobicity of the cyctooctyne ring and a relatively slow rate of reaction.24 
However, the use of polymers to enhance solubility and the implementation of 
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substituents, ring fusion and heteroatoms have increased the rate of this reaction 
sufficiently to allow its use in vivo and in imaging studies.5,24,35,60,61 
Other potential cycloaddition and click strategies exist, such as norbornenes and 
tetrazole photoclicks, but again these techniques have yet to be tested extensively in 
vivo to fully assess biocompatibility: the latter being suggested as a non-bioorthogonal 
photo-crosslinking reagent due to lack of specificity.62–66 Finally, the Diels-Alder 
reaction is a well-understood diene/dienophile reaction that proceeds in aqueous 
solution, but its slow rate, reversibility and susceptibility to hydrolysis makes it 
difficult to use in forming a stable bioconjugate.24 
The Staudinger ligation or copper-free click chemistries are therefore currently the 
gold standard when it comes to bioorthogonal chemistry whilst more investigation is 
required to validate the use of other strategies. Thus the introduction of an affinity tag, 




1.3. Polymeric bioconjugates 
Polymers have found their uses in biological systems due to their ability to mimic 
biological macromolecules67–70, biocompatibility71–74, and capacity to contain 
triggerable functionalities75–79. In particular, polymers are useful in many fields as they 
can both mimic the local structure of a biomacromolecules and bulk properties such 
as amphiphilicity70. Bioorthogonal chemistry can serve as a toolbox with which 
biocompatible, bio-functional polymers can be produced.24,80–85  
Protein therapeutics, though potentially useful in toxin elimination or mimickry of 
native proteins, are often intrinsically instable and vulnerable to degradation, in oral 
delivery where they are destroyed by the digestive system, and in injectables where 
they are rapidly renally excreted.86 Polymer conjugation can enhance the retention of 
these protein therapeutics, reduce immunological, proteolytic or other reactions by 
masking the protein surface, as well as provide the opportunity for targeted delivery.86–
88 Increasing the size of the protein by conjugation slows kidney ultrafiltration and 
promotes accumulation into target, permeable, tissues by the EPR (enhanced 
permeation and retention) effect.87–89 
Protein/polymer conjugation by PEGylation has been used extensively in 
bioconjugates, as adding a PEG chain onto a biologic has been shown to increase 
stability, reduce aggregation and enhance solubility (see Figure 1-6).86,89–98 Various 
PEGylated therapeutics have so far been approved (such as PEG-alpha interferon 2b 
developed by Scherling Plough’s PEG-Intron, and PEG-alpha interferon 2a developed 
by Hoffman-La Roche’s Pegasys) or filed for approval (such as PEG-granulocyte 
colony stimulating factor developed by Amgen, and PEG-human growth hormone 
antagonist developed by Pharmacia).86  
There exist a variety of enzymatic or chemical strategies for PEGylation, which can 
each confer different functional properties on the resultant conjugate, such as through 
the conjugation of protein surface lysine ε-amino groups to activated PEG, though this 
occurs non-specifically and results in multiple, non-specific polymer/protein 
linkages.86,89,90,93,98 Studies by Abuchowski et al.99,100 have demonstrated enhanced 
retention of PEGylated (1900 and 5000 Da) albumin, as a reduction in antibody 
production that leads to free albumin removal, or catalase, as a reduction in both 
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antibodies and proteolysis, and enhanced enzymatic activity (around tenfold higher) 
relative to free catalase over the course of 3 days. 
In particular, many studies have shown interest in PEGylation of interferon protein for 
treatment of hepatitis C or cancer.94,101,102 For example, Bailon et al.103 synthesized 
monoPEGylated interferon R-2a (with a 40 kDa branched PEG), with PEGylated at 
one of interferon’s 4 lysine residues (Lys31, 121, 131 and 134). These conjugates were 
found to have 70-fold increased serum half-life and severalfold increased antitumor 
activity in mice, relative to free interferon. 
 
Figure 1-6. Stability in blood of PEG and PEG5000-interferon conjugates. A) PEG 
molecular weight dependence on half life in blood after intravenous administration. 
Figure taken from Caliceti and Veronese89. B) Retention of catalase activity in blood 
of Acatalasemic mice, of catalase (X) and PEG5000-catalase (O). Individual points are 
an average of four animals. Half of the animals in the investigated were injected by 
the tail vein with either 100 perborate units of free catalase or PEG5000-catalase 
conjugate. Animals were then injected thrice weekly (day 2, 4 and 7). After 15 mins, 
6-, 12-, 24-, 36- and 48-hrs, 0.15 mL of blood was taken from the eye orbit and 
assayed according to Feinstein’s protocol. Different sets of animals were used for 
each bleed, except for the same animals used for the 15 minute and final bleed. This 
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assay was performed after the first (B.1), 13th (B.2), 26th (B.3) and 39th (B.4) 
injection. Figure taken from Abuchowski et al.100 
Oxytocin is used to prevent post-partum haemorrhaging, but it is unstable in aqueous 
solution, especially at elevated temperatures.104 Polymer-peptide conjugates formed 
using reversible disulfide bridges between the protein and a dithiophenol maleimide-
functionalised polymer showed greater stability than native protein (less than 5 % of 
free oxytocin remained after 28 days incubated at 50 °C relative to ~90 % when 
attached to a conjugate), though further assays are required to assess biocompatibility 
and activity relative to the native protein.104 Shi et al.105 demonstrated azidized testis-
specific protease 50 immobilisation via alkyne-azide “click” onto propargyl-
containing polymer nanofibres, developed from a copolymer of 5-methyl-5-
propargyloxycarbonyl-1,3-dioxan-2-one and L-lactide. These fibres attached 
specifically to the azide groups on the protein, with reversible detachment (with 75 % 
efficient reattachment) under exposure to a solution of pH 2.2. 
These studies demonstrate the capacity to develop fully bioorthogonal techniques to 
form polymer bioconjugates. There are, however, multiple points at which a polymer 
can be functionalised: the polymer backbone, side groups off the polymer backbone, 
through the addition of branching, or through the end groups. The inherent nature of 
polymers is such that there are a variety of chain lengths in any synthesized polymer 
mixture, and therefore dispersity exists in the number of functionalities if implemented 
in the polymer chain or through branching, and therefore it stands to reason that end 
group functionalisation is the best method to introduce one moiety to the polymer 
chain for a proposed 1:1 polymer:protein conjugate. Various studies have looked into 
developing specific bioorthogonal strategies to form these 1:1, site-specific 
bioconjugates.95,106–112 
Reynhoult et al.113  developed a hybrid triblock structure, with a synthetic polystyrene 
(PS)-b-PEG113 conjugated to myoglobin or horseradish peroxidase. ATRP was used 
to provide the copper catalyst, and the bromide at the chain end of the was converted 
to an azide to allow “click” onto the alkyne-terminal Zn-conjugating protoporphyrinIX 
cofactor to allow subsequent protein attachment. The resultant conjugates formed 
different structures (vesicles, micellar rods, vesicles, toroids, figure of eights or 
octopuses) depending on the ratio of the diblock elements of the synthetic polymer 
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unit: for example, increasing the chain length of the polystyrene resulted in a shift 
from micelle to micellar rod structure. The obvious drawback of this strategy, despite 
the delicate design of the bioconjugate, is the use of the ATRP polymerisation and 
copper “click” methods, and the subsequent presence of cytotoxic copper. 
Lim et al53. propose the novel bioorthogonal pair of p-nitrodiphenylazirine and 
dimethyl fumarate, and their use in lysozyme conjugation under biological conditions. 
The reaction involves rapid (~2 minute) “click” of an azirine to an alkene initiated by 
302 nm UV light, though the use of visible light may be possible upon the adding of 
auxochromic groups to the azirine’s phenyl rings to make them photoactive. Simon et 
al114 successfully introduced an N-terminal azido-homoalanine and a C-terminal 
cysteine into a designed ankyrin repeat protein with high yield (30 mg) and stability. 
These doubly-modified proteins allowed PEGylation (20 kDa PEG) at the N-terminus 
and Alexa488 fluorophore at the C-terminus, and the final conjugate showed 
promising binding activity and kinetics with tumour cells, with an approximately 
fourfold increase in the association constant (kon) of the conjugate relative to non-
PEGylated protein (4 x 104 M-1 s-1) and a similar dissociation constant (koff).  
The drawback of these techniques is unfortunately limits on simplicity and 
biocompatibility, with the use of copper, UV light and unnatural amino acids.53,113,114 
There is a therefore definite need to address these drawbacks and develop fully 
bioorthogonal, facile polymer/protein bioconjugates. 
1.3.1. RAFT Polymerisation 
Bioothogonal polymer synthesis requires the use of techniques that afford control over 
molecular weight, dispersity and architecture. Many synthetic techniques exist that 
produce such polymers (termed controlled radical polymerisation) by delaying 
termination of the propagating polymer chains by establishing a dynamic equilibrium 
between dominant polymer chains and active radicals.205-207 The majority of the 
chains, as dormant species, must be activated in order to chain extend, but do not 
terminate. 
The work herein makes use of reversible addition-fragmentation chain transfer 
(RAFT) polymerisation. RAFT utilises free radical polymerisation, with a chain 
transfer agent (CTA) that is transferred between chains during propagation to mediate 
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chain growth.208-214 This technique is versatile (tolerant of a wide variety of monomer 
structures, solvents and initiators), resulting in polymers with low dispersity.210-214 In 
particular, RAFT polymerisation generates polymers with predictable end-group 







Nanoparticles (NPs) have a large surface area:volume ratio, but are sufficiently small 
enough to be colloidally stable, soluble and functionalisable, in size ranges typically 
1 to 100 nm.115,116 Unlike polymers, their shape, size and softness/hardness can be 
tuned as properties of the nanoparticle core.115,117 Studies have shown their use as 
contrast agents, drug delivery vehicles, diagnostic tools or as theranostic 
agents.115,117,118 A variety of nanoparticle types exist from metallic and magnetic to 
quantum dots, polymeric and silica. 
1.4.1. Types of nanoparticle core 
Mimicking the self-assembly of biomacromolecules underlies the development of 
polymeric nanoparticles, which must be carefully designed to achieve the desired size, 
shape and surface functionality.118–122 In particular, polymeric nanoparticles may serve 
as excellent drug delivery vehicles due to their ability to encapsulate active agents, 
thereby affording physical protection to reduce degradation and enhance efficacy, an 
opportunity for targeted delivery, and a size compatible with intracellular delivery (1-
100 nm).123 
Amphiphilic polymers, synthetically or naturally-derived, self-assemble in polar 
solvent to enhance hydrophobic functionalities’ interactions with bulk solvent and 
bury hydrophobic functionalities.119 Block copolymers in particular serve as a good 
building block for self-assembled nanoparticles. For example, AB diblocks 
(containing two separated A and B repeat units) form micelles, worms, polymersomes 
and hollow tubes. Changes in the block ratio/length, hydrophobic/hydrophilic block 
positioning or functional groups used result in changes in structure.120 The polymer 
nanoparticle preparation procedure can determine whether nanospheres or 
nanocapsules form, with the former being a packed matrix of polymer with 
constituents dispersed throughout, and the latter a polymeric vesicle (polymersome) 




Figure 1-7. Polymer NP structures (A) and incorporation of drugs (B). Figure based 
on Zhao et al.123 
Metallic nanoparticles (Au, Ag, Cu etc., see Table 1-2) are easily synthesized, purely 
from metal precursors, in a range of shapes and sizes, afford easy functionalisation 
(forming stable covalent-like thiol bonds) and have been shown to be 
biocompatible.118 Conductive electrons also oscillate along the particle surface, with 
their resonant frequency being a function of surface composition.118 This is termed 
surface plasmon resonance (SPR).  
Magnetic nanoparticles (Fe, Mn, Co etc.) have potential as MRI contrast agents, are 
biocompatible, though they have been found to accumulate in biological tissue.118 
Silica nanoparticles have lower density than metallics, are biocompatible and have 
potential optical properties such as fluorescence.118 Of interest herein are these 
colloidal inorganic nanoparticles, consisting of an inorganic core dispersed in a 
solvent, with surface conjugation of organics or biomolecules generating a hybrid 
material that can have specific surface function and greater biocompatibility in 




Table 1-2. Colloidal NP cores. 
 
1.4.2. Bioconjugation to nanoparticles 
The use of NPs as a scaffold for protein conjugation combines the properties of the 
NPs with those of the conjugated proteins.116 The challenge of nanoparticle 
bioconjugates stems from their non-uniform nature: there are several coating 
molecules or conjugates present on individual NPs, but the number of surface 
functionalities available for further conjugation or activity varies widely and is 
dependent on the surface area they cover, and these details can only be obtained as a 
statistical distribution.45,115,130 Different coatings, such as different numbers of DNA 
molecules attached to the core, may be separated by techniques such as gel 
electrophoresis, but this can be laborious and unnecessary for application of these 
Core type  Properties Advantages 
Metallic  
(Au, Ag, Cu) 
Surface plasmon resonance 
determined by composition, 
size, shape. 
Covalent-link bonds with 
thiols. 
Facile synthesis of range of sizes/shapes. 
Easily functionalised. 
Biocompatible (low cytotoxicity, except 
in oxidation to Ag+) 
Can be used in cell-labelling, diagnostics. 
Magnetic  
(Fe, Mn, Ni) 
Ferromagnetic/ 
superparamagnetic. 
Biocompatible (low cytotoxicity). 
Accumulates in target tissue 






Able to encapsulate compounds. 
Biocompatible (low cytotoxicity) 
Can be used in drug delivery, biosensors 
or fluorescence imaging. 
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materials.45 Nanoparticle design benefits from simplicity, with layers of conjugate 
molecules linked together by at their terminals. Conjugation techniques must consider 
desired surface density, orientation upon attachment, and the length of linker required 
to give full access for biomolecule activity (see Figure 1-8).130 
 
Figure 1-8. Typical nanoparticle layer-by-layer bioconjugate concept.  
The surface functionalisation of the nanoparticles, or the NP’s corona, determines the 
interaction with the environment: coatings affect colloidal stability, surface 
functionality and any targeting of biomolecules.45,130,131 In particular, we are interested 
in the interactions between NPs and native biomolecules through covalent bonds, 
hydrogen bonds, acidity, electrostatics, coulombic forces or van der Waals, though the 
delivery mechanism has an affect on this, with many injectables becoming coating 
with serum albumin in the body.116,130 Polymer coatings can sterically stabilise NPs, 
with dispersity of shape or patchy coating risking aggregation, but terminal carboxylic 
acids can stabilise via electrostatic repulsion.45 After coating, unconjugated coatings 
must be removed from the reaction mixture, or the modified NPs purified (for 
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example, by specific column chromatography) to avoid false positives, or potential 
crosslinking and subsequent NP aggregation.45,130 
The conjugation of enzymes to a nanoparticle surface has been shown in several 
studies to enhance their activity relative to free enzyme, which suggests a potential 
application as nanofactories able to rapidly, repeatedly perform the enzyme’s 
function.116 When attached to a surface, enzyme activity is reduced due to steric 
hindrance, slower diffusion, or alterations in conformation due to attachment. 
Attachment to NPs potentially affords greater flexibility than surface immobilisation, 
allowing both an increase in activity and long-term enzyme stability. There is therefore 
particular interest in developing enzyme-NP constructs as well as other 
biomolecule/NP constructs. 
Bioconjugation strategies must have several properties, similar to the definition of 
bioorthogonality. Though difficult to achieve in practice, ideal chemistries would 
result in a predictable and reproducible number of functionalities present on the NP 
surface (valence), ie. minimal dispersity.115 This also means a reliable distance and 
attachment point on the linker attaching the biomolecule, and controlled orientation to 
allow retention of both NP and biomolecule function. These chemistries must be 
bioorthogonal: proceeding selectively under rapid, mild aqueous conditions. Finally, 
we desire these linkages to be stable, but with triggerable lability if required for, for 
example, drug delivery. 
Bioconjugation to nanoparticles can be through direct binding to an inorganic NP core 
via, for example, thiol groups, electrostatic adsorption of positive to negative 
macromolecules, specific covalent linkages of functionality pairs, or non-covalent 
receptor/ligand systems.45,115,130,132–145 Biomolecules may also be encapsulated in the 
nanoparticle core, but we are interested only in surface-functionalisation here. Direct 
biomolecule/nanoparticle strategies usually involve dative bonds, but they require 
delicate design of all components to ensure NP stability in reaction conditions, and 




Figure 1-9. Select enzymatic conjugation strategies. Note that there are various 
biotinylation strategies used depending on the desired coupling. Shown here is the 
site-specific enzymatic strategy using BirA ligase to attach biotin to a lysine residue 
in a 23 amino acid tag on the (C- or N-) terminal of a recombinant protein in aqueous 
solvent; another method is the non-site-specific EDC/NHS coupling in organic 
solvents. 
As with polymer bioconjugation strategies, there are many studies using enzymatic 
strategies to form the NP linkage.118,146–149 Biotin/avidin coupling is commonly used 
for bioconjugation due to its specificity and extremely high affinity despite it being a 
non-covalent interaction (see Figure 1-9).115,118 The chemistry has been applied to 
many different reporters, but with often heterogeneity in labeling and poor control of 
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the binding site. Biotin ligase systems have enabled site-specfic labelling, such as BirA 
ligase transferring biotin to a specific lysine side chain which have then been applied 
to labelling of live cells using streptavidin-coated quantum dots. As another example, 
Sortase A enzyme (from Staphylococcus aureus) is a transpeptidase used to covalently 
ligate proteins specifically to glycine groups (see Figure 1-9).149,150 These enzymatic 
strategies are generally very specific and mild, but they can induce aggregation and 
add another layer of complexity to this already-complex chemistry.  
EDC/NHS coupling (between amines and carboxylic acids, activated by ethyl-3-(3-
dimethylaminopropyl)carbodiimide) is commonly used due to its simplicity, but it is 
often called “shotgun labelling” due to lack of specificity (see Figure 1-11).115 EDC 
activation of surface carboxylic acids forms an unstable, less-soluble, o-acylisourea 
intermediate that can undergo rapid hydrolysis. This can be stabilized by increasing 
EDC concentration, though the increase in surface intermediate formation can 
destabilize the NP in solution. Alternatively, sulfinated succinimides such as N-
hydroxysuccinimide (NHS) can convert the intermediate to a more stable sulfonated 
succinimidyl ester intermediate without the need for excess EDC. Although this 
chemistry can, efficiently, multivalently display biomolecules on NP surfaces, they 
are totally non-specific, forming uncontrolled, multiple, random linkages between NP 
surface carboxylic acids, and any surface amines on the protein target. This can 
drastically affect the structure and function of the protein conjugated, and therefore 
these shotgun labeling techniques are best avoided. 
Site-specific “click” chemistries potentially application to these purposes include 1,3-
dipolar cycloadditions, Diels-Alder cycloadditions, Staudinger ligations and inverse 
electron demand Diels-Alder reactions (see Figures 1-5 and 1-10).130,151 These 
chemical bioconjugation methods each have their advantages and disadvantages: for 
example, the Staudinger ligation between esters and azides requires no catalyst, but is 




Figure 1-10. Select chemical conjugation strategies.  
Copper catalysed “click” has been used by a variety of research groups to functionalise 
NPs, with the obvious drawback being the use of a cytotoxic copper catalyst (see 
Figure 1-5).133,134,144,145,151,152 Lin et al.151 showed a method of conjugating C-terminal 
alkynated proteins to azido groups on a silica oxide-coated magnetic iron oxide 
nanoparticle surface via Cu(I)-catalysed alkyne azide [2+3] cycloaddition. The 
activity of this site-specifically alkynated protein was higher than that exhibited by 
random linkages to amine groups: the EDC/NHS strategy showed significantly lower 
fluorescent intensity in a protein microarray relative to the cycloadditions method. 
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Copper “click” was used to conjugate human serum albumin (HSA) to iron oxide NPs 
by Polito et al.145.  The protein has one unpaired cysteine at which alkyne acrylamide 
was added by Michael addition, and the protein was attached to an azide-terminal 
tetraethylene glycol linker on the NP surface via copper-catalysed “click”. Anti-HSA 
antibody assays showed agglomerisation of the nanoparticles in a time- and dose-
dependent manner relative to HSA concentration, suggesting that this method retained 
protein activity. 
 
Figure 1-11. Select non-site-specific conjugation strategies. 
Examples of copper-free bioorthogonal linkages also exist in the literature (see Figure 
1-5).118,153–156  Nanoparticles are reported to respond to tumours’ enhanced 
permeability and retention (termed the EPR effect)s, meaning they are observed to 
accumulate specifically in these tissues.153,154 These techniques require the pre-
targeting of conjugates. Koo et al.153 introduced unnatural azido-sialic acids (by intra-
tumoral injection of tetraacetylated N-azidoacetyl-d-mannosamine). Successful azido-
sialic acid incorporation was confirmed by staining of modified a549 (human 
adenocarcinoma) cells and tumour-specific attachment of dibenzyl cyclooctyne-
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terminated, PEGylated liposomes dose-dependently in mice, with an approximately 
20-fold increase in near infrared fluorescence intensity in excised, azide-sialic acid 
decorated mouse tumours. Alternatively, studies have used copper-free click for 
biomolecule attachment: Feldborg et al.156 found this technique to be faster than 
copper “click”, Michael addition, and oxime ligation to liposomes with tumour 
targeting peptide, dependent on where the relevant functionalities were introduced 
onto the PEG polymer linker. All these liposome-immobilisation reactions were found 
to require at least 1 hour to reach a plateau, however. 
Although bioorthogonal strategies usually require pre-modification of the target 
biomolecule, the addition of unnatural amino acids with azide groups can be difficult 
in proteins, so alternative, more facile, procedures have also been developed. Pasold 
et al.157 displayed a beautifully simple method wherein fluorescent SiNPs were surface 
functionalised with maleimide groups using a PEG24 linker (see figure 1-11).  
Thiolated insulin-like growth factor was produced by incubation with 2-iminothiolane, 
desalted and reacted with the SiNP surface maleimide groups via a simple mixing 
procedure, followed by cysteine solution to block any free surface maleimide and 
washing. These IGF-1@SiNPs showed biocompatibility, cell viability and enhanced 
cell attachment and metabolic activity on a collagen-based tissue culture scaffold (with 
120 μm infiltration after 7 days and ~5-fold increase in chondrocyte metabolic activity 
relative to the control without collagen). 
Alternatively, easily-implemented, reliable affinity tags present in recombinant 
proteins can be used to selectively capture these proteins when paired with the 
appropriate chemistries.118,158 Cysteine residues are readily functionalisable if present 
on the protein surface (see Figure 1-12).118,159 Disulfide bonds can spontaneously form 
in a stable manner, and this has seen wide application. Soft-soft thiol interactions and 
Michael addition to a maleimide are both spontaneous, simple and occur rapidly. Such 
thiols are easily introduced to peptide via site-directed mutagenesis, but their use can 
be non-specific if other unpaired surface cysteines exist, and it can affect protein 





Figure 1-12. Select conjugation strategies utilising short peptide or fusion protein 
tags. 
Hexahistidine-tags (His-tags) are an obvious choice for site-specific conjugation due 
to their easy, common use in affinity purification of recombinant proteins, with many 
studies using Ni-NTA (Ni-bis-nitrilotriacetic acid) groups to biocompatibly, 
selectively capture His-tagged proteins (see Figure 1-12).19–23,118,159,160 This tag is 
small, specific and can be attached at either protein terminal. For example, Lai et al.19 
used a fluorescent Ni-NTA-probe (formed of NTA conjugated with a fluorophore and 
arylazide, followed by Ni2+ ion coordination) to show the intracellular location of a 
His-tagged DNA repair protein, Xeroderma pigmentosum group A. Despite the ease 
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of their use, His-tag capture is limited due to the non-covalent nature of the linkage, 
such that the binding affinity is low and could lead to dissociation; though this 
reversibility can be a positive as purified proteins can be isolated from Ni-NTA resins 
using imidazole solution. 
Other larger and non-toxic peptide tags may also be useful for selective protein capture 
without the risk of steric issues due to attachment to the main protein structure, such 
as SNAP-tag and Halo-tag, and these tags have been used previously to detect 
bioreactive small molecules in vivo (see Figure 1-12).30,158,161,162  These tags are 
directional, efficient and site-specific, but their larger sizes have the potential to be 
immunogenic.118 The Halo-tag is a modified haloalkane dehalogenase (a 33 kDa 
bacterial enzyme) that can covalently interact via an active site aspartate reside with 
chloroalkane linkers, termed Halo-tag ligands, bound to a variety of molecules such 
as dyes or surfaces.158,162 This reaction has been used to detect cellular membrane 
potassium ion dynamics, using a potassium-detecting fluorescent probe conjugated to 
a GPCR/Halo-tag fusion protein. In this study by Hirata et al.163, the full probe 
construct assembled at the cellular membrane onto the membrane-bound GPCR/Halo-
tag, via a Halo-tag-ligand/K+ probe, and fluorescence turned on in response to the 
infusion of high [K+] buffer solution. 
The SNAP-tag (a mutant of the human 19 kDa O6-alkylguanine-DNA 
alkyltransferase) reacts selectively with O6-benzylguanine groups via an active site 
cysteine residue, and has therefore been used to form semi-synthetic fluorescent 
probes for small molecule detection in cellular environments.30,32–34,36,163–165 Srikun et 
al.34 synthesized a boronate-capped SNAP-Peroxyl-Green probe able to 
biocompatibly detect intracellular hydrogen peroxide. In this work, an organelle-
targeting protein/SNAP tag fusion protein was produced and attached to a H2O2-
reactive fluorescent probe via a covalent interaction with a terminal benzylguanine or 
benzyl-2-chloro-6-aminopyrimidine group. This strategy allows the detection of H2O2 
in specific subcellular locations, such as the plasma membrane or nucleus, by confocal 
microscopic visualization of fluorescence changes. Bannwarth et al.165 proposed a 
calcium sensor consisting of Indo-1 dye fused to SNAP-tag fusion protein (again using 
a subcellular location-targeting protein) using the indole ester group (previously used 
in Indo-1-NP conjugation) coupled to benzylguanine amine. Confocal microscopy 




Figure 1-13. The SNIFIT labelling strategy. Figure reproduced from Ueda et al.158  
Johnsson et al.166 developed a larger fusion construct of acetylcholinesterase (AChE), 
CLIP tag labeled with a Förster resonance energy transfer (FRET) donor, and SNAP 
tag tethered to a FRET acceptor and AChE ligand, altogether called Ach-SNIFIT (see 
Figure 1-13). This SNIFIT protein shows a change in fluorescence depending on 
whether the FRET donor and acceptor are in close proximity (1-10 nm). The FRET 
donor and acceptor are two fluorescent groups, with the donor excited at the 
wavelength applied to the sample, and the acceptor only able to emit upon excitation 
by the wavelength emitted by the donor when it is close enough. This means that, 
when acetylcholine (Ach) is present, it displaces the SNAP-tag-tethered AChE ligand 
from the AChE active site, resulting in an increased distance between the FRET donor 
and acceptor, which is detected as a change in the ratio of fluorescence emitted by the 
donor and acceptor molecules: this this construct serves as an exquisitely-designed 
detector of applied ACh. In this way, the SNIFIT fusion protein, also an option for NP 
conjugation can be used in the detection of larger, more complex molecules than the 
SNAP-tag concept alone.164,166–168 
It is clear that many fully bioorthogonal techniques exist for the nanoparticle 
bioconjugation. However, there is a need to further develop techniques to be applied 
in situ in biological systems, and this is challenging as it requires expertise in both 
molecular biology and chemistry. 
1.4.3. Gold nanoparticle conjugates 
Gold nanoparticles (AuNPs) are the most stable metal nanoparticles, and have a 
variety of other useful properties for bioconjugation.169 Historically they have been 
used medicinally since the middle ages for their anti-inflammatory activity, such as 
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against rheumatoid arthritis.130 AuNPs can be easily synthesized in a wide variety of 
shapes, sizes and hardness (see Figure 1-14).115,118,130,169–175 AuNPs have also shown 
catalytic properties, electrochemical application, facile characterisation by dynamic 
light scattering, and the capacity to be detected (for NPs ≥ 100 nm) strongly by dark-
field microscopy.169,173,176,177 AuNPs are able to both exhibit fluorescence when 
fluorescent markers are attached, or quench fluorescence, depending on the distance 
of the fluorophore’s linker to the AuNP surface.115,169 
Due to their high biocompatibility and low cytotoxicity, biological applications have 
included cell-labelling, gene therapy, nucleotide delivery and biosensing.118 In 
particular, TEM has been extensively used to detect the intracellular localisation of 
AuNPs in cellular uptake studies.178–182 For example, Gunduz et al.182 showed 
intracellular AuNP accumulation on mammalian cells over the course of 2 months’ 
incubation, with no detectable cell death, but elevated endoplasmic reticulum stress. 
TEM as a technique is used to determine AuNP size, shape and dispersity as AuNPs 
have very high contrast under the electron beam.169,171,173,178–181,183 Scanning 
tunnelling microscopy and atomic force microscopy may also be used for these 
purposes. X-ray photoelectron spectroscopy (XPS) and inductively coupled plasma 
linked to either mass spectrometry (ICP-MS) or optical emission spectroscopy (ICP-
OES) are used to determine Au concentration in complex mixtures, with XPS able to 
determine changes in Au oxidation state after coating.169 
Spherical AuNPs are coloured red in water, reflecting the surface plasmon resonance 
(SPR) where visible light is broadly absorbed in the 517-575 nm region (though 
AuNPs < 2 nm diameter do not show a visible SPR maximum).130,169 This SPR is due 
to collective oscillation of electrons at the AuNP surface (6s electrons) that happen to 
resonate with a visible light wavelength. The maximum peak of SPR (SPRmax) changes 
as a function of AuNP shape, size, the thickness and composition of surface 
functionality and the dielectric properties of the medium surrounding the 
AuNPs.115,118,130,169,172 Therefore change in surface functionality, resulting in a shift in 




Figure 1-14. Various AuNP shapes and sizes. Small (a) and large (b) nanospheres, 
(c) nanorods, (d) sharpened nanorods, (e) nanoshells, (f) nanocages/frames, (g) 
hollow nanospheres, (h) tetrahedra/octahedra/cubes/icosahedra, (i) rhombic 
dodecahedra, (j) octahedra, (k) concave nanocubes, (l) tetrahexahedra, (m) rhombic 
dodecahedra, (n) obtuse triangular bipyramids, (o) trisoctahedra, and (p) nanoprisms. 
Figure taken from Dreaden et al.184 
Colloidal AuNPs, as other metallic NPs, form bioorthogonal, stable linkages with, and 
thus can be stabilised in solution by thiols, citrate, phosphines, amines (eg. Lysine) 
and even isocyanide, attached to the AuNP surface through a simple mixing 
procedure.118,130,151,169,171 Thiols are reported to form the strongest bonds, as a 
covalent-like Au-S bond, and as such it is predicted than dithiothreitol (DTT) has the 
capacity to strip of surface functionality via displacement using the small DTT 
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ligand.169,185 Recent studies have shown this displacement is dependent on ligand 
affinity, and is not wholly efficient.169 Luo et al.186 recently presented a possible 
displacement of small molecules via a Staudinger ligation-like displacement, wherein 
thiol-derivatized Rhodamine B dye was displaced with organic azide molecules, as 
detected by the dye’s fluorescence when released into solution. Au-S bonds form 
through reductive elimination of the thiol hydrogen to form hydrogen gas or water, 
whilst disulfides are reported to be split upon chemisorption to the AuNP surface.130  
This thiol-Au linkage has been used for the attachment of both thiol-terminated 
polymers (the majority being PEG or PVP) and small molecules to the AuNP surface, 
used either alone or as linkers for further modification, with a representative change 
in SPRmax observed.115,169,179,181,187 As with other metallic NPs, AuNP show greater 
stability upon coating.169,188 These structures also allow tuning of the coating density 
and thickness, as well as tuning properties such as hydrophobicity, patchiness and 
linker length: longer linkers result in greater stability but slower interaction with 
external stimuli.169,188 UV-Vis has successfully detected a wide range of surface 
modification, from antibodies (Abs) directly attached to the AuNP surface, followed 
by the binding of these AuNP-surface Abs to their target proteins (such as anti-biotin 
conjugated via an oligonucleotide linker, IgG1, to biotin).189 This is detected as the 
AuNP solution changing colour from red to blue upon the increase in size or 
aggregation (due either to a decrease in colloidal stability or AuNP clustering) of the 
AuNPs. Other methods for detection of surface functionality include IR and TGA, 
which can also be used to determine the average number of surface functionalities.169 
Glyco-AuNPs have been widely investigated due to the facility of their synthesis, their 
capacity to incorporate both NP core properties and glycan biofunctionality, and their 
ability to mimic cell-surface glycan clusters.151,169,188,190–193 This is of particular 
interest due to glycans being pivotal in the infection mechanisms of various bacteria, 
bacterial toxins and poisons, and in the signalling and sugar uptake of cancer cells in 
tumours.190,191,194,195 Lin et al.193 demonstrated the binding of mannosylated AuNPs to 
the adhesive FimH protein on Escherichia coli pili. Richards et al.188,191 have looked 
into glyco-AuNP coating dependent specific detection of bacterial lectins (specific 
glycan-binding proteins often involved in cellular adhesion), wherein both the choice 
of carbohydrate displayed, coating density and the linker length play an important role 




Figure 1-15. Aggregation of glycan-coated AuNPs in response to SBA lectin. 
Characteristic pink à blue colour change results from optimisation of AuNP coating 
for SBA interaction, suggesting their potential use in identification of target lectins. 
Figure taken from Richards et al.188. 
AuNPs also serve as biocompatible, easily-functionalised, bioconjugate 
scaffolds.130,152,169,175,196–203 Thermally-stable DNA/AuNP conjugates were 
synthesized through direct Au-S linkages by Li et al.198, using a variety of thiol 
structures: aliphatic and cyclic, mono- and bi-dentate. They found colloidal stability 
to be greater with higher DNA packing density (higher density with monodentate 
ligands) and aliphatic anchor structures, as determined by the slower release of DNA 
from the conjugates upon exposure to 85 °C heat. Studies by the Mirkin group have 
looked into DNA detection with oligonucleotide-AuNP conjugates, and their 
sequence-dependent stability.196,197 In these studies, complementary oligonucleotide 
sequences on AuNPs caused aggregation of AuNPs coated with their respective target 
DNA, detected as a pink à blue solution colour shift.189 
In another study, by Clark et al.199, 80 nm gold was coated with transferrin (Tf) via an 
acid-cleavable linker, to allow crossing of the blood brain barrier by receptor-mediated 
transcytosis. These AuNPs were found in an in vivo mouse model to bind to transferrin 
receptors on one side of the blood brain barrier, and separate from the transferrin 
conjugate due to an increased acidity during the transcytosis process to enable crossing 
into the brain parenchyma. This trafficking was found to be enhanced relative to both 
Tf-AuNP conjugates with non-cleavable linkers, and Ab-AuNP conjugates with acid-
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cleavable linkers, suggesting both the Tf and acid-cleavage are needed. Biodistribution 
of AuNPs was determined in mouse brain tissue slices via the presence of silver-
enhanced AuNP clusters in optical microscopy. 
Tan et al.175 used EDC/NHS chemistry to attach FITC-labelled anti-VEGF (vascular 
endothelial growth factor) antibody to carboxylic acid terminated, PEG-coated AuNPs 
(see Figure 1-11). The shape, size and dispersity of these bioconjugates were assessed 
by TEM and DLS, and protein valency was determined as a function of protein 
fluorescence versus AuNP absorbance spectra. ICP-MS assessed cell internalisation 
of the AuNP bioconjugates, and cell viability was shown to decrease dose-dependently 
with bioconjugate incubation. VEGF induces proliferation in human umbilical vein 
endothelial cells in a dose-dependent, temporal manner.175 This is reduced by pre-
incubation with free anti-VEGF Abs, which act by binding to cellular VEGF. Pre-
incubation with anti-VEGF-PEG-AuNP bioconjugates showed partial retention of Ab 
function by decreasing cell proliferation, but unfortunately Au functionalised with 
anti-horseradish peroxidase control also showed this activity. It could be that the use 
of the uncontrolled, non-specific EDC/NHS coupling reaction for bioconjugation 
resulted in a loss of Ab function: ie. these results could be attributed to the presence 
of any Ab/AuNP bioconjugate. 
AuNP bioconjugates may also been synthesized by more specific “click” or 
bioorthogonal techniques.152,204 Copper-catalysed alkyne/azide chemistry has been 
used to attach azide-functionalised AuNPs with Thermomyces lanuginosus lipase, and 
successful conjugation and retention of the enzymatic activity relative to unconjugated 
lipase was confirmed through gel electrophoresis and a fluorometric activity assay 
respectively (see Figure 1-5).152 Aufaure et al.204 used inverse electron demand Diels-
Alder chemistry, with an alkene-terminal 1-hydroxy-1,1-methylenebisphosphonate 
conjugated to AuNPs. Tetrazine 3,6-dipyridin-2-yl-1,2,4,5-tetrazine was then 
conjugated to the AuNPs in one-pot, bioorthogonal conditions, and verified by XPS. 
Following this experiment, 6-methyl-tetrazine-sulfo-cyanine 5 (a near IR probe) was 
then also successfully conjugated to the original modified AuNPs, as proof that this 
chemistry has possible application in the synthesis of materials for biological imaging.  
Inspired by affinity chromatography techniques, the oligomeric histidine affinity tag 
has also been used to conjugate proteins to the AuNP surface (see Figure 1-12).200,201 
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In a study by Hainfeld et al.201, a His-tagged adenovirus “knob” protein was attached 
to nickel-coordinated, NTA-dipeptide-thiol pre-conjugated to the surface of small 
(either 1.6 or 1.8 nm diameter, though the larger core showed greater conjugation 
success) AuNPs. Successful conjugation was verified by column chromatography, 
UV-Vis and TEM, and the conjugate retained protein receptor binding activity relative 
to unconjugated protein. 
From these various examples, AuNPs are shown to be a good, stable, bioorthogonal 
scaffold for the attachment of biomolecules for the purposes of assessing protein 






There are a variety of scaffolds available for the conjugation of biological or 
biorthogonal moieties, but there is currently a dearth of fully biorthogonal techniques 
to fulfil these conjugations. Chemical techniques tend to have limitations to their 
efficacy or biocompatibility (for example through the use of UV light or copper), 
whilst the use of enzymatic strategies results in a further layer of complexity. 
Herein, novel techniques are proposed to overcome these limitations, with “click”-like 
thiolactone polymer chemistry (Chapter 2) and protein tags on AuNP scaffolds 
(Chapters 3 and 4) in order to investigate protein function. These techniques aim to 
use close-to native protein structure with biocompatible synthetic techniques in order 
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1.7. Thesis summary  
The following chapters detail bioorthogonal approaches to the synthesis of materials 
(nanoparticles and polymers) in order to investigate the activity of adhesive proteins: 
namely, Vibrio cholerae toxin’s adhesive subunit (CTxB), the ice-binding protein 
antifreeze type III, and the proposed adhesive protein segments of Photorhabdus 
bacteria’s Photorhabdus virulence cassettes. 
Chapter 2.  
In the glycobiology sphere, there is interest in the development of multivalent glycan 
mimics that may have applications in anti-adhesive therapy against lectin proteins on 
pathogen cellular surfaces or pathogen toxins. Novel bifunctional glycopolymers with 
tuneable secondary functionality, carbohydrate density and linker length were 
described and tested against CTxB, and the more promiscuous ricin communis 
agglutinin to assess both binding capacity and lectin specificity. Glycopolymers with 
a sugar secondary functionality (glucosamine rather than benzylamine), low 
carbohydrate density (5 % of polymer repeat units), and linker length appropriate to 
interact with CTxB (allyl rather than hexenyl) were found to be more specific and 
active. 
Chapter 3. 
The impact of branching or multivalency on the activity of antifreeze-active 
macromolecules is of interest in the development of biocompatible cryopreservatives 
with enhanced ice recrystallisation inhibitory activity (IRI). The impact of tethering 
antifreeze compounds to a multivalent, dendrimer-like, small (~4 nm diameter) gold 
nanoparticle (AuNP) scaffold was investigated: (poly(vinyl acetate) polymer (PVA) 
and antifreeze type III protein (AFP). These studies showed this tethering to have 
either no impact on activity, with no significant difference between the activity of PVA 
and PVA/AuNP conjugates, or a slight increase in activity, with AFP/AuNP 
conjugates showing a ~10 % decrease in ice crystal sizes relative to free monomeric 






The binding activity of a newly-described adhesive “tail fibre” segment of three 
different Photorhabdus virulence cassette proteins (PVClumt_Pvc13, PVCpnf_Pvc13 
and PVCunit4_Pvc13) was evaluated utilising cell incubation studies of protein/AuNP 
conjugates (assessed by ICP-OES), glycan and lipid arrays, and pull-down assays 
followed by quantitative proteomics. A variety of potential glycan and protein 






2.Doubly-modified thiolactone polymers 
with anti-adhesive activity against 
cholera toxin 
2.1. Chapter Summary 
Multivalent glycomaterials show enhanced binding affinity to lectins due to the cluster 
glycoside effect, but often lack selectivity towards the desired lectin target due to the 
need to simplify a complex glycan structure into monosaccharides presented on the 
polymer side chain. For example, cholera toxin has a deep galactose binding pocket 
with an allosteric site binding neuraminic acid on the native GM-1 glycan, which 
traditional non-specific glycopolymers do not target, and hence offer an opportunity 
to use polymer architecture to tune selectivity. 
Herein we produce more precise mimics of the natural 3-D glycan structures by 
utilising thiolactone chemistry. This chemistry allowed the incorporation of two 
distinct sugar residues in sequence in order, with the aim to interact with both the 
primary and allosteric binding pockets of the cholera toxin subunit. The choice of 
secondary, non-binding unit dramatically influences the affinity and selectivity 
towards cholera toxin. Kinetic analysis by bio-layer interferometry further confirmed 
this effect with the residence times of these glycopolymers, with highest affinity and 
selectivity in the structures with a galactose-linker length appropriate for the CTx 
binding site, and secondary glucosamine residue.  
These doubly-modified glycopolymers, developed using simply “click”-like 






A large proportion of essential cell-cell binding processes are mediated through the 
binding of sugar-binding proteins (lectins) to complex polysaccharides (glycans): 
processes from fertilisation to glycoprotein transport and cancer malignancy.1–6 In 
particular, many pathogens exploit these native glycans in order to adhere to the 
human cell surface, and this adhesion is a key step in both infection and the immune 
response.2,7–13 As examples, mycobacteria interacts with glycan receptors on host 
macrophages14; the first step of influenza infection is the binding to extracellular sialic 
acid receptors7; and HIV binds to native lectins via mannose moieties presented on an 
envelop glycoprotein15.  The exact sequence of the glycan, including stereochemistry, 
serves as a code which is “read” by the native target cell in order to elicit a specific 
response.13 In fact, it is only in the formation of these complex, sometimes branched, 
oligosaccharide chains that so few monosaccharide building blocks can be used for 
such a large number of specific targets in nature.13 The lectin binding pocket is 
therefore finely tuned to maximise the number of hydrogen bonds and hydrophobic 
interactions that form with its specific glycan ligand, which makes any change in 
structure very disfavoured. 
 
Figure 2-1. The principles of anti-adhesion therapy using anti-adhesive polymers.  
Human Epithelium
Adhesion of Toxin to Epithelium
Anti-adhesive Polymers 
interacting with Toxin
Glycan    Toxin    Polymer
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In recent years, anti-adhesion therapy has been proposed as a technique circumventing 
the need for antibacterial therapies, which is desirable given the alarming increase in 
drug-resistant bacterial strains.8,10 In particular, anti-adhesion therapy would involve 
interfering with the initial adhesion of pathogens to their hosts and therefore they avoid 
bactericidal methods that greatly enhance the likelihood of antibiotic resistance 
occurring (see Figure 2-1).8,16 In this therapy, inhibitors can be designed to compete 
with the human host receptors for pathogen binding and thus need not be able to enter 
human cells or interact with them at all.  
The physiological processes in which lectins are involved are adhesive or regulatory, 
with the multimeric structure of many of these lectins affording fine-tuning of the 
extent of response elicited. In monovalent form, glycan ligands bind only weakly to 
their lectins (KD = mM) through noncovalent interactions.13 In their multivalent form 
(as usually displayed on the cell surface) the affinities of these carbohydrates rises 
more than purely the multiple of their constituent residues (KD = nM), and this is 
termed the cluster glycoside effect.4,13,17–21 This effect is not fully understood; however 
it is hypothesized that it is largely an entropic effect of aggregation.20 
Thus, multivalent synthetic systems such as polymers and nanoparticles, with the 
ability to display a large number of carbohydrate residues, have been applied to a range 
of lectin targets.8,12,13,15,17,20,22–24 Reuter et al.7 developed multivalent (dendritic 
polymers of various conformations) sialic acid polyacrylamides that had potentially at 
least 32-fold more activity in preventing influenza-induced agglutination of 
erythrocytes relative to monomeric sialic acid. By tuning the 3-D structure of these 
dendritic polymers, they found comb-branched and dendrigraft polymers have even 
more activity that more linear or spherical polymers, with up to 50,000-fold greater 
activity than the monomer.  
Parry et al.25 also exploited this cluster glycoside effect with glycopolymer-stabilised 
gold nanoparticles that were able to enhance antibody production in cancer cells. The 
Tn-antigen glycan (α-N-acetyl-D-galactosamine) is one of several core 1 mucin-type 
glycans overexpressed on the breast cancer cell surface. In this study, Parry et al. 
produced both polymers with a Tn-antigen glycan side chain and gold nanoparticles 
surface functionalised with this polymer to investigate the effect of the enhanced 
multivalency. They found the nanoparticles to have enhanced IgG antibody titre 
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relative to the polymer after immunisation of New Zealand White rabbits, suggesting 
that these materials might be an avenue for the development of cancer vaccines. 
2.2.1. Anti-adhesion of the Cholera Toxin lectin 
Cholera is a highly contagious major waterborne disease that causes regular epidemics 
in areas of poor water access and sanitation, especially in cases of natural disaster 
where such infrastructure is heavily disrupted. It is estimated that 2.9 million cases, 
and 95,000 deaths, occur yearly worldwide (see Figure 2-2).26 The gram-negative, 
motile Vibrio cholerae bacterium is responsible for the diarrheal symptoms of the 
disease, which cause severe dehydration and death within hours if not treated.27,28 
There is a lot of interest in developing anti-infectives to prevent cholera infection due 
to the limited scope of the current Vaxchora vaccine (which is currently only effective 
for serogroup 01).16,29 
Cholera toxin (CTx, see Figure 2-3), produced by the bacterium Vibrio cholerae 
adheres to the human gut epithelium via GM-1 glycans presented on the cell 
surface.28,30–36 This adhesion, as in all members of the AB5 toxin family (containing 
five effectively-identical adhesive B subunits and one toxic A subunit), allows the 
toxin to enter the host cell, hijack its machinery and induce toxic effects.34,37 The GM-
1 receptor carries CTx from the plasma membrane to the endoplasmic reticulum to 
initiate this process.37 This glycan is a branched pentasaccharide with a terminal 
galactose, and a sialic acid-terminated side chain proposed to also be key in CTx 
adhesion. The specific 3-D structure of this glycan is key in CTx adhesion: secreted 
Vibrio cholerae neuraminidases degrade the mucin layer of the gastrointestinal tract, 
converting higher-order gangliosides to GM-1.30,33,36,38 That the presence of this 
enzyme is essential suggests that a locally-high concentration of GM-1 glycans is 
necessary to enable sufficient CTx attachment for successful infection: the five 
adhesive subunits of the toxin have the capacity to bind five GM-1 receptors at 
once.31,39,40 Multivalency therefore seems a promising characteristic for designing a 




Figure 2-2. Worldwide Cholera cases by region. Data and regional definitions taken 
from Global Health Observatory (GHO).64 It should be noted that these data include 
only cases and deaths as reported by the relevant countries’ authorities. 
In GM-1 binding, both branches show several hydrogen bonding interactions with 
CTx, with galactose buried deeply in the binding pocket, whilst sialic acid residue sits 
in a more spacious shallow pocket (see Figure 2-4).29 ITC studies have shown that 
subnanomolar affinities are achieved for the CTx-GM-1 interaction due to the 3-D 




Figure 2-3. Structure of CTx B subunit from above (A) and side (B), showing barrel-
like conformation. 2CHB PDB file visualised with UCSF Chimera software 
It has so far proved very complex to form monovalent anti-infective ligands for 
CTx.13,40–42 For example, work by Lanne et al.43 displayed the negative effect of even 
small alterations to the structure of the sialic acid. In this study, modified GM-1 
glycolipids modified with amides and alcohols at the C(1) of neuraminic acid were 
immobilized onto blotting membrane surfaces were then exposed to radiolabeled 
CTxB, and this showed that these modifications reduced binding, possibly due to a 
reduced capacity to form hydrogen bonds with the toxin. Bernardi et al.40–42 also 
performed several studies into the structure-function relationship in developing both 
oligosaccharides and monomeric ligands. For example, monomeric GM-1 mimics 
were easily produced through the use of α-hydroxyacids to avoid the difficulty of 
incorporating the neuraminic acid moiety. The terminal galactose and α-hydroxyacids 
were attached to a commercially available cyclohexanediol scaffold representing the 
rest of the pentasaccharide. The highest affinity for GM-1 with these mimics, 
determined by fluorescence spectroscopy, was found to be KD=190 mM, which shows 
significantly weaker binding than the native GM-1, KD=4.61 pM.39 
Due to the difficulty of developing a structure more well suited to CTx’s binding 
pocket than GM-1, many groups have attempted to circumvent this difficulty with 
compounds displaying five GM-1 mimics to exploit the multivalency effect. Wang et 
al.44 developed a pentavalent compound with 5 arms terminated by galactose on a 
pentacycle core, showing the importance of matching the length of the carbohydrate 
spacer (not too long or too short) to the CTx binding pocket. This rationale was 
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extended to corannulene core-based pentavalent GM-1 oligosaccharide compounds 
synthesized by Mattarella et al.45, which showed nanomolar IC50 values. 
 
Figure 2-4. Structure of GM-1 bound to CTx adhesive binding pocket. A) Structure 
of GM-1 ligand. B) GM-1 bound to CTx, 2CHB PDB file visualised with UCSF 
Chimera software. 
Polymers and nanoparticles have the potential to further exploit the cluster glycoside 
effect by displaying more than 5 moieties on one scaffold. With this rationale, the hope 
is that the effect of the very large number of carbohydrates displayed should override 
the reduced binding due to the less precise sequence control achieved in a 
polymer,.41,46 The tunable properties of a polymer are very different to those available 
in small molecules: namely, average chain length, the choice of pre- or post-
polymerisation addition of functionality, density of functionalisation. 
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Das et al.16 developed GM-1-terminated polymers coated onto nanoparticles, and 
showed these materials to have promising anti-CTx activity in vitro and in vivo. This 
study, although presenting a promising mimic of native GM-1 binding, does not 
provide any understanding of how we might tune polymer structure to enhance CTx 
affinity without using the native GM-1 ligand.  
The density of functionalisation and linker length to the polymer chain is key due to 
the freedom of movement required to allow multivalent bonding modes.4,19 Fulton et 
al.47 developed a library of glycopolymers with the ability to adapt galactosyl residue 
density in response to exposure to the CTx protein. In response to their application to 
various immobilised lectin templates in 96-well microplates, acylhydrazine-
containing carbohydrates reversibly conjugated to aldehyde-functionalised polymers. 
In each well, the applied polymers with carbohydrates attached (galactose and/or 
mannose were pre-attached in each case) formed the specific glycopolymer 
composition able to interact with highest affinity with these lectin templates. 
Composition was determined by 1H-NMR spectroscopic monitoring of the sugars’ 
anomeric protons. This templating process enhanced the affinity of these 
glycopolymers to their target lectins, as determined by fluorescence titration of the 
isolated templated polymers, suggesting that lectins’ exhibit higher binding for 
strategically placed carbohydrates over the carbohydrate-dense pretemplated 
glycopolymers. Richards et al. produced a series of poly(methacrylate)s with 
pentafluorophenyl groups on the sidechain, which were converted post-polymerisation 
with amine linkers of various lengths terminated with galactose residues.23 This study 
showed higher affinities were obtained with the longer linker lengths optimized to the 
depth of the CTx pocket, suggesting that it is important to tune this length to the length 
of the native GM-1 glycan. 
The next step in this rational design was to implement the 3-D GM-1 structure by 
interaction with CTx’s shallow allosteric sialic acid binding pocket. Jones et al. 
previously developed a polymer capable of distinguishing PNA (a galactose-binding 
lectin) and CTx by implementing a branched functional motif in addition to terminal 
galactose on the sidechain of a methyl methacrylate polymer scaffold.48 In this study, 
they developed a library of polymers with equivalent spacing between the galactose 
and sialic acid residues to the native GM-1, and found a chlorobenzyl branched group 
to grant 6-fold selectivity for CTx over PNA. Unfortunately, however, this selective 
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compound had a relatively high MIC50 of 0.1 mM. Tran et al.46 also synthesized 
acrylamides with hetero-bifunctional moieties attached to side chains of the polymers. 
The allosteric moieties were chosen out of utility rather than to mimic GM-1’s 
branched sialic acid, but many of these molecules displayed sub mM IC50 values.  
The evidence suggests that further mimicking GM-1’s branched 3-D structure in the 
polymer’s side chain may further enhance both selectivity and affinity: linker length, 





2.3. Chapter aims 
There is a need for the design of glycopolymers tailored to bind specifically to the 
binding pocket of CTxB, involving the involvement of CTxB’s allosteric site. There 
are currently no studies looking into the 3D structure of the glycopolymer side chain 
for this application. To this end, the aims of this chapter are as follows: 
o To synthesis a library of doubly-functionalised glycopolymers with terminal 
galactose, several carbohydrate densities, two different linker lengths and two 
different secondary moieties to interact. 
o To determine the inhibitory activity of the glycopolymers with CTxB and a  
simpler lectin without an allosteric binding site (RCA120 has a shallow binding 
pocket) versus immobilised GM-1 glycan. 
o To assess the binding kinetics of the glycopolymers with CTxB and RCA120. 
o To compare all binding assay data to determine the effect of linker length and 




2.4. Results and Discussion 
2.4.1. Synthesis of poly-hydroxyethyl acrylamide-co-
thiolactone acrylamide 
In this study, we designed bifunctional glycopolymers aiming to interact with both the 
deep galactose-binding pocket and more-shallow sialic acid binding pocket of the CTx 
B subunit (CTxB). This double modification is implicated as a potential strategy to 
further increase affinity for CTx through rational design of a structure mimicking the 
3-D structure of GM-1. Thiolactone-containing polymers have been extensively used 
as doubly modifiable scaffolds which can easily integrate a large variety of functional 
groups via “click”-like chemistry.49–58 Though these polymers have yet to be used in 
biomedical application, their capacity to employ two functionalities using rapid, 
specific, versatile “click”-like chemistry means that the this chemistry could be 
suitable for the production of biorthogonal polymers. Thiolactone acrylamide was 
synthesized, following a well-established procedure previously described by Reinicke 
et al., from the readily available homocysteine thiolactone hydrochloride in a typical 
two-phase system (1:1 dioxane:water) using sodium bicarbonate to deprotect the 
hydrochloride salt.49,52 Acryloyl chloride (an acid chloride) was used to activate this 
compound overnight at room temperature, and the resulting monomer product was 
purified. Structure and purity were validated by 1H and 13C-NMR spectroscopy, the 
presence of the M+Na+ peak at 194 m/z by ESI-MS, and FTIR. 
 



































A library of polymers with different percentages of thiolactone acrylamide included 
in the chain was synthesized using RAFT  (reversible addition fragmentation chain-
transfer) copolymerisation with N-hydroxyethyl acrylamide (see Scheme 2-1). This 
method was chosen for chain length control and its tolerance of the thiolactone and 
acrylamide moieties. The molar ratio of thiolactone acrylamide was varied from 5-20 
%, with homopolymers of both monomers also synthesized for characterisation. 
Polymers were assessed by SEC, NMR and FTIR to determine chain length, and 
dispersity, with all polymers displaying acceptable control (Đ < 1.3) (see Figure 2-5). 
The thiolactone acrylamide monomer displayed reduced reactivity to the N-
hydroxyethyl acrylamide, as indicated by a relative reduction in conversion (see Table 
2-1). 1H-NMR displayed broadening of peaks in the polymer spectra, and the loss of 
the terminal vinyl peaks involved in polymer formation.  
Kinetics experiments were not carried out to assess the structure of the polymer 
backbone, so it is possible that these copolymers may not be random, with some 
clustering of the thiolactone moieties. That the conversion of the TLAm monomer was 
consistently above that of the HEA monomer in all copolymers (see Table 2-1) 
suggests that the reactivity of TLAm may be greater than HEA, which in turn suggests 
that TLAm repeat unit clustering may well have occurred. 



























100 10 96 100 12,000 9,700 1.3 
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a Monomer to RAFT agent molar ratio; b Determined by depletion of vinyl peaks in 
1H NMR using mesitylene as an internal standard (fortunately the vinyl peaks for 
HEA and TLAm were distinct by 1H-NMR); c Determined by SEC. 
 
Figure 2-5. Difference in FTIR spectra (A) and SEC molecular weight distributions 
(B) between different proportions of TLAm in polymer. Of note in FTIR are the 
broad OH-peak at ~3250 cm-1 in pHEA and not pTLAm, and the obvious double 





100 20 76 84 9,700 9,200 1.3 
pTLAm 100 100 - 30 4,700 7,200 1.2 
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2.4.2. Post-polymerisation double modification of thiolactone 
acrylamide-containing copolymers 
 
Scheme 2-2. Modification of pHEA-co-TLAm modified with primary amine, 
galactose with alkene linker, followed by deprotection. 
The thiolactone-containing polymers were doubly modified in a one-pot, two-stage 
process to install functionalities in a manner mimicking the branched 3-D structure of 
GM-1 (See Scheme 2-2). The modification of the different percentages of thiolactone 
Amine (NH2R), Allyl galactose*,
1:1 chloroform:toluene.
25 oC, 16 hrs
ACVA, N2(g),
























































































was undertaken to determine the effect of carbohydrate density on affinity. Two 
different linker lengths were also implemented for the galactose modifications to 
assess whether the allosteric modification did indeed have an effect. The length of the 
polymer chain to the terminal galactose is 12.7 and 16.5 Å for the allyl and hexenyl 
galactose respectively (the length of the entire GM-1 pentasaccharide chain is 16 Å, 
see Figure 2-6). This suggests that the allyl linker length is appropriate to allow 
binding of the secondary unit to the CTxB allosteric site whilst the galactose residue 
sits in the deeper galactose binding pocket. The hexenyl linker is therefore long 
enough to inhibit the interaction of the secondary unit to this allosteric site. In this 
way, carbohydrate density, presence of allosteric moiety and type of allosteric moiety 
could all be assessed for CTx binding in this study. 
 
Figure 2-6.. Linker lengths of the native GM-1 ligand and synthesized polymers. 

































































The secondary modification (either 2-glucosamine or benzylamine) was incorporated 
first by ring-opening the thiolactone to release a free thiol. The primary, galactose-
containing, functionality was then incorporated further down the thiolactone-derived 
side chain in a “thiol-ene” radical click mechanism with this free thiol, using ACVA 
as a radical source. The galactose compounds’ acetate protecting groups were then 
removed by stirring overnight in sodium methoxide followed by dialysis.  
Successful modification was confirmed by increase in Mn by SEC (see Figure 2-7 and 
Table 2-2, though these data are indicative of hydrodynamic volume, not raw 
molecular weight) with most samples showing no significant change in polydispersity 
(suggesting no undesirable side reactions such as disulfide formation), loss of 
thiolactone-indicative peaks by FTIR (suggesting ring-opening) and the presence of a 
shoulder on the carbonyl peak. There are shoulders visible on several of the SEC 
traces, potentially due to undesirable transesterification reactions taking place. The 
removal of acetate protecting groups was confirmed by loss of the large upfield peaks 
in 1H-NMR and C-O peaks in FTIR. The solubility of the modified polymers (except 
the thiolactone acrylamide homopolymer) in water only after the deprotection step was 
both essential for protein activity assays, and indicates successful modification. 
1H-NMR analysis was not consistently useful in confirming modification due to the 
presence of polymer peaks at ~4.5-5.5 ppm (where we would expect to see sugar 
peaks). It should also be noted that most of the final, modified, polymers were only 
soluble in water (or D2O), and therefore the change in the amide peak was not 
observable in most spectra due to it exchanging with deuterium in this solvent. The 
1H-NMR spectra for pHEA-co-TLAm(5 %) polymer’s modification with 2-
glucosamine then allyl-β-D-galactose or hexenyl-β-D-galactose had visible amide 
peaks despite the use of deuterium oxide solvent. These amide peaks showed a change 
in shape, suggesting the presence of the third amide (produced by the 2-glucosamine 
modification during thiolactone ring opening).  
In addition to this, the pHEA-co-TLAm(5 %) (modified with glucosamine/hexenyl-β-
D-galactose) was the only modified polymer readily soluble in methanol as well as 
water, so a 1H-NMR was obtained in this solvent. The integral for this amide peak 
dropped tenfold (from 0.22 to 0.02 using a polymer peak as a standard integral). This 
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suggests that the presence of the modification enables the amides to deuterium 
exchange more readily. 


















Glucosamine 13,500 12,400 1.2 
Benzyslamine 13,100 10,500 1.3 
Hexenyl-β-D-
galactose 
Glucosamine 13,700 13,100 1.7e 







Glucosamine 15,600 14,400 1.2 
Benzylamine 14,800 13,800 1.4 
Hexenyl-β-D-
galactose 
Glucosamine 16,000 16,600 1.4 







Glucosamine 16,400 13,300 1.2 
Benzylamine 15,100 c c 
Hexenyl-β-D-
galactose 
Glucosamine 17,100 14,100 1.3 
Benzylamine 15,900 9,300 1.3 
a Determined by depletion of vinyl peaks in 1H NMR using mesitylene as an internal 
standard (fortunately the vinyl peaks for HEA and TLAm were distinct by 1H-
NMR); b Determined by SEC; c Insufficient polymer to perform characterisation. d 
Determined by SEC. e A shoulder was evidently visible on the SEC of these products 




Figure 2-7. Representative modification of pTLAm polymer to form doubly-
modified pTLAm product. A) FTIR showing change in pTLAm polymer upon 
modification: of note are peaks at 1600 (second overlapping C=O peak) and 1100-
1200 cm-1 (C-O peaks from sugar modifications). B) SEC trace showing shift in 
molecular weight distribution upon modification; shoulder on pTLAm (Benz-All) 
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shows shoulder that may be caused by transesterification. C) FTIR showing the loss 
of acetate groups by the loss of the characteristic 1750 cm-1 C=O peak. Brackets 
denote (SecondaryModification-AlkeneGalactoseLinker). 
 
2.4.3. Microplate assays to determine competitive binding 
A fluorescence-linked binding assay was used to evaluate binding to CTxB and a 
galactose-binding lectin control. RCA120 has a shallow binding pocket and therefore it 
is useful to assess non-specific binding to terminal galactose but not the secondary 
binding moiety.12,24,59 Herein, fluorescently-labelled lectin were incubated with a 
serial dilution of polymer concentrations. This mixture was then incubated on a high-
binding microplate pre-surface-functionalised with GM-1 (prepared as previously 
described by Richards et al.48) and washed to remove unbound lectin. Fluorescence 
emission was assessed in a plate reader, with more fluorescence indicating more free 
lectin (not bound to the applied glycopolymers) and less fluorescence indicated higher 
affinity for the synthesized glycopolymers. 
Representative binding curves are displayed (Figure 2-9 and minimum inhibitory 
concentrations (MIC50) for all compounds are displayed in Figure 2-8 as total 
calculated galactose concentration. Compounds showing binding activity display a 
sigmoidal curve shape on increasing concentration, with a steep increase in binding as 
the binding of some lectin molecules facilitates further binding, and a maximum 
plateau at which point all lectin molecules are engaged. MIC50 values are calculated 
as the concentration at which this sharp increase occurs (at which 50% of toxin units 
are engaged), and therefore those compounds which do not display this sigmoidal 
binding activity do not have MIC50 values: thus, Figure 2-8 does not have any values 
for the polymers with benzylamine, or the hexenyl galactose at 10 and 20 % 
carbohydrate density, as these compounds showed no competitive binding activity (ie. 




Figure 2-8. MIC50 values by galactose concentration, excluding those without 
sigmoidal curve fits. Axes labels for polymers are in the format TOXIN-
TLAmDensity-SecondaryModification-AlkeneGalactoseLinker. Full data in 
appendix. Error from experiments performed in triplicate. 
 
Figure 2-9. Representative Microplate assay binding curves (full set of curves in 
appendix, all assays undertaken in triplicate). 
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As the carbohydrate units were installed by post-polymerisation modification, any 
changes in activity due to linker length or secondary unit can be isolated as 
independent of changes in chain length, density or dispersity. The modified 
thiolactone acrylamide homopolymers showed no binding activity. This could be due 
to too-high carbohydrate density, or because these polymers were insoluble in aqueous 
media (HEPES buffer was used for all other solutions), and therefore were applied in 
DMSO (no other samples contained DMSO), which could have had other effects. 
These polymers were excluded from further study. 
The RCA120 control displayed no significant preference for either secondary binding 
motif, as would be expected due to its shallow binding pocket having no capacity to 
interact beyond the terminal galactose. RCA120 binding also exhibited no significant 
differences between linker lengths. Conversely, the presence of the benzyl secondary 
unit dramatically decreased CTxB binding to the extent that no binding activity was 
observed at all, potentially due to this group not interacting favourably with the sialic 
acid allosteric site.  
 
Figure 2-10. Model of shorter linker glycopolymers bound to CTxB binding pocket. 
Glycopolymer TLAm repeat unit modified with glucosamine and allyl-β-D-
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galactose, fitting in CTxB binding pocket, produced using SwissDock online 
server60. 
The glucosamine-containing polymers with allyl (shorter) linkers had binding 
interactions with CTxB and RCA120 at all densities, but with affinity reducing with 
greater carbohydrate density. This reduced density could be favourable due to an 
increased freedom of movement allowing the side chain to exhibit a similar 3-D 
orientation to native GM-1, where the presence of more long ring-opened thiolactone-
derived chains sterically inhibits lectin interaction.19 As predicted (see Figure 2-10_, 
the longer linker length (the hexenyl galactose) cancels out the enhanced binding 
effect of the secondary functionality, meaning that both the benzyl and glucosamine 
had comparable activity with CTxB. This confirms the hypothesis that it is the 
secondary unit binding to the allosteric site eliciting the change in binding activity. 
2.4.4. Bio-layer interferometry studies to determine kinetics of 
cholera toxin binding 
In addition to a fluorescence-linked sorbent assay, bio-layer interferometry (BLI) was 
employed to understand the kinetics of binding over multiple, longer, timepoints. This 
assay was also employed to understand the affinity of these glycopolymers for CTxB 
rather than their capacity to inhibit GM-1 binding to CTxB. BLI is a label-free 
technique which analyses the interference pattern of white light reflected from two 
different layers. White light reflected off an internal standard layer is compared to 
white light reflected off the biosensor tip (which consists of the immobilized protein 
and any ligands that may be attached). In this way, it is able to detect changes in the 
binding of ligands to the biosensor probe during the assay, and thereby quantitatively 
and precisely measure ligand association and dissociation in real time. Such kinetic 
studies are essential in uncovering what is happening on a molecular level, analyzing 
a different aspect of ligand binding to competition assays (such as the fluorescence-
linked sorbent assay). See Figure 2-11 for a demonstration of a typical BLI 
experiment. 
Using the BLI system, lectins were immobilized onto BLI sensors with simple 
EDC/NHS coupling: this is desirable due to its utility, however it should be noted that 
this type of immobilization is non-specific and may lead to binding to random, 
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multiple amine residues anywhere on the protein surface. Alternative methods, such 
as biotin-streptavidin, are available. Optimal lectin binding on the sensors was 
determined using a dilution series. A concentration series of polymers were applied to 
test dose-dependent activity, and a 2:1 model was selected as the closest available 
curve fitting for the raw data (see Figure 2-14 for representative curve fits). 
 
Figure 2-11. Typical curve observed on Octet system during BLI assay, with labels 
to indicate the different stages of the assay. These curves show the steps using 
amine-reactive sensors (to attach a ligand via EDC/NHS coupling). 
From a cursory glance at the binding curves, we can assess the relative mass of 
polymer bound to the bound lectins as a simplistic measure of binding activity. These 
raw intensity values correlated closest to MIC50 values from the Microplate binding 
assays. For both RCA120 and CTxB, increases in carbohydrate density led to decreased 
activity (with less change between 10 and 20 %). For both lectins, the benzylic 
secondary unit also decreased activity (to a larger extent with CTxB), with a reduced 
decrease in activity for the hexenyl linker. In fact, with the longer hexenyl linker the 
binding activity with the secondary benzyl is increased. Conversely, the longer linker 
decreases activity with the 2-glucosamine secondary unit (see Figure 2-12); perhaps 
related to a positive interaction with the binding pocket that is not possible with the 
longer linker. This is supported by models of the CTxB binding site showing that only 
the shorter linker enables the secondary functionality to interact with CTxB’s binding 




Figure 2-12. The effect of linker length on CTxB binding. Graph shows total mass of 
glycopolymer captured (Δmax) by lectins immobilised on BLI probe (experiments 
performed in triplicate) 
The strength of BLI, however, lies in understanding the kinetics of these binding 
interactions rather than the raw intensity of binding. KD is the binding constant for a 
ligand interacting with a specific lectin, calculated from a concentration series. This 
constant is derived by dividing the association constant, kon, by the dissociation 
constant, kdis. The KD of a particular ligand-lectin pairing is therefore led either by kon 
or kdis (see Figure 2-13). The parameter we are interested in most is the residence time 
of the polymer once bound to the lectin, defined as the average length of time a ligand 
spends in a binding pocket. This residence time is key as a high residence time of a 





Figure 2-13. KD values by polymer concentration. Axes labels for polymers are in 
the format TOXIN-TLAmDensity-SecondaryModification-AlkeneGalactoseLinker. 
Full data in appendix. Due to the sensitivity limitations of the instrument, 1 x 10-12 is 




Figure 2-14. Representative BLI fitted response curves (full set of curves in 
appendix). 
The KD values obtained were estimated by the BLI’s accompanying software, with 
slow dissociation constants resulting in low KD values. One series of results did change 
with kon (the association rate constant), which is the constant defining the kinetics of 
formation of the ligand-lectin complex: the RCA120 control with the hexenyl linker 
and benzyl secondary unit had slower binding with increases in carbohydrate density. 
All other samples showed no change in kon despite changes in ligand structure. 
With CTxB, there seemed to be no kinetic trend with carbohydrate density, with all 
glucose/allyl polymers showing fast dissociation regardless of density (see Figure 2-
13). This suggests that, even if these polymers show high binding activity, their 
residence times in the binding pocket are low. In contrast, although the benzylic 
secondary unit showed lower binding activity, kdis values were consistently lower than 
with the glucosamine unit, suggesting longer residence times (see Figure 2-42). This 
could be due to either more stable complex formation, or due to hydrophobic 
interactions barring the release of the polymer from the lectin’s binding pocket.61 No 
significant kinetic trends were observed with change in linker length.  
With RCA120, there were no obvious kdis trends relating to linker length. Dissociation 
of polymers with benzylic rather than glucosamine secondary units, or with higher 
carbohydrate densities, was consistently slower than the glucosamine unit.  
Previous studies have shown the native GM-1 ligand to have a dissociation rate 
constant (kdis) of around 40 nM.29 All the polymers herein had lower dissociation 
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constants than this, suggesting that the residence times of the GM-1 are longer, perhaps 
due to other parts of the polymer chain interacting with other CTxB subunits. 
However, the relatively low values obtained are typical of multivalent systems, 
suggesting there is promise in the use of these doubly-modified polymers. 
 
Figure 2-15. Plot of CTxB-binding MIC50 values (from fluorescence-linked sorbent 
assay) versus Δmax (maximum mass of glycopolymer bound to CTxB probe, from 
BLI assay). 
Due to the difference between the nature of the inhibitory and BLI assays, it is not 
expected that their results will necessarily agree: the former comparing the binding of 
immobilised GM-1 and the analyte to CTxB at one time point, and the latter showing 
the kinetics of binding to immobilised CTxB with no native GM-1 ligand present. 
Accordingly, the kinetic parameters did not agree with the inhibitory data, showing no 
link between inhibition of GM-1/CTxB binding and glycopolymers residence times in 
CTxB. There was potentially a correlation seen (in Figure 2-15) between the MIC50 
values from inhibitory assays and the maximum response seen in the BLI assay 
(related to the mass of glycopolymers bound to the CTxB probe), with Δmax (greater 
binding in the BLI association step) correlating to a lower MIC50 value (a lower 
concentration of glycopolymers required to inhibit GM-1/CTxB binding).  
Although models produced using the SwissDock server (see Figure 2-10) support the 
rationale of designing a doubly functionalized glycopolymers in order to interact with 
both the galactose and neuraminic acid binding sites in the CTxB binding pocket, the 
experimental data suggest that the glycopolymers/lectin interaction is incredibly 
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complex. These data do, however, show wide differences between the interactions 
with RCA and CTxB, suggesting that lectin discrimination and selectivity are possible 





This chapter demonstrated the synthesis of a library of doubly-modified 
glycopolymers with a variety of secondary modifications and linker lengths between 
the primary and secondary modifications and an analysis of their interaction with the 
CTxB lectin. Precursor copolymers of thiolactone acrylamide and N-hydroxyethyl 
acrylamide, with different percentage thiolactone incorporation, were polymerised by 
RAFT polymerisation. These polymers were subsequently modified in a one-pot, two 
step process with either benzylamine or 2-glucosamine, followed by allyl- or hexenyl-
β-D-galactose. 
Fluorescence-linked sorbent assays were performed to determine concentration-
dependent lectin binding affinity, and BLI to determine the kinetics and residence 
times of polymer ligands in the lectin binding pockets. As expected, the glucosamine-
containing polymers with shorter linker length and lower carbohydrate density had 
lower MIC50 values. This suggests that a hydrophilic secondary unit has favourable 
interactions with the CTxB allosteric site; the shorter linker length confirming that this 
effect is due to the secondary unit. In contrast, CTxB residence times by BLI were 
enhanced by a benzylic secondary unit, and not affected significantly by carbohydrate 
density or linker length.  
The kinetic parameters from the BLI assay showed no link to the inhibitory assay data 
versus the native GM-1 ligand (the fluorescence-linked sorbent assay). A correlation 
was instead seen between the MIC50 values and Δmax from the BLI assay (related to 
the mass of glycopolymers bound to the CTxB probe), which suggests that the amount 
of glycopolymers that binds during the association step may have an effect on capacity 
to inhibit CTxB’s binding to its native GM-1 ligand. These data combined suggest that 
the 3-D structure of a GM-1 mimic has a dramatic effect on its interaction with CTxB 
and other galactose-binding lectins. Increased complexity through both tuning linker 
length and the use of bifunctional glycopolymers may have application as specific 
anti-adhesives against Cholera.  
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2.6. Materials and Methods 
2.6.1. Materials 
Ultra-pure water with resistance < 18 Ω, was obtained from a Milli-Q© Integral Water 
Purification System. All chemicals were purchased from Sigma-Aldrich and used as 
supplied unless otherwise stated. 15 and 40 nm citrate-stabilised gold colloid solution 
was purchased from BBI solutions. GM1-ganglioside was purchased from 
Carbosynth. Deuterated solvents used (methanol, chloroform, water) were purchased 
from Sigma-Aldrich). n-Hexane, THF, DMF and ethyl acetate were purchased from 
Fisher. The toxins used in fluorescence-linked assays were Cholera toxin B subunit, 
FITC-conjugate, lyophilized powder from Sigma-Aldrich and Fluorescein labelled 
Ricinus Communis Agglutinin I (RCA I, RCA120) from Vector Laboratories. HEPES 
buffer stock solution was prepared with the following concentrations, and adjusted to 
pH 7.5 using the minimum volume required of 0.1 M HCl(aq) and 0.1 M NaOH(aq): 
10mM HEPES, 0.15 M NaCl, 0.1 mM CaCl2 and 0.01 mM Mn2+. The toxins using in 
bio-layer interferometry were Cholera toxin B subunit, lyophilized powder from 
Sigma-Aldrich and Unconjugated Ricinus Communic Agglutinin I (RCA I, RCA120) 
from Vector Laboratories. 
2.6.2. Analytical Methods 
1H and 13C-NMR spectra were obtained using a Bruker DPX-400 or Bruker DPX-300 
NMR Spectrometer; all chemical shifts are reported in ppm (δ) relative to residual 
non-deuterated solvent. Mass spectrometry was carried out in pure methanol or water 
on the Agilent 6130B ESI-Quad instrument using electrospray in positive mode. FTIR 
spectroscopy was carried out on a Bruker Vector 22 FTIR spectrometer with a Golden 
gate diamond attenuated total reflection cell. SEC measurements were carried out on 
an Agilent 390-LC MDS instrument equipped with a dual angle light scatter (LS), 2 x 
PLgel Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent 
was DMF or THF with 5 mmol NH4BF4 additive. Samples were run at 1ml/min at 
50oC. Poly(methyl methacrylate) standards (Agilent EasyVials) were used for 
calibration between 955,000 – 550 gmol-1. Analyte samples were filtered through a 
nylon membrane with 0.22 μm pore size before injection. Respectively, experimental 
molar mass (MnSEC) and dispersity (Đ) values of synthesized polymers were 
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determined by conventional calibration using Agilent SEC software.  Fluorescence 
plate readings were performed on a BioTek Synergy HT Microplate Reader. Bio-layer 
interferometry was performed on a ForteBio Octet Red 96 Bio-layer Interferometer 
using Dip and ReadTM Amine Reaction Second-Generation (AR2G) Biosensors.  
2.6.3. Synthetic Methods 
Synthesis	 of	 2-(dodecylthiocarbonothioylthio)-2-methylpropionic	 acid	
(DMP/DDMAT)	
 
Dodecane thiol (4.75 mL, 19.8 mmol) was added dropwise to a stirred suspension of 
K3PO4 (4.02g, 18.9 mmol) in acetone (60 mL). The reaction vessel was placed in an 
ice bath. Carbon disulfide (3.20 mL, 53.0 mmol) was added and the solution turned 
bright yellow, but was still cloudy. After stirring for ten minutes, 2-bromo-2- 
methylpropionic acid (3.00 g, 18.0 mmol) was added and a precipitation of KBr was 
noted.  The ice bath was removed after 10 minutes and the reaction was left stirring at 
room temperature for 16 hours. Solvent was removed in vacuo and the residue was 
extracted into DCM (2 x 50 mL) from 1 M HCl (100 mL). The organic extracts were 
further washed with water (100 mL) and brine (100 mL) and dried over MgSO4. 
Recrystallisation from n-hexane yielded a bright yellow solid (1.80 g, 27.5%). 
 
1H NMR (400 MHz, CDCl3) δppm: 3.28 (2H, t, JHH=7.5, H6); 1.66 (6H, s, H3/4); 
1.10-1.25 (20H, alkyl, H7-16); 0.79 (3H, m, H17). 
13C NMR (400 MHz, CDCl3) δppm: 220.86 (C5); 178.04 (C1); 55.51 (C2); 37.08 
(C7); 31.92 (C6); 29.64, 29.57, 29.46, 29.35, 29.12, 28.98, 27.82 (C8-15); 25.23 












2) CS2 25 oC, 16 hrs

















FTIR (solid, νmax/cm-1): 2910 (CH2); 1710 (C=O); 1440 (C-C); 1305 (C-O); 1070 
(S-(C=S)-S).  
ESI-MS, positive mode (m/z): 365.2 (M+H+, expected 365.63), 387.1 (M+Na+, 
expected 387.61).  
Synthesis	of	N-Thiolactone	Acrylamide	
 
D,L-homocysteine thiolactone hydrochloride (7.04 g, 45.6 mmol) was dissolved in 1:1 
dioxane: water (100 mL). The reaction vessel was transferred to an ice bath, and 
sodium hydrogen carbonate (19.2 g, 228 mmol) was added whilst stirring. After 30 
mins stirring, acryloyl chloride (7.45 mL, 91.2 mmol) was added dropwise. The 
reaction was stirred for 16 hours at room temperature. The reaction was extracted into 
ethyl acetate (200 mL) from brine (200 mL). The organic layer was dried over Na2SO4, 
filtered and concentrated in vacuo to yield a white solid (5.57 g, 71.3%). 
 
1H NMR (400 MHz, CDCl3) δppm: 6.35 (1H, m, H7); 6.17 (1H, m, H8, trans); 5.73 
(1H, m, H8, cis); 4.61 (1H, s, H1); 3.41 (1H, m, H3); 3.3 (1H, m, H3); 3.02 (1H, m, 
H2); 1.99 (1H, qd, JHH=12.5(x3), 6.9, H2). 
13C NMR (400 MHz, CDCl3) δppm: 165.83 (C), 129.93 (CH, C1), 127.73 (CH2, C3), 
59.59 (CH, C6), 32.07 (CH2, C7), 27.70 (CH2, C3). 
2) Added dropwise in ice.
























FTIR (solid, νmax/cm-1): 3290 (N-H); 2900 (CH2); 1680 (C=O); 1560 (N-H); 1405 
(C-C stretch in ring); 1210 (C-N aliphatic); 1005 (=C-H bend); 930 (alkene).  




Sodium acetate trihydride (2.06 g, 20.2 mmol) was ground by mortar and pestle and 
stirred in a 60oC oil bath. D(+)-galactose (2.00 g, 11.1 mmol) was added, and a 
condenser was attached to the reaction vessel. Acetic anhydride (10 mL, 106 mmol) 
was added dropwise. The reaction was refluxed for 10 minutes, after which it was 
cooled to room temperature and left stirring overnight. Ethanol (22 mL) was added to 
evolve acetic acid. The mixture was concentrated in vacuo, extracted into DCM (40 
mL) and washed with warm water (2 x 40 mL). The organic layer was dried over 
MgSO4, filtered and concentrated in vacuo. Ethanol (25 mL) was added, as was a few 
spatulas of activated charcoal, and the reaction was refluxed for 20 mins, cooled, 
filtered and recrystallized in ethanol to yield white crystals (1.30 g, 30%).62 
 
1H NMR (300 MHz, CDCl3) δppm: 5.72 (1H, d, JHH=8.2, H1); 5.45 (1H, br s, H4); 
5.36 (1H, t, JHH=9.3 x 2, H2); 5.11 (1H, m, H3); 4.17 (2H, m, H6); 4.07 (1H, m, H5); 
2.19, 2.15, 2.07, 2.02 (15H, 4 x s, acetyl groups). 
13C NMR (300 MHz, CDCl3) δppm: 92.17 (CH, C1), 71.12 (CH, C4), 70.88 (CH, 
C2), 67.82 (CH, C3), 66.79 (CH, C5), 61.03 (CH2, C6), 20-21 (CH3, Acetyls). 


























FTIR (solid, νmax/cm-1): 2973 (CH2); 1765 (C=O); 1374 (C-H); 1210 (C-O stretch); 
957 (=C-H bend); 900 (C-H “oop” bend). 
ESI-MS, positive mode (m/z): 413.1 (M+Na+, expected 413.33) 
Synthesis	of	1-b-allyl-D-galactose	pentaacetate	
 
Beta-D-galactose pentaacetate (2.00 g, 5.13 mmol) was dissolved in DCM (40 mL). 
Allyl alcohol (0.425 mL, 6.25 mmol) was added whilst stirring in an ice bath. Boron 
trifluoride dietherate (1.35 mL, 7.11 mmol) was added dropwise. 20 minutes later, the 
reaction was taken out of the ice bath and stirred for 16 hours. Anhydrous potassium 
carbonate (1.08 g, 7.24 mmol) was added whilst stirring. 30 minutes later, the reaction 
was filtered and washed with water (2 x 50 mL) and brine (50 mL). The organic layer 
was dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
by column chromatography on silica using an eluent comprising 2:3 ethyl acetate: 40 
– 60 oC petroleum ether to yield a yellow oil (1.02 g, 51.2%). 
 
1
H NMR (300 MHz, CDCl3) δppm: 5.88 (1H, m, H8); 5.41 (1H, d, JHH=3.2, H1); 5.34 
(1H, m, H4); 5.28 (1H, m, H2); 5.17 (1H, m, H9); 5.05 (1H, m, H3); 4.5 (2H, m, H6); 
4.15 (2H, m, H7); 4.13 (1H, m, H5); 2.15, 2.06, 2.05, 1.99 (15H, 4 x s, acetyl groups) 
13
C NMR (300 MHz, CDCl3) δppm: 117.61 (CH2, C9), 100.12 (CH, C8), 70.96 (CH, 
C1), 70.67 (CH, C4), 70.04 (CH2, C7), 69.01 (CH, C2), 67.07 (CH, C3), 61.30 (CH2, 
C6), 30.94 (CH, C5), 20-21 (CH3, Acetyls). 
FTIR (solid, νmax/cm-1): 3027 (O-H); 2920 (CH2); 1754 (C=O); 1495 (C-H); 1220 











1) BF3.Et2O, DCM, 0 oC
2) After addition of all reactants,















ESI-MS, positive mode (m/z): 411.1 (M+Na+, expected 411.36) 
Synthesis	of	1-b-hexyl-D-galactose	pentaacetate	
 
Beta-D-galactose pentaacetate (4.00 g, 10.26 mmol) was dissolved in DCM (60 mL). 
5-hexen-1-ol (1.25 mL, 12.5 mmol) was added whilst stirring in an ice bath. Boron 
trifluoride dietherate (2.70 mL, 14.2 mmol) was added dropwise. 20 minutes later, the 
reaction was taken out of the ice bath and stirred for 16 hours. Anhydrous potassium 
carbonate (2.0 g, 14.5 mmol) was added whilst stirring. 30 minutes later, the reaction 
was filtered and washed with water (2 x 100 mL) and brine (100 mL). The organic 
layer was dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by column chromatography on silica using an eluent comprising 2:3 ethyl 
acetate: 40 – 60 oC petroleum ether to yield a clear oil (1.45 g, 32.7%) 
 
1
H NMR (300 MHz, CDCl3) δppm: 5.83 (1H, m, H11); 5.41 (1H, m, H1); 5.23 (1H, 
m, H4); 5.12 (1H, m, H2); 5.00 (3H, m, H12/3); 4.49 (1H, m, H5); 3.92 (2H, m, H6); 
3.68 (2H, m, H7); 2.07 (15H, m, acetyl groups); 1.5 (4H, m, H8/9). 
13
C NMR (300 MHz, CDCl3) δppm: 114.69 (CH2, C12), 101.36 (CH, C11), 70.98 
(CH, C1), 70.60 (CH, C4), 70.00 (CH2,, 7), 68.94 (CH, C2), 67.69 (CH, C3), 67.09 
(CH, C5), 61.30 (CH2, C6), 33.31 (CH2, C10), 28.82 (CH2, C8), 25.07 (CH2, C9), 
20.69 (CH3, Acetyls). 
FTIR (solid, νmax/cm-1): 3014-2823 (alkyl/alkenyl CH2); 1743 (C=O); 1430 (weak, 
alkyl C-H); 1369 (C-O); 1216 (C-H stretch); 1045 (C-O); 906 (monosubstituted 
alkene). 












1) BF3.Et2O, DCM, 0 oC
2) After addition of all reactants,




















The following procedure describes a reaction with a theoretical degree of 
polymerisation (DP) of 100 repeat units. 4,4-azobis(4-cyanovaleric acid) (5 mg, 0.018 
mmol), 2- (dodecylthiocarbonothioylthio)-2-methylpropanoic acid (CTA, 32 mg, 
0.088 mmol) and N-hydroxyethyl acrylamide (1 g, 8.8 mmol) were dissolved in 1:1 
methanol: toluene (4 mL) in a glass vial with a stirrer bar. Mesitylene (200 μL) was 
added and a sample was removed for 1H-NMR analysis in CDCl3. The reaction 
mixture was degassed by N2 for 30 minutes, sealed and placed in a 70°C oil bath. After 
90 minutes, the solution was opened to air and quenched by submerging the flask in 
N2(l). The polymer (pHEA) was precipitated three times from methanol into diethyl 
ether to give a light yellow solid.  
 
Conversion (NMR): 83.6%; Mn (theoretical): 7051 g.mol
-1; Mn (SEC) 13904 g.mol
-
1; Mw (SEC) 14969 g.mol
-1; Mw/Mn (SEC): 1.1.  
1
H NMR (300 MHz, D4-MeOH) δppm: 4.60-4.90 (br s, H6), 3.55-3.75 and 3.05-3.20 


































FTIR (solid, νmax/cm-1):  3300 (N-H and O-H stretch), 2854 (alkyl C-H stretch), 1641 
(amide C=O stretch), 1555 (N-H bend), 1443 (alkane), 1225 (C-O stretch), 1060 (C-




The following procedure describes a reaction with a theoretical degree of 
polymerisation (DP) of 50 repeat units, with 0.9 equivalents HEA and 0.1 equivalents 
TLA. 4,4-azobis(4-cyanovaleric acid) (2.5 mg, 0.0089 mmol), 2- 
(dodecylthiocarbonothioylthio)-2-methylpropanoic acid (CTA, 32 mg, 0.088 mmol), 
N-hydroxyethyl acrylamide (0.458 g, 3.98 mmol) and N-thiolactone acrylamide (69 
mg, 0.44 mmol) were dissolved in 1:1 methanol: toluene (3 mL) in a glass vial with a 
stirrer bar. Mesitylene (100 μL) was added and a sample was removed for 1H-NMR 
analysis in CDCl3. The reaction mixture was degassed by N2 for 30 minutes, sealed 
and placed in a 70°C oil bath. After 2 hours, the solution was opened to air and 
quenched by submerging the flask in N2(l). The polymer (pHEA-co-pTLAm) was 
precipitated three times from methanol into diethyl ether to give a light yellow solid. 

















































For 5% TLAm: Conversion (NMR): 95.2%; Mn (theoretical): 4402 g.mol-1; Mn 
(SEC) 8585 g.mol-1; Mw (SEC) 9958 g.mol-1; Mw/Mn (SEC): 1.2. For 10% TLAm: 
Conversion (NMR): 93.2%; Mn (theoretical): 4540 g.mol-1; Mn (SEC) 8912 g.mol-
1; Mw (SEC) 10079 g.mol-1; Mw/Mn (SEC): 1.1. 
1H NMR (300 MHz, D4-MeOH) δppm: 7.9-8.15 (br s, N-H (H4/11)); 4.75-4.90 (br s, 
H6/14); 3.6-3.8 and 3.05-3.20 (2 x br s, H5/13); 2.55-2.7 (br s, H12 (this peak is less 
visible in 5 or 10% TLAm copolymer)), 2.00-2.40 (the left shoulder of this peak is 
less visible in 5 or 10% TLAm copolymer) and 1.50-1.85 (2 x br m, H1/2/8/9). 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2854 (alkyl C-H stretch); 1641 
(amide C=O stretch); 1555 (N-H bend); 1443 (alkane); 1225 (C-O stretch); 1060 (C-
O stretch, peak has a shoulder). 
Representative	 Double	 Modification	 of	 TLAm-containing	 copolymer:	
Aminolysis	and	Thiol-ene	“click”	
 
Polymer (100 mg of 5% pTLAm copolymer) and amine (e.g. 56 mg of 2-glucosamine, 
5 equivalents per TLAm moiety) was dissolved in 1:1 methanol: water (5 mL) and 
stirred overnight at room temperature. Alkene-galactose pentaacetate (e.g. 67.4 mg of 
1-b-allyl-D-galactose pentaacetate, 5 equivalents per TLAm moiety) and 4,4-azobis(4-






Amine (NH2R), Allyl Galactose,
1:1 Chloroform: Toluene.
25 oC, 16 hrs
ACVA, under N2 atmosphere,
















































degassed by N2 for 30 minutes, sealed and placed in a 70°C oil bath. After 2 hours, the 
solution was opened to air and quenched by submerging the flask in N2(l). The reaction 
mixture was concentrated in vacuo, re-dissolved in methanol and filtered. The polymer 
was then precipitated three times from methanol into diethyl ether to give a light 
yellow solid. The different precipitation behaviour (all polymers were very difficult to 
dissolve in solution) was an indication of successful modification. The polymer was 
subsequently dissolved in methanol (5 mL) and deprotected with sodium methoxide 
(0.5 μL of 5.4 M solution in methanol) and precipitated three times from methanol 





384-well high-binding PS plates were incubated for 16 hours with 50 μL of 100 
μg.mL-1 GM-1 glycolipid (in PBS). Unbound glycolipid was removed by washing 
with water (x3). Polymer solutions were made up as serial dilutions (up to 12 dilutions 
by 2 from 1 mg.mL-1 in HEPES). CTx-FITC (4 μL of 100 μg.mL-1 in 10mM HEPES 
buffer with 0.15 M NaCl, 0.1 mM CaCl2 and 0.01 mM Mn2+ (pH 7.5)) was added to 
36 μL of polymer solution. The CTx/polymer solutions were then transferred to the 
GM-1-coated plates and incubated at 37oC for 60 minutes. The wells were then washed 
(x3) with HEPES buffer. Fluorescence of wells was measured at excitation/emission 






































triplicate, using pure CTx-FITC wells (with no polymer) as controls. The above 
protocol is repeated for RCA-FITC to compare polymer inhibitory activity. 
Bio-layer	interferometry	assay	for	polymer	inhibitory	activity	
The tips of a row of 8 AR2G sensors were soaked in water for 30 minutes before 
running the assay. Each dipping solution was prepared in an 8-well row of a 96-well 
plate with 200 μL in each well, as follows. During the assay, these sensor tips were 
then dipped in water for baseline, dipped in EDC/NHS solution for activation, dipped 
in toxin (25 μg/mL in HEPES buffer) for loading and ethanolamine (1 M solution in 
water) for deactivation before being exposed to polymer sample solutions. Polymer 
solutions were made up as serial dilutions (7 dilutions by 10 from 1 mg.mL-1 in 
HEPES). Association was run for 15 minutes in polymer solution, followed by 








Figure 2-16. 1H-NMR spectra showing depletion of monomer vinyl peaks upon 
polymerisation. A) Formation of pHEA from HEA monomer. B) Formation of 
pTLAm from TLAm monomer. The red and blue boxes denote the vinyl peaks in the 
HEA and TLAm respectively. Here it can be seen that the HEA vinyl peak (~5.6 





Figure 2-17. 1H-NMR spectra showing difference between polymer peaks from 
pHEA (soluble in methanol) and pTLAm (soluble in chloroform). 5/10/20 % 
pTLAm content resulted in polymers still soluble in methanol. A) pHEA. B) 
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pTLAm. Asterisks denote solvent impurities: chloroform, methanol, water, acetone, 
grease, diethyl ether (used in purification). 
 
Figure 2-18. 1H-NMR spectra showing change in amide peak. A) pHEA-co-TLAm(5 
%). B) pHEA-co-TLAm(5 %) modified with glucosamine, hexenyl-β-D-galactose. 
C) pHEA-co-TLAm(5 %) modified with glucosamine, allyl-β-D-galactose. 
 




Figure 2-20. 1H-NMR spectra showing difference between polymer peaks from 
pHEA-co-TLAm 5/10/20 %  (A/B/C respectively). Top) Heteroatom region showing 
amide peak. Bottom) Polymer peak region, showing enrichment of ~2.75 ppm peak 
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with increasing proportion of TLAm. Asterisks denote solvent impurities: methanol, 
grease, diethyl ether (used in purification). 
 
Figure 2-21. Solid-phase FTIR of pHEA-co-TLAm(5 %) before and after 
modification. Brackets after polymer name indicate modification, ie.: secondary 
modification (glucosamine or benzylamine) – galactose linker (allyl or hexenyl). Of 
note are potential C-O sugar peaks at ~1000 cm-1 and a shoulder on the ~ C=O peak 
suggesting an additional C=O amide peak in the modified samples. 
 
Figure 2-22. Solid-phase FTIR of pHEA-co-TLAm(10 %) before and after 
modification. Brackets after polymer name indicate modification, ie.: secondary 
modification (glucosamine or benzylamine) – galactose linker (allyl or hexenyl). Of 
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note are potential C-O sugar peaks at ~1000 cm-1 and a shoulder on the ~ C=O peak 
suggesting an additional C=O amide peak in the modified samples. 
 
 
Figure 2-23. Solid-phase FTIR of pHEA-co-TLAm(20 %) before and after 
modification. Brackets after polymer name indicate modification, ie.: secondary 
modification (glucosamine or benzylamine) – galactose linker (allyl or hexenyl). Of 
note are potential C-O sugar peaks at ~1000 cm-1 and a shoulder on the ~ C=O peak 




Figure 2-24. DMF SEC molecular weight traces for modification of pHEA-co-
TLAm(5 %). Several traces are bimodal potentially due to transesterification 
reactions having taken place. 
 










Figure 2-27. 1H-NMR spectra showing difference between allyl-D-galactose 
precursor (A) and pTLAm homopolymer modified with this compound (B). Key is 
the loss of the acetate peaks at ~2-2.5 ppm. Asterisks denote solvent impurities: 




Figure 2-28. Fitted Microplate assay binding curves with CTxB for pHEA-co-TLAm 
(5 % TLAm) with different galactose linkers and secondary unit modifications. Data 





Figure 2-29. Fitted Microplate assay binding curves with CTxB for pHEA-co-TLAm 
(10 % TLAm) with different galactose linkers and secondary unit modifications. 
Data was fitted using a heterogeneous sites (2:1) model. It is possible that, excluding 
the high polymer concentration values in the hexenyl graphs, a sigmoidal fit might 






Figure 2-30. Fitted Microplate assay binding curves with CTxB for pHEA-co-TLAm 
(20 % TLAm) with different galactose linkers and secondary unit modifications. 
Data was fitted using a heterogeneous sites (2:1) model. It is possible that, excluding 
the high polymer concentration values in the benzylamine/hexenyl graph, a 





Figure 2-31. Fitted Microplate assay binding curves with RCA120 for pHEA-co-
TLAm (5 % TLAm) with different galactose linkers and secondary unit 
modifications. Data was fitted using a heterogeneous sites (2:1) model. Note that a 
peak is seen in the hexenyl samples at ~0.078 mg/mL polymer, potentially signifying 





Figure 2-32. Fitted Microplate assay binding curves with RCA120 for pHEA-co-
TLAm (10 % TLAm) with different galactose linkers and secondary unit 
modifications. Data was fitted using a heterogeneous sites (2:1) model. Note that a 
peak is seen in the hexenyl samples at ~0.078 mg/mL polymer, potentially signifying 





Figure 2-33. Fitted Microplate assay binding curves with RCA120 for pHEA-co-
TLAm (20 % TLAm) with different galactose linkers and secondary unit 
modifications. Data was fitted using a heterogeneous sites (2:1) model. Note that a 
peak is seen in the hexenyl samples at ~0.078 mg/mL polymer, potentially signifying 





Figure 2-34. Fitted Microplate assay binding curves with CTxB and RCA120 for 
pTLAm homopolymer with allyl-β-D-galactose and different secondary unit 
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Figure 2-35. BLI fitted curves with CTxB for pHEA-co-TLAm (5 % TLAm) with 




Figure 2-36. BLI fitted curves with CTxB for pHEA-co-TLAm (10 % TLAm) with 






Figure 2-37. BLI fitted curves with CTxB for pHEA-co-TLAm (20 % TLAm) with 






Figure 2-38. BLI fitted curves with RCA120 for pHEA-co-TLAm (5 % TLAm) with 






Figure 2-39. BLI fitted curves with RCA120 for pHEA-co-TLAm (10 % TLAm) with 






Figure 2-40. BLI fitted curves with RCA120 for pHEA-co-TLAm (20 % TLAm) with 









Figure 2-42. kdis values by polymer concentration. Axes labels for polymers are in 
the format TOXIN-TLAmDensity-SecondaryModification-AlkeneGalactoseLinker. 
Due to the sensitivity limitations of the instrument, 1 x 10-7 is the minimum value 
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3.Multivalent presentation of antifreeze 
macromolecules, polymers and 
proteins 
3.1. Chapter summary 
Understanding the activity and more of action of both antifreeze proteins and synthetic 
mimics is required to translate them to applications. In particular the impact of 
architecture is of interest in its capacity for multiple binding to the same ice face, or 
bridging to other ice crystal faces.  
Herein a multivalent AFP type III was conjugated to an AuNP scaffold with various 
types of linkers. The AFP-SNAP recombinant attached to the AuNP scaffold showed 
enhanced activity relative to the same number of moles of free AFP, which confirms 
the assertion that a larger linker length is required to make the entirety of AFP’s ice 
binding face available. 
PVA of different lengths was also conjugated to an AuNP scaffold, which was 
expected to have reduced IRI activity relative to linear PVA of the same molecular 
weight. This was not the case with larger PVA, however, and it is proposed that this 
is due to a relatively low grafting density resulting in an increased freedom of 
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Cryopreservation of human tissues and cells remains a major challenge in all health 
systems and their related industries. Cold storage of material for future use, or for 
transportation to where it is needed, requires additives to ensure the material is not 
damaged in the freezing or thawing process. These additives tend to be in the form of 
osmolytic cryopreservatives that dehydrate cells, and current formulations often 
include glycerol or DMSO, which can cause damage themselves to the material 
stored.1–3 Therefore it stands to reason that cryopreservatives used by cold-surviving 
organisms in nature can form the basis for developing novel, more suitable, 
procedures. 
Antifreeze proteins are expressed by a variety of cold-dwelling organisms and have a 
variety of different methods of binding to ice to inhibit its growth: from bacterial 
ability to bind to ice and form a biofilm, to Arctic fish inhibiting the growth of lethal 
ice shards in its blood.4–10 Fish express antifreeze glycoproteins and type I, II and III 
antifreeze proteins. The AFPs are classified by their general structure and the planes 
of ice that they bind to. A commonly-used AFP class, type III AFP, are small (~6.5 
kDa), globular proteins with a single α-helix turn and several short β-strands. These 
type III AFPs’ mode of action is through a binding site that binds both the secondary 
and pyramidal planes of ice (shown in Figure 3-1), though how this planar specificity 
is achieved is unknown. The particular antifreeze activity of interest is ice 
recrystallization inhibition (IRI) as it is this activity that inhibits the potentially-lethal 
Ostwald ripening process in nature whereby smaller ice crystals melt whilst the larger 
crystal grow inside the organism. The antifreeze activity of such macromolecules can 
also be detected as thermal hysteresis (TH) activity; a depression in the freezing point 




Figure 3-1. The antifreeze protein family, with a focus on the properties of type III 
AFP. The antifreeze protein family, with a focus on the properties of type III AFP. 
The following PDB files were used for structures: 1MSI for AFGP; 4DTS for insect 
AFP; 1WFA for type I; 2PY2 for type II and 1OP2 for type III AFP. 
AFP function may be enhanced through its fusion to a larger scaffold; for example, 
Baardsnes et al. in 2003 developed a dimer with two AFP binding sites at opposite 
ends of the molecule.11–20 In this study they showed a gain in antifreeze activity (0.8 
instead of 0.4 °C thermal hysteresis activity for the dimer rather than the monomer 
with 1 binding site knocked out) attributed to the simultaneous binding of two ice sites 
(not just multivalency), and that was only present when the AFP’s entire binding site 
was sterically available. This study was supported by the work of both Can et al.15 and 
Phippen et al16., who developed a trimer and an oligomer respectively with several-
fold increases in TH activity. It was proposed that this activity results from the capacity 
to span the interstitial space and bind several ice crystals at once. Stevens et al.12 
synthesized a dendrimer-linked AFP that also showed small enhancements to TH 




Figure 3-2. Hypotheses for beneficial interactions of antifreeze protein multimer 
constructs with the ice surface. 
Many of these studies suggested a binding model wherein the larger size of the 
scaffold onto which the AFP is bound, and its orientation, is key due to the necessity 
of having the entire AFP binding site available to bind several ice sites simultaneously. 
Moreover, Stevens et al. proposed that the size of the AFP on a small scaffold inhibits 
the capacity for more than a few AFPs bound on the same scaffold to bind to the same 
surface, but that upon increasing the size of this scaffold more AFPs on the same plane 
are able to interact with ice. 
Other enhancements to the activity of these AFP molecules can be achieved through 
the synthesis of macromolecular mimics: those that retain their IRI and TH activity 
but without the need to use recombinant protein, which can have lower yields and be 
more expensive to manufacture. Polymers are a good choice for these mimics as facile 
synthesis can afford the large molecule sizes required for mimicking AFP activity. A 
variety of such materials have been proposed, from metallohelices to self-assembled 
amphipathic fibres.1,6,21–24 One particular material of interest is poly(vinyl alcohol) 
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(PVA), which has molecular weight-dependent antifreeze activity but actually little 
similarity to the natural AFPs.25–32  
PVA has both IRI activity, the capacity to shape ice crystals and weak TH activity: 
several studies have emerged showing its potential for use in cryopreservation due to 
its biocompatibility.3,33 Congdon et al.32 found that PVA chain of over ~15 units 
displayed IRI activity, maintained at concentrations as low as 0.05 mg.mL-1, but that 
the removal of 20 molar % hydroxyls from the chains resulted in a marked decrease 
in activity. This suggests that the conformation of the pure PVA chain is essential to 
its antifreeze activity, or hydrogen bonding to the ice surface. Congdon et al. also saw 
3-armed PVA stars had equal activity to 2-arm stars, which suggests that branching is 
unfavourable.34  
 
Figure 3-3. The binding of PVA structures to the ice crystal prismatic face from 
modelling data. Figure from Naullage et al.25 The spacing of the hydroxyl residues 
allows pattern matching along the c axis. with a 2-arm PVA (a), but this is not 
possible with the 3-arm structure (b) due to different hydroxyl spacing in this 
dimension. Red circles indicate binding to the ice hydroxyls, whilst blue circles are 
residues not bound. 
Computational work by Naullage et al.25 elucidated that PVA binding to the prismatic 
plane of ice through a zipper-like mechanism wherein each residue attaches to the ice 
surface following its neighbour. It was indicated that this binding is not enhanced 
through branching of the PVA, as the 3rd arm could not engage in favourable hydrogen 




3.4. Chapter aims 
Understanding the relationship between the valency and the antifreeze activity of both 
antifreeze proteins and synthetic mimics is key in enhancing this activity. There are 
currently differing accounts in the literature as to whether multivalent analytes have 
more activity than the equivalent molar concentration of the monovalent analyte. To 
this end, the aims of this chapter are as follows: 
o To establish synthetic routes to spherical AFP hybrid materials through the use 
of gold nanoparticle scaffolds. 
o To obtain structure-function relationships in branched materials through the 




3.5. Results and Discussion 
 
Scheme 3-1. Synthesis of antifreeze/AuNP conjugates. 
 
3.5.1. Synthesis of small gold nanoparticle “templates” 
In order to obtain multivalent AFPs, small spherical AuNPs (<5 nm diameter) were 
synthesized. The small size of these AuNPs allows the development of dendrimer-like 
structures using an easily conjugated core. Two different methods were used for this 
synthesis: 1) the citrate reduction method, wherein gold chloride and citrate are mixed, 
with larger concentrations of citrate employed to “cap” larger AuNP growth; 2) the 
citrate reduction method, adding ice-cold sodium borohydride as a reducing agent in 
order to slow the formation of larger nanoparticles by conjugating gold atoms.35–38 
 
Scheme 3-2. Synthesis of PVA and attachment to AuNPs. 
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The size of these AuNPs was assessed initially by DLS. DLS is used to determine the 
distribution of particle sizes in a solution. A monochromatic light source is shone into 
the sample, and the pattern of diffracted (or scattered) light resulting from the sample 
is measured. An autocorrelator compares the pattern of scattered light at short time 
intervals, and measures the decay of the correlation. Smaller particles move more 
rapidly in solution, resulting in faster decay, and therefore the decay of the 
autocorrelation function can be determined as a function of particle size in solution. 
Initial assessment demonstrated that NaBH4 was required for the formation of 
diameters <5 nm: the standard citrate reduction method resulted in ~15 nm 
citrate@AuNP diameters, see Figure 3-14 in appendix. 
To narrow the distribution of AuNP sizes, the solution was centrifuged and the 
supernatant taken to remove a low number of larger nanoparticles.39–41 These solutions 
are also not stable over longer than several months due to the tendency of these 
relatively-unstable citrate@AuNPs to aggregate. 
3.5.2. Synthesis of thiol-terminated poly(vinyl acetate) and 
attachment to gold nanoparticles 
Various lengths of thiol-terminated PVA were synthesized by RAFT/MADIX 
polymerization procedure (which varies from RAFT only by the use of a xanthate 
mediator rather than a dithioester or thiocarbamate), installing a thiol at the ω-terminus 
via a xanthate chain transfer agent (S-benzyl O-ethyl carbodithioate). Various ratios 
of chain transfer agent were employed to produce a panel of poly(vinyl acetate)s 
(PVAcs), which were then deprotected with hydrazine to produce a library of thiol-
terminal PVAs. Successful deprotection was demonstrated by the loss of acetate 
methyls in 1H-NMR. SEC characterisation demonstrated the removal of acetates and 
dispersity of the PVAcs, confirming agreement with theoretical Mn values, and the 
dispersity values suggested a reasonably narrow dispersity with the monomer used, 





Scheme 3-3. Synthesis of PVA and attachment to AuNPs. 
 
Figure 3-4. SEC molecular weight distributions showing the library of PVA 
polymers used in this study. 




Mn (THEO)   
(g.mol-1)b 
Mn (SEC)   
(g.mol-1)c 
Đc 
PVAc6 10 72 600 500 1.41 
PVAc18 40 59 2,000 1,600 1.24 
PVAc42 60 68 3,500 3,600 1.38 
PVAc98 100 45 3,900 8,500 1.37 
PVAc140 250 56 12,000 12,000 1.53 
a Monomer to RAFT agent molar ratio; b Determined by depletion of vinyl peaks in 
1H NMR using mesitylene as an internal standard; c Determined by SEC. 
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To form multivalent PVAs, synthesized PVAs were dissolved in citrate@Au4 solution 
and incubated on a roller for 1 hour at room temperature before washing 4 times to 
remove excess polymer in solution. It was immediately apparent that several of the 
PVA-AuNP samples were unstable due to a red shift in their UV-Vis spectrum, which 
is indicative of aggregation. Therefore only two of the PVA-AuNP samples were used 
for further characterisation and analysis: PVA98@Au4 and PVA140@Au4. 
Table 3-2. Poly(vinyl acetate)/AuNP conjugate characterisation. 
Particle Dh (DLS) (nm)a DTEM (nm)b ζ potential (mV)c SPRmax (nm)d 
Citrate@Au4 4.3 ± 6.8 3.9 ± 0.7 -19.4 ± 2.7 e 510 
PVA98@Au4 18.2 ± 5.6 4.4 ± 1.4 -5.5 ± 0.6 f 522 
PVA140@Au4 19.4 ± 9.0 3.6 ± 0.9 -4.5 ± 0.4 f 521 
a Hydrodynamic diameter determined by DLS distribution by number of particles, 
averaged over 3 measurements; b Gold core diameter, average of 100 particles by 
TEM; c Averaged over 3 measurements; d Maximum of SPR peak determined by 
UV-Vis spectroscopy; e Solution pH 8.93; f AuNPs suspended in PBS buffer, pH 
7.25. 
Changes in size and shape of these conjugates were assessed using DLS and 
transmission electron microscopy (TEM) measurements. TEM involves firing an 
electron beam through an ultrathin sample, and measuring the electrons transmitted. 
AuNPs have high contrast in TEM, and therefore this technique is ideal in visualising 
the NP core of these samples. In the conjugation of PVA to the citrate@Au4 samples, 
the AuNP core did not change significantly in shape or size, with all samples being 
around 4 nm. In the analysis of the PVAn@Au4 samples relative to the citrate@Au4 
precursors, the DLS size distribution did not broaden, but an increase in the 
hydrodynamic diameter is observed, as expected with the conjugation of ~100/150 DP 
PVA on a small AuNP core. 
Successful conjugation of PVA to the AuNP core was also assessed by X-ray 
photoelectron spectroscopy (XPS) and zeta potential measurements. XPS entails 
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irradiation of the surface (penetrating up to 10 nm into a sample) of dried samples with 
an x-ray bean, and measuring the kinetic energy and number of escaped electrons. This 
data enables determination of the elemental composition of a sample as it changes 
upon modification (though some contaminants are possible in the modified samples 
relative to the citrate@Au4 starting material). Polymer conjugation to the gold surface 
was detected as a change in the organic character of the sample: such as an increase in 
the N 1s peak from 0 (citrate@Au4) to 1.5 % and 0.3 % (PVA98@Au4 and 
PVA140@Au4 respectively), and an increase in the C 1 s peak from 46 % in the 
precursor to ~65 % in both PVA@AuNP conjugates. Due to the presence of surface 
coatings, a decrease in Au 4f composition from 0.3 to 0.04 % was also observed.  
 
Figure 3-5. Characterisation of PVA@Au4 samples. A-C) TEM micrographs of 
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citrate@Au4, PVA98@Au4 and PVA140@Au4 respectively. D) Size data from 
TEM. E) Size distributions by number of particles, from DLS measurements. F) C 1s 
peak from XPS spectrum showing carbon enrichment upon PVA conjugation. G) 
Photograph showing the red shift of smaller PVA chains conjugated to Au4: the 
“more blue” PVA6, PVA18 and PVA42@Au4 samples aggregated. 
Zeta potential is a measure of surface charge of particles in a solution, as a difference 
in charge between the particle surface and bulk solution. The citrate-stabilised gold 
has a more negative zeta potential, at -19 mV, but this becomes significantly less 
negative upon polymer conjugation, at -5.5 and -5 mV for the PVA98 and 
PVA140@Au4, as the electrostatically-bound citrate ions are replaced. This change in 
charge indicates a change in the surface composition of the AuNPs. 
To ascertain the mass of polymer coated onto the AuNP scaffold, thermogravimetric 
analysis (TGA) was used. This is as a simple procedure wherein a dried sample is 
heated gradually, and the organic components’ decomposition can be observed as a 
mass loss. The mass of polymer attached for a given solution of gold nanoparticles 
was determined, as 0.24 mg of PVA98 and 0.32 mg of PVA140 present in 1 mL of 
undiluted PVA@Au4 solution, and this allows calculation of the density of these 
polymers on the AuNP surface. The removal of free PVA was confirmed through IRI 
assays of the washing steps, as detailed in the next section. 
3.5.3. IRI activity of PVA@Au4 conjugates 
The IRI activity of these PVA@Au4 particles was determined by the “splat” assay, 
wherein small ice crystals formed at -80 °C were incubated at -8 °C for 30 minutes to 
observe Oswald ripening to form larger ice crystals. Smaller ice grain sizes relative to 
a PBS control indicate greater IRI activity. From previous studies of branched PVA 
structures, we expect branched structures only to show comparable activity to their 
longest (highest molecular weight) linear chain. This is because the hypothesized 
binding mode of PVA molecules to ice is via a pattern matching of hydroxyl residues 
along the c axis of the ice crystal prismatic face, which is not possible with a branched 
arm.25 
To ensure free PVA was not present, supernatants were also assayed for IRI. These 
measurements showed IRI activity in the first wash, demonstrating that free PVA was 
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removed in the washing steps, but not in the two final washes, demonstrating that no 
more free PVA was present. 
 
Figure 3-6. Characterisation of IRI activity of PVA@Au4 samples. A-B) Size of ice 
grains in PVA98 and PVA140 samples respectively by “splat”. “Splat” optical 
micrograph scale bars are 10 μm. MGS denotes the mean grain size of all ice grains 
visible by light microscopy. Note that only 2 measurements of the PVA98@Au4 were 
taken as there was a large grain size at a high concentration, indicating that this 
analyte did not reduce ice grain size. 
Free PVA of both chain lengths gave ice crystals of less than 20 % the size of the PBS 
control ice crystals at around 0.1 mg.mL-1 concentration, demonstrating high IRI 
activity. At the same concentration of PVA98@Au4, ice crystals grew to 80 % of the 
size of the PBS control, showing that IRI activity of these PVAs is decreased upon 
tethering to an AuNP scaffold. Conversely, the PVA140@Au4 conjugates retained IRI 




Figure 3-7. Ice shaping and binding images. Full figure taken from Stubbs, C., 
Wilkins, LE. et al.42 A-C) Cryomicrographs from sucrose “sandwich” ice shaping 
assays showing ice shapes in H2O (-6 °C), PVA140 (-5.5 °C, 0.2 mg.mL-1) and 
PVA140@Au4 (-4.0 °C, 0.2 mg.mL-1  of PVA) samples respectively, with zoomed 
images of crystals of interest. Scale bars = 100 μm.  D) Pattern-matching of PVA to 
ice prismatic face. E) 3-arm PVA star structure binding to ice, with the third arm 
showing little binding due to a pattern mismatch. Red circles indicate binding to the 
ice hydroxyls, whilst blue circles are residues not bound. Adapted from Naullage et 
al25. F) Schematic of PVA@AuNP binding to ice prismatic face, wherein the low 
grafting density, with the long PVA chain length, does not constrain the polymer’s 
orientation. 
Sucrose “sandwich” assays were also performed to allow visualisation of ice crystal 
shape, with change relative to a control with no PVA indicating ice-binding (see 
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Figure 3-7). In these assays, test solution is added to a concentrated sucrose solution 
(used to reduce the rate of ice growth and nucleation), and placed onto a 
cryomicroscopy stage, with the temperature gradually lowered until ice crystals are 
visible. Without a test solution, disc-like ice shapes are observed. Both the free PVA 
and PVA conjugate samples had different ice shapes to the control, with dendritic ice 
crystals forming (see Figure 3-7), confirming that these materials are indeed binding 
to the ice surface.  
These IRI and ice shaping assays together suggest that these PVA/AuNP hybrid 
materials retain the full activity of free PVA polymers despite the immobilisation of 
the PVA chain end. Previous studies have showed that the longer PVA molecules 
account for the majority of the polymer solution’s IRI activity26, and that PVA’s IRI 
activity may be attributed to a “zipper mechanism” whereby binding of repeat unit 
residues in a chain leads to facile binding of the subsequent residues in the chain25. It 
should also be noted that previous studies exploring the activity of branched PVA have 
not involved branched chains of ~100 chain length. Therefore we could hypothesize 
that part of the retained activity of our PVA140@Au4 conjugates may stem from the 
>100 DP length of PVA “branches” applied to the scaffold. With a longer PVA chain, 
the activity of the residues may be less sterically constrained by the AuNP scaffold 
(see Figure 3-7), and more able to orientate itself to interact favourably with the ice 
crystal prismatic face. This enhanced freedom of movement may also be attributed to 
the low grafting density of PVA on the AuNP scaffold. These data signify that, in the 
design of such PVA/NP materials, the grafting density and polymer chain length must 
both be considered to retain the capacity to bind the ice prismatic face, which confirms 




3.5.4. Synthesis of pentafluorophenol-terminated RAFT 
polymers and post-polymerisation modification of end 
group 
Encouraged by results PVA@AuNP, we wanted to see if similar results are obtained 
for AFP@AuNP hybrids, which may interact by different mechanisms. Therefore we 
devised a conjugation method to enable multivalent presentation of AFPs (see Scheme 
3-4). 
 
Scheme 3-4. Synthesis of PFP-pHEA polymers and post-polymerisation 
modification to add functional primary amine group. 
RAFT polymerisation was utilised to synthesize pentafluorophenol-terminal 
poly(hydroxyethyl acrylamide) (PFP-pHEA), with a PFP-ester at the α-terminus and 
a trithiocarbonate at the ω-terminus. These polymers were synthesised to serve as 
steric stabilisers on the surface of AuNPs that may be functionalised to capture a 








































































PFP-pHEA17 d 26 64 17 2,500 3,000 1.1 
PFP-pHEA45 e 47 94 45 5,700 8,300 1.1 
PFP-pHEA47 f 47 94 45 5,700 8,300 1.1 
PFP-pHEA95 103 93 95 11,000 15,000 1.3 
a Monomer to RAFT agent molar ratio; b Determined by depletion of vinyl peaks in 
1H NMR using mesitylene as an internal standard; c Determined by SEC; d Used in 
His-AFP-Ni-NTA-pHEA17@Au4 conjugates; e Used in SNAP-AFP-BG-
pHEA45@Au4 conjugates; d Used in Maleimide-pHEA47@Au4 conjugates. 
PFP-terminated polymers with three different chain lengths were synthesized: 
approximately 25, 50 and 100 monomers in length. 1H-NMR was used to determine 
the theoretical Mn, by observing the reduction of the vinyl peak relative to a mesitylene 
standard peak. SEC, 1H and 19F-NMR were used to confirm the molecular weight, 




Figure 3-8. Characterisation of PFP-pHEA library, and the removal of the PFP 
group. A-B) 19F-NMR spectra showing depletion of PFP peaks. C-D) FTIR spectra 
showing depletion of C-F peaks at 1070 cm-1. E) Molecular weight distributions, by 
SEC, of PFP-pHEA library. 
The α-terminus was functionalised through the replacement of the PFP group with 
amino-benzylguanine (BG) or Nα,Nα-Bis(carboxymethyl)-L-lysine hydrate (NTA). 
Successful displacement was confirmed by 19F-NMR, by the removal of the three PFP 
peaks at ~155-165 ppm, and by the depletion of ~1750 cm-1 C-F peaks in FTIR (Figure 
3-8). The use of excess primary amine in this reaction is also expected to displace the 
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RAFT chain transfer agent end group to liberate a ω-terminal thiol: as required for 
AuNP immobilisation. 
3.5.5. Synthesis of AFP@Au4 conjugates 
Two different linkers were used to attach AFP to the AuNP scaffold: 1) Ni-NTA-
pHEA of relatively short length to interact electrostatically with His-AFP; 2) BG-
pHEA of ~50 chain length to interact with the large SNAP tag via covalent attachment 
of the benzyl group to a cysteine. A maleimide-pHEA of ~50 chain length was also 
attempted to interact via a bioorthogonal “click” to a recombinant terminal cysteine, 
but these conjugates were not stable in initial screens, so were discarded. 
 
Scheme 3-5. Synthesis of AFP@AuNP conjugates. 
All NTA-, BG- and PFP-pHEA polymers were dissolved in citrate@Au4 solution and 
incubated at room temperature for 1 hour on a roller before being washed at least 3 
times to remove excess, unattached, polymer. Polymer@Au4 samples were initially 
assessed by UV-Vis spectroscopy and DLS size measurements to determine the most 
stable chain length of pHEA polymer. Larger shifts in size or the presence of multiple 
peaks by DLS size measurements and large shifts in UV-Vis SPRmax showed 
aggregation. From these analyses, the most stable polymer@Au4 samples were 
selected for further characterisation and protein attachment: NTA-pHEA17, BG-
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pHEA45, PFP-pHEA47@Au4. Polymer of ~50 chain length were required to stabilise 
the benzylguanine and pentafluorophenyl terminals conjugated to the AuNP, 
potentially due to their hydrophobic nature requiring a longer length of hydrophilic 
polymer. On the other hand, the more hydrophilic NTA end group required only a 
shorter, ~25, chain length polymer. The NTA-pHEA17@Au4 sample was 
functionalised with Nickel (II), and this sample was shown not to aggregate by 
analysis by DLS and TEM.  
The PFP-pHEA47@Au4 sample was subjected to the same conditions as the PFP-
pHEA precursor polymers: heated overnight with excess maleimide amine and 
triethylamine to substitute the PFP group for the desired maleimide. The removal of 
this PFP end group was performed after AuNP conjugation rather than earlier to avoid 
forming a cross-linked polymer. Successful modification of the polymer end group 
was determined by XPS and zeta potential analysis, showing a loss of fluorine and a 
change in surface charge respectively. This maleimide-pHEA47@Au4 began to 
sediment out of solution when stored in PBS solution in the fridge overnight so was 
deemed unstable. The sample was thus not fully characterised. 
Recombinant AFP type III from ocean pout (N-terminally modified His-AFP, SNAP-
AFP and Cys-AFP) were produced by Dr. Muhammad Hasan, University of Warwick 
by recombinant expression in E. coli followed by IMAC purification and HPLC. His- 
and SNAP-AFP were incubated for 2 hours on a roller at room temperature with the 
prepared AuNP scaffold (Ni-NTA-pHEA17@Au4 and BG-pHEA45@Au4 
respectively). These incubations were then washed at least 4 times to remove excess 
AFP. 
Table 3-4. AFP@Au4 nanoparticle characterization  
Particle Dh (DLS) (nm)a DTEM (nm)b ζ potential (mV)c 
Citrate@Au4 4.3 ± 6.8 3.9 ± 0.7 -19.4 ± 2.7 d 
NTA-pHEA17@Au4 8.5 ± 8.3 3.7 ± 0.8 -15.9 ± 4.8 e 
Ni-NTA-pHEA17@Au4 7.7 ± 7.2 3.9 ± 0.8 -6.2 ± 1.1 f 
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His-AFP@Au4 8.9 ± 9.7 4.3 ± 0.9 -7.0 ± 1.3 f 
BG-pHEA45@Au4 16.5 ± 10.6 3.9 ± 1.0 -10.2 ± 1.9 e 
SNAP-AFP@Au4 8.9 ± 10.3 4.0 ± 1.1 -4.4 ± 0.9 f 
a Hydrodynamic diameter determined by DLS distribution by number of particles, 
averaged over 3 measurements; b Gold core diameter, average of 100 particles by 
TEM; c Averaged over 3 measurements; d pH 8.93; e pH 7.6; f AuNPs suspended in 
PBS buffer, pH 7.25. 
 
Figure 3-9. Characterisation of AFP@Au4 particles. A-B) Size distributions by 
number of particles, from DLS measurements, of SNAP-AFP-BG-pHEA45@Au4 
synthesis and His-AFP-Ni-NTA-pHEA17@Au4 respectively. C-E) TEM micrographs 
of citrate@Au4, SNAP-AFP@Au4 and His-AFP@Au4 respectively. F) Size data 
from TEM. 
DLS and TEM measurements were used to assess the shape and size of all successfully 
conjugated, stable AuNP samples. TEM showed no significant change in the size and 
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shape of the AuNP core, with a size of 4 nm for all AuNPs. DLS showed an increase 
in the hydrodynamic volume (an indication of the size of the AuNP and protective 
shell in solution) of the conjugates relative to the citrate@Au4 precursors without a 
significant broadening of the size distributions that would suggest aggregation. The 
hydrodynamic diameters of the His-AFP and SNAP-AFP@AuNP conjugates were 
both 4.5 nm greater than the citrate@Au4 (4.3 nm diameter), which demonstrates that 
the coatings caused a significant change in AuNP solution behaviour. 
 
Figure 3-10. Characterisation of AFP@Au4 AuNP coatings. A-B) N 1s peak from 
XPS spectra showing change upon conjugation of AFP protein – note that the 
different samples were not subjected to the same conditions before performing this 
analysis. C-D) Zeta potential change upon conjugation of AFP protein, from 
readings in triplicate. 
Successful conjugation of polymers, followed by modifications and protein, were 
assessed by XPS and zeta potential measurements, with the former allowing 
determination of the elemental composition of a sample (though some contaminants 
are possible in the modified samples relative to the citrate@Au4 starting material). 
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Upon the conjugation of the recombinant AFPs, the organic character of the samples 
changed. For example, the N 1s proportion increased from 0 % in the citrate@Au4 to 
~12 % in both AFP@AuNP conjugates, whilst the O 1s peak decreased from 53 % to 
22 % and 25 % in the His-AFP and SNAP-AFP@AuNP conjugates respectively. The 
Au 4f peak also decreased from 0.33 % in the citrate@Au4 to 0.19 and 0.17 in the His-
AFP and SNAP-AFP@AuNP conjugates respectively. These changes evidence 
successful successive coating of the AuNPs, and the conjugation of organic molecules. 
The analysis also showed the change in specific peaks to evidence a specific change 
in composition: with a loss of the fluorine 1 s peak upon substituting the maleimide 
end group for the pentafluorophenol on the PFP-pHEA47@Au4, and a decrease in the 
Ni 2p peak from 0.15 to 0.12 % when His-AFP is conjugated to the Ni-NTA-
pHEA45@Au4. 
The zeta potential shows the surface charge of the AuNPs, and changes in this result 
from a change in surface composition. The zeta potential of the citrate@Au4 
precursors was approximately -19 mV, and conjugation of polymer resulted in a 
reduction in negativity, due to the replacement of surface citrate ions to around -16 
and -10 mV for the NTA-pHEA and BG-pHEA@AuNP conjugates respectively. The 
conjugation of AFP decreased this negativity again by over 5 mV for both samples, 
which shows a further change in surface composition. 
In order to confirm that all SNAP-AFP present in the SNAP-AFP@Au4 conjugate 
solutions was tethered to the AuNP scaffold, the concentration of SNAP-AFP in the 
post-conjugation washes was determined by nanodrop absorption analysis. These 
measurements showed that no free SNAP-AFP was present in the third and fourth 
washes, so no free AFP will be present in the final conjugate solutions. TGA was used 
to determine the mass of organic matter attached to the inorganic AuNPs in each 
sample. Upon each successive conjugation, the mass of coating added was determined 
from the change in mass of the sample, showing there to be approximately 4 μg BG-
pHEA45 and 0.64 mg SNAP-AFP in 1 mL of undiluted SNAP-AFP@Au4 conjugate 
in PBS.  
Finally, SEC and SDS-PAGE were used to determine that a covalent linkage occurred 
between the SNAP-AFP and BG-pHEA45. A shift was observed in the SEC sample 
containing both AFP and polymer, relative to both the free SNAP-AFP and BG-
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pHEA45 (see Figure 3-11), which suggests that at least some of the molecules have 
bound to each other. By SDS-PAGE, mixing the BG-pHEA45 and SNAP-AFP together 
resulted in an increase in molecular weight (an shift upwards in the gel, closer to the 
35 kDa molecular weight mark). 
 
Figure 3-11. BG-pHEA45/SNAP-AFP interaction. A) SEC showing peak shift upon 
polymer conjugation. B) Blot of SDS-PAGE gel showing shift in molecular weight 
upon conjugation. 
 
3.5.6. IRI activity of AFP@Au4 conjugates 
Previous investigations have shown an increase in antifreeze activity upon the 
development of multimeric AFP structures.12–14,17,19 In this study we therefore 
synthesized a multimeric scaffold on which to attach several AFPs. Three different 
protein tags were employed with the aim of investigating the impact of different linker 
types and lengths on AFP’s antifreeze activity. For the three different protein tags, 
three different polymer linker structures were proposed to bridge the AFP to the AuNP 
scaffold: 1) the relatively short Ni-NTA-pHEA17 interacts electrostatically with the 
His tag; 2) the large BG-pHEA45 forms a covalent bond to the SNAP tag; 3) 
maleimide-pHEA47 was proposed to attach Cys-AFP to Au4, but this conjugate was 
unfortunately not stable in PBS buffer. 
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It has been shown previously that the entire AFP ice-binding site must be sterically 
available to see the gain in antifreeze activity with multimeric AFP designs. This 
suggests that a large scaffold, or longer linker to a scaffold, is preferable to give the 
attached AFP the freedom of movement to orientate its ice-binding site favourably – 
and enhanced activity from these constructs would suggest an ice crystal bridging 
hypothesis of IRI enhancement. Meanwhile, a smaller scaffold, or shorted linker to a 
scaffold, would result in the AFP molecules spacing closer together, which would 
support the hypothesis of multiple AFPs binding to the same surface enhancing IRI 
activity. In this study, it was therefore possible to directly compare the shorter His tag 
linker directly to the longer SNAP tag linker to see which of these hypotheses was 
supported in our results. 
 
Figure 3-12. Characterisation of IRI activity of AFP and AFP@Au4 samples. A-B) 
Size of ice grains in PVA98 and PVA140 samples respectively by “splat” assay. 
“Splat” optical micrograph scale bars are 10 μm. 
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The “splat” assay is used to probe IRI activity by measuring the capacity of an analyte 
to inhibit the ice nucleating Oswald ripening effect during a 30 minute incubation at -
8 °C. Larger ice crystals form in samples with less IRI activity (relative to a PBS 
control). These assays compared AFP conjugates to the same concentration of free 
monomeric recombinant AFP to allow a direct comparison in molar concentration. As 
expected, even at concentrations less than 20 μg.mL-1, the unconjugated recombinant 
AFPs showed ice crystals at less than 30 % of the size of ice crystals in the PBS 
control. The His-AFP@Au4 conjugates showed ice crystals at 90% the size of the PBS 
control up to 2 mg.mL-1, which suggests that the conjugation process inhibits the 
activity of the AFPs. As the linker used is site-specific, this could be due to the use of 
a non-covalent linker, or due to the smaller linker length resulting in steric hindrance 
of the ice-binding site. 
Conversely, SNAP-AFP@Au4 showed higher IRI than free monomeric SNAP-AFP, 
with ice crystals ~10 % smaller in size for the conjugates relative to the equivalent 
concentration of free SNAP-AFP up to 0.5 μg.mL-1. This enhanced activity could 
suggest that either a covalent linker is required, or that a lower surface density, longer 
linker and large fusion protein tag allows freer movement than the His-AFP conjugates 
with a shorter linker. This may support the hypothesis of enhancement by bridging 
between ice crystals, but it is unclear, however, how large the scaffold must be to 
enhance antifreeze activity with this mechanism. We would need to understand the 
spacing of these ice crystals in nature to know whether this mechanism is viable at all. 
In biological systems, AFP results in the formation of shard-like ice crystal shapes, 
which can damage cells. Ice shaping assays were performed in sucrose solution 
sandwiched between two glass cover slips to allow visualisation of the ice shapes 
formed upon the addition of the monomeric and multimeric SNAP-AFP samples. The 
recombinant His and SNAP-AFP samples resulted in sharp linear shapes, similarly to 
native AFPs.4,5 Both conjugates formed branched, feathery structures, which suggests 
a change in the interaction with ice. It has been hypothesized that the shape of ice that 
forms upon exposure to AFP occurs due to bulk steric hindrance of ice growth12, and 
therefore it stands to reason that AFP molecules forming different shapes in space will 




Figure 3-13. Characterisation of antifreeze activity of AFP and AFP@Au4 samples. 
A-D) Optical micrographs from sucrose “sandwich” ice shaping assays showing ice 
shapes in AFP-SNAP-BG-pHEA45@Au4, SNAP-AFP, His-AFP-Ni-NTA-
pHEA17@Au4 and His-AFP respectively. E) Freezing point depression in thermal 
hysteresis assay of SNAP-AFP and SNAP-AFP@Au4 samples. Scale bars 100 μm. 
Another feature of antifreeze activity that AFPs exhibit is thermal hysteresis (TH) – 
wherein the freezing point of a solution, but not its melting point, is depressed. SNAP-
AFP and conjugates were assessed in a TH assay by the Davies group at Queen’s 
University, Canada, and both showed TH temperatures around 1.2 °C for the same 
concentration of SNAP-AFP. This suggests that the conjugates retain the activity of 
the free AFP, and that multivalent presentation gives a small increase in activity, by 






This chapter demonstrates the preparation of several antifreeze macromolecules 
displayed on a multivalent AuNP scaffold: PVA98 and PVA140@Au4, and His-AFP 
and SNAP-AFP@Au4.  
AuNPs (~4 nm diameter) were coated with a library of PVAs of different chain lengths 
synthesized by RAFT polymerisation. The longer length PVA-AuNP conjugates were 
found to have comparable IRI activity to linear PVA architectures of the same 
molecular weight. This is hypothesized to be due to the long length and low coating 
density on the AuNP scaffold allowing free orientation of the PVA in space. This free 
orientation allows the PVA attached to the AuNP scaffold to benefit from the same 
binding modalities seen in linear PVA. 
Separately, terminally functionalised pHEA polymers prepared by RAFT were 
conjugated onto the Au4 scaffold, followed by AFP conjugation. Two different types 
of “multimeric AFP” were prepared: SNAP-AFP-BG-pHEA45@Au4 and His-AFP-Ni-
NTA-pHEA17@Au4. These two types of linker and tag allowed us to investigate the 
affect of linker length on activity, and we found that the longer linker was necessary 
to afford an enhancement of AFP IRI activity. 
Ultimately, these data suggest that AuNPs may be a valuable scaffold for the formation 
of IRI-active antifreeze materials. In particular, the capacity to coat these AuNPs less 
densely, with higher molecular weight molecules, allows us to form multimeric 
molecules with freedom of movement and orientation but without steric hindrance. 
Incorporation of a metal core may also provide contrast for future cryo-EM studies of 




3.7. Materials and Methods 
3.7.1. Materials 
Ultra-pure water with resistance < 18 Ω, was obtained from a Milli-Q© Integral Water 
Purification System. All chemicals were purchased from Sigma-Aldrich or Thermo 
Fischer Scientific and used as supplied unless otherwise stated. THF, DMF and ethyl 
acetate were purchased from Fisher. For washing of  AuNPs, Amicon Ultra-0.5 
centrifugal filter units with Ultracel-30 or Ultracel-100 membrane were used. The 
pET20b-AFPIII plasmid encoding for a hexahistidine-tagged AFPIII from ocean pout 
(rQAE isoform, M1.1HISPET20b) was kindly provided by Peter Davies (Queens 
University, Kingston, Canada). Competent Escherichia coli BL21(DE3) cells were 
sourced from New England Biolabs. IMAC Sepharise 6 Fast Flow columns, HiLoad 
16/600 Superdex 75 pg gel filtration columns and PD10 desalting columns were 
purchased from GE Healthcare and used according to manufacturer’s instructions. 
Thermo Scientific Pierce BCA assay kit was used according to the manufacturer’s 
protocols to determine all protein concentrations. Phusion® High-Fidelity DNA 
Polymerase and pSNAP-tag® (T7)-2 vector were purchased from New England 
Biolabs. 
3.7.2. Analytical Methods 
1H, 13C and 19F-NMR spectra were obtained using a Bruker DPX-400 NMR 
Spectrometer; all chemical shifts are reported in ppm (δ) relative to residual non-
deuterated solvent. Mass spectrometry was carried out in pure methanol or water on 
the Agilent 6130B ESI-Quad instrument using electrospray in positive mode. FTIR 
spectroscopy was carried out on a Bruker Vector 22 FTIR spectrometer with a Golden 
gate diamond attenuated total reflection cell. SEC measurements were carried out on 
an Agilent 390-LC MDS instrument equipped with a dual angle light scatter (LS), 2 x 
PLgel Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard column. The eluent 
was DMF with 5 mmol NH4BF4 additive. Samples were run at 1ml/min at 50°C. 
Poly(methyl methacrylate) standards (Agilent EasyVials) were used for calibration 
between 955,000 – 550 gmol-1. Analyte samples were filtered through a nylon 
membrane with 0.22 μm pore size before injection. Respectively, experimental molar 
mass (MnSEC) and dispersity (Đ) values of synthesized polymers were determined by 
conventional calibration using Agilent SEC software. Nanoparticle size was 
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determined using Dynamic Light Scattering (DLS), performed on a Malvern 
Instruments Zetasizer Nano- ZS with 4mW HeNe laser 632.8 nm. UV/Vis 
spectroscopy, optical density and fluorescence plate readings were performed on a 
BioTek Synergy HT Microplate Reader. UV-vis spectroscopy was used to determine 
nanoparticle size according to a method developed by Haiss et al.43 Transmission 
electron microscopy (TEM) was performed on a JEOL 2100 LaB6 high-resolution 
microscope. X-ray photoelectron spectroscopy (XPS) was carried out on the Kratos 
Axis Ultra with a delay-line detector. Analysis of the XPS data was performed using 
CasaXPS software, with mixed Gaussian-Lorentzian lineshapes – only individual 
measurements were taken, so no errors can be given for this data. Bacterial cell lysis 
was performed using a STANSTED ‘Pressure Cell’ FPG12800 homogeniser. Thermal 
hysteresis measurements were performed using standard procedures.44 Protein 
concentration was determined by measuring absorbance at 280 nm on a NanoDropTM 
2000 spectrophotometer. 
 
3.7.3. Synthetic and Experimental Procedures 
Synthesis	of	citrate@Au4	
 
AuNPs were synthesized as follows, based on a method by Ieong et al.35 All glassware 
was washed with aqua regia prior to commencing the experiment, to reduce 
nucleation. 240 mL of a 0.21 mmol.L-1,  (0.08 mg.mL-1) aqueous solution of HAuCl4 
was prepared at room temperature. To this was added 13.8 mg (0.05 mmol) of 
trisodium citrate to give a final citrate concentration of 0.21 mmol.L-1. 5 mL of an ice-
cold 0.1 M (0.5 mmol, 18.5 mg) solution of NaBH4 was added to the gold/citrate 
solution and stirred at room temperature overnight. Assuming complete reduction of 
the HAuCl4 to gold particles, the total gold concentration in the final solution was 0.21 
HAuCl4(aq)
HOC(COONa)(CH2COONa)2




mmol.L-1 (0.04 mg.mL-1). As these small AuNPs did not pellet upon centrifugation, 
small AuNPs were isolated by taking the supernatant after centrifugation at 13.2 
kRPM for 10 mins at 25 °C. Nanoparticle size and dispersity was measured by TEM, 
UV-Vis spectroscopy and size and zeta potential measurements by DLS. 
Nanoparticle diameter (UV-vis): 3-4 nm; TEM: 3.86 nm (standard deviation 0.74 nm). 
Synthesis	 of	 2-(dodecylthiocarbonothioylthio)-2-methylpropionic	 acid	
(DMP/DDMAT)	
 
Dodecane thiol (4.75 mL, 19.8 mmol) was added dropwise to a stirred suspension of 
K3PO4 (4.02g, 18.9 mmol) in acetone (60 mL). The reaction vessel was placed in an 
ice bath. Carbon disulfide (3.20 mL, 53.0 mmol) was added and the solution turned 
bright yellow, but was still cloudy. After stirring for ten minutes, 2-bromo-2-
methylpropionic acid (3.00 g, 18.0 mmol) was added and a precipitation of KBr was 
noted.  The ice bath was removed after 10 minutes and the reaction was left stirring at 
room temperature for 16 hours. Solvent was removed in vacuo and the residue was 
extracted into DCM (2 x 50 mL) from 1 M HCl (100 mL). The organic extracts were 
further washed with water (100 mL) and brine (100 mL) and dried over MgSO4. 
Recrystallisation from n-hexane yielded a bright yellow solid (1.80 g, 27.5%). 
 
1H NMR (400 MHz, CDCl3) δppm: 3.28 (2H, t, JHH=7.5, H6); 1.66 (6H, s, H3/4); 
1.10-1.25 (20H, alkyl, H7-16); 0.79 (3H, m, H17). 
13C NMR (400 MHz, CDCl3) δppm: 220.86 (C5); 178.04 (C1); 55.51 (C2); 37.08 
(C7); 31.92 (C6); 29.64, 29.57, 29.46, 29.35, 29.12, 28.98, 27.82 (C8-15); 25.23 
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FTIR (solid, νmax/cm-1): 2910 (CH2); 1710 (C=O); 1440 (C-C); 1305 (C-O); 1070 
(S-(C=S)-S).  
ESI-MS, positive mode (m/z): 365.2 (M+H+, expected 365.63), 387.1 (M+Na+, 
expected 387.61). 
Synthesis	 of	 pentafluorophenyl	 2-(dodecylthiocarbonothioylthio)-2-
methylpropionic	acid	(PFP-DMP/PFP-DDMAT)		
 
2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid (DMP) (0.500 g, 1.37 
mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 
(0.390 g, 2.05 mmol), and 4-(dimethylamino)pyridine (DMAP) (0.250 g, 2.05 mmol) 
were dissolved in DCM (50 mL) and stirred for 20 minutes under N2. 
Pentafluorophenol (PFP) (0.780 g, 4.24 mmol) in 5 mL DCM was added. The reaction 
was stirred overnight at room temperature. The reaction was washed with 3 M HCl 
(100 mL), 1 M NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered 
and then concentrated in vacuo to evolve a yellow solid with melting point close to 
room temperature (0.437 g, 60.2%). 
 
1H NMR (300 MHz, CDCl3) δppm: 3.24 (2H, t, JHH=7.4 x 2, H12); 1.62 (6H, m, 
H9/10); 1.26 (20H, alkyl, H13-22); 0.81 (3H, m, H23). 
19F NMR (300 MHz, CDCl3) δppm: 151.54 (m, F2/6), 157.74 (m, F3/5), 162.3 (m, 
F4). 
FTIR (solid, νmax/cm-1): 2934 (CH2); 1705 (C6F5C=O); 1439 (C-C); 1260 (C-O); 
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This species’ ESI-MS did not show any of the expected peaks, though the above 
characterisation was deemed sufficient to prove successful synthesis 
General	Procedure	for	Synthesis	of	pHEA	(or	PFP-pHEA)	polymer	
 
The following procedure describes a reaction with a theoretical degree of 
polymerisation (DP) of 50 repeat units. 4,4-azobis(4-cyanovaleric acid) (5 mg, 0.018 
mmol), pentafluorophenyl 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid 
(CTA) (47 mg, 0.088 mmol, for the polymer without a PFP-end group, DMP was used 
instead of PFP-DMP) and N-hydroxyethyl acrylamide (1 g, 8.8 mmol) were dissolved 
in 1:1 methanol: toluene (4 mL) in a glass vial with a stirrer bar. Mesitylene (200 μL) 
was added and a sample was removed for 1H-NMR analysis in CDCl3. The reaction 
mixture was degassed by N2 for 30 minutes, sealed and placed in a 70°C oil bath. After 
90 minutes, the solution was opened to air and quenched by submerging the flask in 
N2(l). The polymer (pHEA) was precipitated three times from methanol into diethyl 
ether to give a light yellow solid.  
Conversion (NMR): 94.0%; Mn (theoretical): 5664 g.mol-1; Mn (SEC) 8253 g.mol-1; 
Mw (SEC) 9231 g.mol-1; Mw/Mn (SEC): 1.1.  
1H NMR (300 MHz, CDCl3) δppm: 8-8.15 (br s, N-H (H4)); 3.4-3.8 and 3.05-3.2 (2 
x m, H5); 1.9-2.35 and 1.4-1.8 (2 x m, H1/2). 
19F NMR (300 MHz, CDCl3) δppm: 155.29, 161.61, 165.67. 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2854 (alkyl C-H stretch); 1641 
(amide C=O stretch); 1555 (N-H bend); 1443 (alkane); 1225 (C-O stretch); 1060 (C-
O stretch); 950 (C-F peak on shoulder of 1060 peak). 



























Synthesis of BG-pHEA polymer. 
 
Synthesis of NTA-pHEA polymer. 
PFP-pHEA (90.8 mg, 0.018 mmol) and primary amine (6-((4-
(aminomethyl)benzyl)oxy)-7H-purin-2-amine (BG) or Nα,Nα-Bis(carboxymethyl)-
L-lysine hydrate(NTA)) (0.088 mmol) were dissolved in DMF (5 mL).  To the stirred 
mixture, triethylamine (35 μL) was added, and the reaction was moved to a 50 °C oil 
bath for 16 hours. The polymer was precipitated three times from methanol into diethyl 




























































































Mn (SEC) 12960 g.mol-1; Mw (SEC) 15977 g.mol-1; Mw/Mn (SEC): 1.2. 
1H NMR (300 MHz, D4-MeOH) δppm: 4.8-5 (br s, H6), 3.44-3.85 and 3.05-3.22 (2 x 
br s, H5), 1.94-2.35 and 1.31-1.86 (2 x br s, H1/2). 
19F NMR (300 MHz, CDCl3) δppm: no peaks visible. 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2854 (alkyl C-H stretch); 1641 
(amide C=O stretch); 1555 (N-H bend); 1443 (C-H alkane); 1225 (C-O stretch); 1060 
(C-O stretch) (C-F shoulder on 1060 peak is no longer present). 
 
NTA-pHEA17 polymer 
Mn (SEC) 3040 g.mol-1; Mw (SEC) 3355 g.mol-1; Mw/Mn (SEC): 1.1. 
1H NMR (300 MHz, D4-MeOH) δppm: 4.8-5 (br s, H6), 3.44-3.85 and 3.05-3.22 (2 x 
br s, H5), 1.94-2.35 and 1.31-1.86 (2 x br s, H1/2). 
19F NMR (300 MHz, CDCl3) δppm: no peaks visible. 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2944 (alkyl C-H stretch); 1627 
(amide C=O stretch); 1562 (N-H bend); 1390 (C-H alkane); 1060 (C-O stretch) (C-F 

























General	 Procedure	 for	 Synthesis	 of	 Polymer-Coated	 AuNP4	 (NTA-pHEA17,	
PFP-pHEA47	or	BG-pHEA45@Au4)	
 
1 mg of polymer (either PFP-pHEA48, BG-pHEA45 or NTA-pHEA6) was added to 1 
mL of citrate@Au4 in a 1.5 mL Microcentrifuge tube. This was left, agitating, for 60 
minutes. The solutions were concentrated by centrifugation in Amicon Ultra-0.5 
centrifugal filter units with an Ultracel-30 membrane, before being re-dispersed in the 
same volume of water. The nanoparticles were washed in this manner a further 3 times 
before being re-dispersed in the same final volume of distilled water and stored in the 
fridge until required. Nanoparticle size and dispersity was measured by TEM, UV-Vis 
spectroscopy and size and zeta potential measurements by DLS. 
BG-pHEA45@Au4: Nanoparticle diameter (UV-vis): 3-4 nm; TEM: 3.87 nm (standard 
deviation 1.04 nm). 
NTA-NTA17@Au4: Nanoparticle diameter (UV-vis): 3-4 nm; TEM: 3.70 nm (standard 
deviation 0.74 nm). 
PFP-pHEA17@Au4: Nanoparticle diameter (UV-vis): 3-4 nm; TEM: 4.38 nm 





















PFP-pHEA47@Au4 solution (500 μL) and N-(2-Aminoethyl)maleimide 
trifluoroacetate salt (0.00088 g,  3.4 μmol) were dissolved in DMF (500 μL) in a 1.5 
mL polypropylene microcentrifuge tube and vortexed 30 secs to dissolve.  To the 
stirred mixture, triethylamine (3.5 μL, for 0.5 M solution) was added, and the reaction 
was moved to a 50 °C oil bath for 16 hours. The solutions were added to 4.5 mL of 
H2O before being concentrated by centrifugation in Amicon Ultra-0.5 centrifugal filter 
units with an Ultracel-30 membrane. The AuNPs were re-dispersed in 500 μL of PBS 
buffer, pH 7.5. The nanoparticles were washed by concentration and re-dispersion a 
further 2 times and stored in the fridge until required.  Nanoparticle size and dispersity 
was measured by TEM, UV-Vis spectroscopy and size and zeta potential 
measurements by DLS. 

















































































NTA-pHEA17@Au4 solution (1 mL) was concentrated by centrifugation in Amicon 
Ultra-0.5 centrifugal filter units with an Ultracel-30 membrane. To this concentrate 
was added the same volume Nickel(II) Chloride Hexahydrate (1 mL of 500 μM 
solution at pH 8 in 10 mM HEPES, 100 mM NaCl buffer). This was left, agitating, for 
120 minutes. The solutions were concentrated by centrifugation in Amicon Ultra-0.5 
centrifugal filter units with an Ultracel-30 membrane, before being re-dispersed in the 
same volume of pH 7.5 HEPES/NaCl buffer. The nanoparticles were washed in this 
manner a further 3 times before being re-dispersed in the same final volume of buffer 
and stored in the fridge until required. Nanoparticle size and dispersity was measured 
by TEM, UV-Vis spectroscopy and size and zeta potential measurements by DLS. 
Nanoparticle diameter (UV-vis): 3-4 nm; TEM: 3.89 nm (standard deviation 0.75 nm). 
3.7.3.3. General	Synthesis	of	protein-conjugated	Au4	(SNAP-AFP,	
His-AFP,	Cys-AFP)	
Polymer@Au4 solution (500 μL) was concentrated by centrifugation in Amicon Ultra-
0.5 centrifugal filter units with an Ultracel-30 membrane. SNAP-tagged AFP was 
conjugated to the BG-pHEA45-AuNP4; Cys-AFP was conjugated to Mal-pHEA47-
AuNP4; and His-tagged AFP was conjugated to Ni-NTA-pHEA17-AuNP4. To this 
concentrate was added the same volume of protein solution as desired. This was left, 
agitating, for 120 minutes at room temperature. The solutions were concentrated by 


























































membrane, before being re-dispersed in the same volume of pH 7.5 PBS buffer. The 
nanoparticles were washed in this manner a further 2 times before being re-dispersed 
in the same final volume of PBS and stored in the fridge until required. Protein 
concentration in the washes was determined by measuring absorbance at 280 nm. 
Nanoparticle size and dispersity was measured by TEM, UV-Vis spectroscopy and 
size and zeta potential measurements by DLS. 
3.7.3.4. Synthesis	of	S-benzyl	O-ethyl	carbondithioate.	
PERFORMED BY CHRISTOPHER STUBBS. Acetone (40 mL) was added to a 
round bottom flask equipped with a stirrer bar. Potassium ethyl xanthogenate (2 g, 
0.0124 mol, 1 eq.) was added and left to dissolve for 30 minutes. Benzyl bromide (2.13 
g, 0.0124 mol, 1eq.) was added and stirred for 24 hours at 50 °C. The solution was 
filtered and the filtrate concentrated in vacuo. The resulting yellow oil was purified on 
a column of silica with DCM as eluent. Yield 1.26 g 48 %.  
1H NMR (300 MHz, CDCl3): δppm = 1.3 (CH3CH2OC(S)S, t, 3H), 4.3 (OC(S)SCH2, 
s, 2H), 4.6 (CH3CH2OC(S)S, q, 2H), 7.2 (C(S)SCH2C6H5, br, 5H).  
13C NMR (400 MHz, CDCl3): δppm = 14 (CH3CH2), 40 (C(S)SCH2), 70 (CH3CH2), 
127 (para CH), 128 (meta  CH), 129 (ortho CH), 213 (OC(S)S).  
3.7.3.5. General	procedure	for	synthesis	of	poly(vinyl	acetate).		
PERFORMED BY CHRISTOPHER STUBBS. As a representative example, vinyl 
acetate (3 g, 3.21 mL, 34 mmol, 1000 eq), S-benzyl O-ethyl carbondithioate (0.074 g, 
0.34 mmol, 10 eq.),  4,4’azobis(4-cyanovaleric acid) (0.0098 g, 0.034 mmol, 
1 eq.) and mesitylene (0.1 g, 0.086 mL) were added to a 10ml vial and sealed with 
a subaseal. The solution was left to degas under nitrogen for 15 minutes, before being 
placed into an oil bath at 68 °C. The reaction was left for 24 hours before being 
plunged into liquid nitrogen. Poly(vinyl acetate) was recovered as a sticky yellow oil 
after precipitation into diethyl ether.  
1H NMR (400 MHz, CDCl3) dppm = 4.90 – 4.70 (CH2CH(OOCH3), br, 1H), 2.07 
(CH2CH(OOCH3), br, 3H), 1.90-1.60 (CH2CH(OOCH3), br, 2H).  
FTIR (solid, νmax/cm-1): C-H 2954 cm-1, C=O 1729 cm-1, C-O 1407 cm-1.  
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Mn (SEC, THF) = 8500 Da, Mw/Mn = 1.4.  
Data are shown for poly(vinyl acetate)98. 
3.7.3.6. General	procedure	for	synthesis	of	poly(vinyl	alcohol).	
PERFORMED BY CHRISTOPHER STUBBS. As a representative 
example, poly(vinyl acetate) (1 g) was dissolved in methanol (5 mL) in a round bottom 
flask and stirred until dissolved. Hydrazine hydrate solution (15 mL, 78-82 % in water) 
was added and the reaction heated to 50 °C in an oil bath for 24 hours. The solution 
was cooled and diluted with water (50ml) before being purified by dialysis (100-500 
MWCO) followed by lyophilization to form a white powder. Representative 
characterization data for poly(vinyl alcohol)98:  
1H NMR (400 MHz, D2O) d = 4.00 – 3.80 (CH2CH(OH), br, 1H), 1.80 – 1.30 
(CH2CH(OH), br, 2H). 
FTIR (solid, νmax/cm-1) = O-H 3000-3400 cm-1, C-H 2917 cm-1, C-O 1411 cm-1. Data 
are shown for poly(vinyl alcohol)98. 
3.7.3.7. Recombinant	expression	of	AFPIII-His	
PERFORMED BY DR. MUHAMMAD HASAN. A pET20b-AFPIII plasmid 
encoding for a hexahistidine-tagged AFPIII from ocean pout (rQAE isoform, 
M1.1HISPET20b) was kindly provided by Peter Davies (Queens University, 
Kingston, Canada). The plasmid was transformed into competent Escherichia coli 
BL21(DE3) cells (New England Biolabs). A colony was selected to inoculate 50 mL 
of LB-medium containing 100 µg/mL ampicillin and was grown overnight at 37 °C 
under continuous shaking of 180 rpm. The following day, 5 mL of the preculture was 
added to 500 mL of LB-medium in a 2 L Erlenmeyer flask and grown at 37 °C with a 
shaking speed of 180 rpm till an OD600 of 0.6 was reached. The temperature was then 
reduced to 16 °C and IPTG was added to a final concentration of 0.4 mM.  The 
overexpression of the protein was allowed to take place overnight following which the 
cells were centrifuged at 4000 g for 30 minutes at 4 °C.  
Pelleted cells were resuspended in PBS supplemented with Pierce protease inhibitor 
mini-tablets. The suspension was passed through a STANSTED ‘Pressure Cell’ 
FPG12800 homogeniser in order to lyse the cells. The cell lysate was centrifuged at 
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14,000 g and the supernatant was passed through a 0.45 nm filter and applied to an 
IMAC Sepharose 6 Fast Flow (GE Healthcare) column charged with Ni(II) ions and 
pre-equilibrated with PBS. The column was washed with 20 column volumes of 20 
mM imidazole in PBS. Bound AFPIII was eluted using 300 mM Imidazole in PBS. 
The AFPIII was further purified using a HiLoad 16/600 Superdex 75 pg gel filtration 
column (GE Healthcare) with PBS as the running buffer. Fractions exclusively 
containing the AFPIII were pooled and concentrated to 5 mg.mL-1. Purity was 
estimated using SDS-PAGE and protein concentration determined using Thermo 
Scientific Pierce BCA assay kit. This was verified by measuring absorbance at 280 
nm and obtaining protein’s extinction coefficient [as predicted by ProtParam 
(http://web.expasy.org/protparam/)] for use in Beer-Lambert law. 
3.7.3.8. Recombinant	expression	of	AFPIII-Cys	
PERFORMED BY DR. MUHAMMAD HASAN. The terminal Ala in the pET20b-
AFPIII plasmid was mutated to Cys by site-directed mutagenesis using the primer 
sequence 5’-GTTAAAGGTTACGCTTGTCTCGAGCACCAC-3’ and employing 
Phusion® High-Fidelity DNA Polymerase (New England Biolabs) according to the 
manufacturer;s protocol. The expression and purification was performed as detailed 
for AFPIII with the exception that 2 mM β-mercaptoethanol was added to all buffers 
when performing IMAC and gel filtration to prevent the formation of disulfide bonds. 
The β-mercaptoethanol was removed prior to use by buffer exchanging using PD10 
desalting columns (GE Healthcare). 
3.7.3.9. Recombinant	expression	of	AFPIII-SNAP	
PERFORMED BY DR. MUHAMMAD HASAN. A genetic fragment encoding for 
AFPIII fused to a hexahistidine tag was amplified from the pET20b-AFPIII plasmid 
using 5’-GTACGGATCCAACCAGGCTAGCGTTGTG-3’ (BamHI site underlined) 
as the forward primer and 5’-ATTAGCGGCCGCAGCCGGATCTCAGTG-3’ (NotI 
site underlined) as the reverse primer. The BamHI/NotI digested products were ligated 
into a pSNAP-tag® (T7)-2 vector (New England Biolabs). The plasmid was then 
transformed into competent Escherichia coli BL21(DE3) cells (New England 





PERFORMED BY DR. CAROLINE BIGGS AND CHRISTOPHER STUBBS. The 
sample was prepared in PBS solution, and a 10 µL was dropped onto a glass 
microscope coverslip atop an aluminium plate cooled to -78 °C with dry ice. The thin 
wafer of ice that forms upon contact with the coverslip was transferred to a cryostage 
held at -8 °C using liquid nitrogen, and left to anneal for 30 minutes at this temperature. 
Three images were taken at different locations on this wafer at 20 x zoom under cross 
polarizers. Using ImageJ, the number of crystals in the images were counted and the 
average crystal size per wafer was calculated as mean grain area (MGA). 
3.7.3.11. Modified	Sucrose	Sandwich	Ice	Shaping	Assay	
PERFORMED BY ALICE FAYTER. Samples dissolved in PBS buffer containing 
45% sucrose were sandwiched between two glass coverslips and sealed with 
immersion oil. Samples were cooled to −50 °C on a Linkam Biological Cryostage 
BCS196 with T95-Linkpad system controller equipped with a LNP95-Liquid nitrogen 
cooling pump, using liquid nitrogen as the coolant (Linkam Scientific Instruments UK, 
Surrey, U.K.). The temperature was then increased to −8 °C and held for 1 hour to 
anneal. The samples were then heated at 0.5 °C.min-1 until few ice crystals remained 
and then cooled at 0.05 °C.min-1 and the shape of ice crystals observed. Micrographs 
were obtained every 0.1 °C using an Olympus CX41 microscope equipped with a UIS-
2 20x/0.45/∞/0−2/FN22 lens (Olympus Ltd., Southend on sea, U.K.) and a Canon EOS 







Figure 3-14. Size distribution of AuNPs of 4 nm size before and after purification by 
centrifugation, from DLS measurements of distribution by number. 
 
Figure 3-15. Size distributions by number of particles, from DLS measurements of 
distribution by number. Shows size of commercial samples (from BBI) and the first-





Figure 3-16. Representative FTIR of PVAc converted to PVA. 
 
Figure 3-17. UV-Vis spectra showing red shift in PVA@Au4 samples. 
 
Figure 3-18. Thermogravimetric analysis of PVA@Au4 showing decomposition of 
samples over increasing temperature. PVA98@Au4 contains 0.24 mg.mL-1 and 
PVA140@Au4 0.32 mg.mL-1 of PVA. 
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Table 3-5. PVA@Au4 elemental composition determined by XPS. 
Particle C a O a N a S b Au c 
Citrate@Au4 46.4 52.8 0.00 0.43 0.33 
PVA98@Au4 65.5 29.0 1.45 0.24 0.04 
PVA140@Au4 65.1 30.3 0.28 0.25 0.04 
a 1s peak; b 2s peak; c 4f peak. 








Figure 3-20. Sucrose sandwich assay optical micrographs showing ice formation 
over decreasing temperature. A) PVA98 0.24 mg.mL-1; B) PVA98@Au4 0.24 mg.mL-
1 PVA; C) PVA140@Au4 0.32 mg.mL-1 PVA; D) PVA140 0.32 mg.mL-1. All scale 
bars 100 μm. 
 




Figure 3-22. Molecular weight distributions, by SEC, of NTA-pHEA derived from 
PFP-pHEA. 
 
Figure 3-23. Size distributions by volume of particles, from DLS measurements. 
Shows change in size upon conjugation of different lengths of NTA-pHEAn 
polymer. In this case, the number distribution showed no aggregation, but the 





Figure 3-24. Size distributions by volume of particles, from DLS measurements. 
Shows change in size upon conjugation of different lengths of BG-pHEAn polymer. 
In this case, the number distribution showed no aggregation, but the volume 
distribution shows more large aggregates forming with the longer pHEA chain 
length. The BG-pHEA17@Au4 conjugate was not stable at all, precipitating out 
during the washing stage. 
 
Figure 3-25. Size distributions by volume of particles, from DLS measurements. 
Shows change in size upon conjugation of different lengths of PFP-pHEAn polymer. 
In this case, the number and volume distributions showed no aggregation, but the 
intensity distribution shows more large aggregates forming with the longer pHEA 
 
 176 
chain length. The PFP-pHEA17@Au4 conjugate was not stable at all, precipitating 
out during the washing stage. 
 
 
Figure 3-26. MALDI spectrum of SNAP-AFP recombinant protein. Peak at 29100 
Da (Mw is 29107 Da) 
 
Figure 3-27. MALDI spectrum of His-AFP recombinant protein. Peak at 8010 Da 




Figure 3-28. Size distributions by number of particles, from DLS measurements. 






Figure 3-29. TEM micrographs and size distributions (from 100 particles analysed 
by TEM) or Au4 samples. A) citrate@Au4; B) BG-pHEA45@Au4; C) SNAP-AFP-
BG-pHEA45@Au4; D) NTA-pHEA17@Au4; E) Ni-NTA-pHEA17@Au4; F) His-AFP-
Ni-NTA-pHEA17@Au4; G) PFP-pHEA47@Au4; H) Maleimide-pHEA47@Au4; I) 




Figure 3-30. XPS survey scan data of SNAP-AFP@Au4 sample and precursor AuNP 





Figure 3-31. XPS survey scan data of His-AFP@Au4 sample and precursor AuNP 





Figure 3-32. XPS survey scan data of Cys-AFP@Au4 sample and precursor AuNP 














Table 3-6. AFP@Au4 elemental composition determined by XPS. 
Particle C a O a N a F a S b Au c Ni d 
Citrate@Au4 46.41 52.82 0.00 - 0.43 0.33 - 
NTA-pHEA17@Au4 66.06 23.10 9.21 - 1.51 0.12 - 
Ni-NTA-pHEA17@Au4 67.40 19.45 9.62 - 3.30 0.06 0.15 
His-AFP-Ni-NTA-
pHEA17@Au4 
63.93 21.98 12.42 - 1.36 0.19 0.12 
BG-pHEA45@Au4 68.40 23.65 7.37 - 0.35 0.23 - 
SNAP-AFP-BG-pHEA45@Au4 58.48 24.74 12.27 0.30 0.22 0.17 - 
PFP-pHEA47@Au4 72.85 19.80 6.59 0.29 0.42 0.05 - 
Maleimide-pHEA47@Au4 73.28 21.05 4.89 0.00 0.48 0.30 - 
Cys-AFP-Maleimide-
pHEA47@Au4 
52.68 32.98 7.17 0.32 0.18 0.33 - 
a 1s peak; b 2s peak; c 4f peak; d 2p peak. 






Figure 3-33. Nanodrop measurements of washes after SNAP-AFP conjugation to 
BG-pHEA45@Au4. 
 
Table 3-7. Masses of organic substances present in AFP@Au4 samples determined 
by TGA. 
Particle 
Mass present in sample 
(mg.mL-1) a 
NTA-pHEA17 onAu4 0.048 
His-AFP on Au4b 2.32 
BG-pHEA45 on Au4 0.042 
SNAP-AFP on Au4b 0.64 
a All calculations were taken as the mass difference between 150 and 600, and all 
AuNP samples were determined to be the same concentration of gold by UV-Vis 
spectroscopy; b All protein-containing sample calculations were blanked relative to 





Figure 3-34. “Splat” optical micrograph of PBS control. This was used to give test 
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4.Investigations into the binding activity 
of the adenovirus tail fibre-like protein 
of a novel Photorhabdus virulence 
cassette “nanosyringe” construct 
4.1. Chapter summary 
The Photorhabdus bacteria contain highly conserved gene loci for nanosyringe-like 
constructs, termed Photorhabdus virulence cassettes (PVCs). These PVCs are multi-
protein macromolecular structures, used by the bacteria for the delivery of protein 
toxins into host cells. Several recent clinical infection cases of Photorhabdus 
asymbiotica have resulted in interest in understanding the mechanisms by which these 
bacteria infect mammalian cells, and whether these PVCs might be a key infection 
mechanism. Nothing is currently known in terms of molecular targets for PVCs (to the 
best of our knowledge), although each PVC operon is seen to encode a protein 
structurally similar to adenovirus host binding proteins, called Pvc13. Each 
Photorhabdus genome can be seen to encode between 5 and 6 different PVC operons, 
with these Pvc13 binding fibre-like proteins exhibiting the greatest sequence diversity.  
Herein we develop a method of attaching these Pvc13 proteins (for example, from the 
PVClumt operon homologue) to gold nanoparticles (LUMT@AuNP) in order to 
develop assays to assess binding to the A549 cell line. Unfortunately, ICP-OES 
following incubation with both the A549 and SW480 human cell lines demonstrated 
no binding of these LUMT@AuNP constructs. Further experiments were, however, 
undertaken with recombinant Pvc13 tail fibre proteins, which resulted in a range of 
glycan or eukaryotic protein candidates being proposed as binding partners.  
These data suggest that eukaryotic, and even human, targets for these PVCs do exist, 
and that further work in this area could be exciting in leading to a nanosyringe-like 





The work herein was carried out by the author except in the case of collaborative 
research, as outlined below. 
o Recombinant PVClumt_Pvc13 and PVCpnf_Pvc13 tail fibre proteins were 
prepared by Joseph Healey of the Waterfield group.  
o All XPS and data analysis was performed by Dr Marc Walker at the University 
of Warwick. 
o Orbitrap mass spectrometry was performed in the University of Warwick 
Proteomics RTP by Cleidi Zampronio. Perseus and Scaffold analysis was 
performed by me. 
o All A549 and SW480 cells were prepared in the Gibson cell lab, passaged and 
cultured by Trisha Bailey, but I undertook all assays. 
o CACO2 cells were provided ready for lysis by Blessing Anonye of the 
Unnikrishnan group, but lysed and used by me. 
o Recombinant PVCunit4_Pvc13 tail fibre protein was prepared by Dr Alexia 
Hapeshi of the Waterfield group. THP1 and S2 cells were also provided ready 
for lysis by Dr Alexia Hapeshi, but lysed and used by me. Caenorhabditis 
elegans were provided by the Waterfield lab, and lysate preparation was 
performed jointly with Alexia Hapeshi. 
o CryoEM reconstructions of PVCs were performed by Franziska Leidreiter at 





Photorhabdus is a genus of motile, Gram negative, bioluminescent insect pathogenic 
bacteria belonging to the family Enterobacteriacae.1–11 They exist in an obligate 
symbiosis with insect pathogenic Heterorhabditis nematodes.1 The genus contains 
three species insect host restricted P. luminescens and P. temperata and the dual 
insect/human pathogens P. asymbiotica 
Photorhabdus luminescens’ symbiotic nematode partner is Heterhorhabditis 
bacteriophora. The highly-motile bacteria colonise the intestine of an infective 
juvenile (IJ) nematode.1,12 New IJs hatch from eggs retained inside the maternal 
nematode’s body cavities, causing an effect known as endotokia matricida, a 
phenomenon that is apparently vital to the symbiotic re-association and transmission 
of the bacteria.13 These new IJ worms disperse from the previous insect cadaver and 
hunt down and invade other soil-dwelling insect larvae, entering via natural openings 
or directly through the cuticle. Once in the hemocoel (the insect’s open blood system), 
the nematode regurgitates the bacteria. P. luminescens are able to overcome the insect 
immune system and divide unrestricted, producing a variety of toxic compounds such 
as exozymes to kill the insect host by lethal septicaemia. After host insect death, the 
nematode begins to replicate as a hermaphrodite, eating the Photorhabdus bacteria. 
Both the bacteria and nematode are able to undergo several rounds of replication 
within the cadaver before again emerging into the soil as an IJ carrying Photorhabdus, 
looking for the next host insect. In the case of P. asymbiotica, nematodes are believed 
to burrow into human skin and release the bacteria, causing a serious human infection. 
The natural life cycle of these mammalian pathogenic strains also includes insect hosts 
and it is not known if there is a natural (non-human) mammalian reservoir host for 
these in nature.  
Only 10-100 bacterial cells are sufficient to overcome the insect’s immune system, 
and the IJs actually show little specificity in infection, suggesting that the bacteria are 





Figure 4-1. Transmission cycle of P. luminescens in symbiosis with 
Heterhorhabditis bacteriophora nematode. A) Worm anatomy. B) Cartoon of 
transmission cycle. Adapted from Waterfield et al.1 
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P. luminescens contains four major groups of toxins: toxin complexes, Photorhabdus 
insect-related proteins, “make caterpillars floppy” toxins and Photorhabdus virulence 
cassettes (PVCs).1,9,14,15 The genetic loci that encode PVCs consist of 16 conserved 
structural genes, several of which are similar to bacteriophage tail and base plate 
assembly proteins, similar in many respects, generically and visually under the 
electron microscope, to regions of operons encoding anti-bacterial “R-type 
pyocins”.1,9,11,14,16 Importantly, each unique PVC operon encodes specific protein 
toxins similar to type III secretion system delivered effectors at there 3’ end, the so 
called “payload region” of the operon. The current hypothesis is that these PVCs act 
as secreted molecular syringe constructs that inject their toxic payloads directly into a 
host cell, in a presumed similar fashion to Serratia entomophila’s antifeeding 
prophage (these “Afp” constructs show similarity to PVCs in 16 of their 18 gene 
clusters).1,17–19 
Despite some superficial similarity to R-type pyocins, which are produced by several 
other Gram-negative bacteria to give them a competitive advantage over related 
strains, the PVC needle complexes show no antibacterial activity.1 However certain 
PVCs have been shown to be highly toxic to insects, causing rapid killing of the 
immune cells, macrophage equivalents known as hemocytes.1,9,20 Although these 
constructs are bacteriocin-like, they have somehow modified to exclusively attack 
eukaryotes. There are also multiple PVCs present in all Photorhabdus species’ 
genomes, suggesting their acquisition by horizontal gene transfer.1 The bacteria are 
readily culturable away from their nematode symbiont hosts. 
Yang et al.11 demonstrated the injectable insecticidal activity of recombinant E. coli 
expressing various PVC operons using Photorhabdus cosmids and the larvae of the 
wax moth (Galleria mellonella). Bleeding the larvae also demonstrated that 
hemocytes were destroyed within 30 mins of injection, which suggests that successful 
pathogenicity occurs through compromising the host’s immune cells. Heat treatment 
prior to injection eliminated toxicity, and the P. asymbiotica PVCs also showed the 
greatest insecticidal activity. 
Investigations have shown PVCs effector payload toxins transiently expressed inside 
tissue culture cells rearranged the actin cytoskeleton, targeting actin condensation in 
particular.1,11,14 What is not understood, however, is whether hemocytes are their 
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primary target, or if they are less specific. The delivery mechanism of their toxic 
payload, and whether this is truly syringe-like, is also unknown. 
Invertebrates constitute both more extant species and individual “infectable” animals 
than the better-studied mammalian diseases, and have been exposed to pathogens for 
a longer period of evolutionary time. As invertebrates also serve as hosts of vectors 
for many vertebrates pathogens (for example, flea vectors for bubonic plague), it 
makes sense that pathogens commonly target invertebrates.5 As PVCs are regurgitated 
directly into the insect blood system, they are evidently well adapted to the dealing 
with the immediate phagocytic challenge of the innate immune system. Phagocytosis 
uses free radicals and killer proteases to degrade foreign agents and is a crucial 
response in both insect and mammalian innate immune systems.1 
 
Figure 4-2. PVC products in Photorhabdus luminescens and asymbiotica. Not to 
scale. Adapted from Waterfield et al.1 
As previously mentioned, there are three species of Photorhabdus, each with their own 
variety of PVC products. P. luminescens has been studied and used for agricultural 
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purposes as a biological pest control agent, but P. asymbiotica is of interest due to its 
survival at 37°C, and its capacity to infect mammals.1,8  
P. asymbiotica also exists in symbiosis with a nematode, and has been isolated from 
human infections in North America and Australia.1,8,12,20–26 The bacteria has the 
capacity to infect otherwise healthy humans as a primary pathogen rather than 
opportunistically, with incidence likely higher than reported due to the bacteria not 
being present on standard clinical bacteriology databases.1,27 Clinical cases of 
infection are correlated only with outdoor activity, with limb infection related to 
contact with soil, with the symbiont nematode (Heterorhabditis gerradii) presumably 
serving as an inoculation vector.1 The bacteria locally invade soft tissue to form a 
painful necrotic ulcer, but often, remote soft tissue infections are observed, suggesting 
bacteremic spread (bacteria present in the blood, which is abnormal). This is evidenced 
through bacteria being isolated from blood and even sputum as well as pus. 
Macrophage cultures infected with P. asymbiotica showed replication inside both 
murine and human immune cells, and both P. asymbiotica and P. luminescens have 
shown resistance to human serum, which suggests that these bacteria could survive 
the blood stream through compromising the host immune system.1,28 In contrast to P. 
luminescens, P. asymbiotica seems to be able to invade cells as an intracellular 
infection.28 It seems reasonable to hypothesise that that invaded macrophages act as 
vehicles for dissemination of bacterial cells in humans. 
PVC products may be important in the adaptation of Photorhabdus to different insect 
species and even human infection, with all species showing a variety of them in their 
genomes (see Figure 4-2).1,29 Due to their capacity to invade hemocytes, it could be 
that these PVCs have a central role in invasion of the host immune system, which is 
key in infecting a variety of species.11 Of particular interest are the “tail fibres” near 
the baseplate-like region of the PVC construct, which are hypothesized to attach 




Figure 4-3. Structure of PVC and AFP needle complexes. A) Transmission electron 
micrograph of relaxed PNF PVC product, showing outer sheath. B) Micrograph of 
contracted PNF PVC product with outer sheath (black arrow) and inner “needle” 
(white arrow). A-B taken from Yang et al.11 C) Reconstructed structure of AFP from 
Serratia entomophila, taken from Heymann et al.18: 1.  Cap; 2. Tube containing toxic 
payload; 3. Phage baseplate-like fibres; 4. Needle. The similarity of this structure to 
PVCs is is supported by reconstructions of PVC structure by CryoEM as seen in the 




4.4. Chapter aims 
PVClumt_Pvc13 is a protein produced by the Photorhabdus asymbiotica bacterium 
suspected to be involved in pathogenesis, but its mammalian binding target is entirely 
unknown. To this end, the aims of this chapter are as follows: 
o To synthesis and characterise AuNP conjugates of recombinant 
PVClumt_Pvc13 (a PVC operon known to be expressed in simulated human 
infection environment) followed by assays in human cell lines to determine 
binding activity. 
o To assess glycan, lipid and protein binding of the recombinant 
PVClumt_Pvc13 tail fibre protein through glycan microarrays, lipid arrays and 
pull-down assays with whole cell lysates. 
o To assess protein binding of the alternative recombinant Pvc13 tail fibre 
proteins, encoded by PVCpnf_pvc13 and PVCunit4_pvc13 operon genes via 




4.5. Results and Discussion 
4.5.1. Synthesis of PVClumt_Pvc13 protein conjugated to 
AuNPs 
Previous studies have indicated that Photorhabdus asymbiotica is pathogenic in 
humans.3,21,28,30–32 The gene sequences and synteny of PVC operons are generally 
well-conserved. We hypothesised that the adenovirus fibre like Pvc13 proteins 
represent the needle complex subunits responsible for host cell binding. To test this 
we immobilised heterologously expressed (in E. coli) P. asymbiotica Pvc13 proteins 
from the PVClumt operon onto an AuNP scaffold, in order to use these to help us 
understand a possible role for PVCs in the Photorhabdus asymbiotica infection 
mechanism. Briefly, recombinant His-tagged PVClumt_Pvc13 tail fibre protein 
(simply referred to as “LUMT” below) was conjugated to AuNPs via a sterically 
stabilising polymer linker, in order to allow the AuNP scaffold to serve as a marker 
for Pvc13 protein adhesion to cells and function. 
Pentafluorophenol-terminated (at the α-terminus) poly(hydroxyethyl acrylamide)s 
(PFP-pHEAs) were synthesized by controlled RAFT polymerisation to act as steric 
stabilisers when conjugated to AuNP, especially upon exposure to the buffer solution 
required in the use of proteins. pHEA of DP ~50 was also synthesized without a PFP-
containing chain transfer agent. Three different chain lengths of PFP-pHEA were 
synthesized (approximately 25, 50 and 100 DP). Conversion and theoretical molecular 
weight was determined by 1H-NMR vinyl peak reduction relative to a mesitylene 
standard peak (see Table 4-1). 19F-NMR, SEC and FTIR were used to further confirm 




Scheme 4.1. Synthesis of NTA-pHEA polymers and control pHEA. 










pHEA46 56 82 46 5,600 8,500 1.2 
PFP-pHEA17 26 64 17 2,500 3,000 1.1 
PFP-pHEA45 d 47 94 45 5,700 8,300 1.1 
PFP-pHEA95 103 93 95 11,000 15,000 1.3 
a Monomer to RAFT agent molar ratio; b Determined by depletion of vinyl peaks in 
1H NMR using mesitylene as an internal standard; c Determined by SEC; d Used in 
His-LUMT-Ni-NTA-pHEA45@Au40 conjugates. 
The PFP α-terminal group was functionalised by substitution with excess Nα,Nα-
Bis(carboxymethyl)-L-lysine hydrate (NTA) in DMF overnight, with triethylamine as 
a base. This amine terminal was selected to allow subsequent capture of His-tagged 
protein. PFP elimination was confirmed by the loss of three PFP peaks by 19F-NMR 





































































Figure 4-4. Excess primary amine also liberates a ω-terminal thiol, conveniently for 
AuNP conjugation.  
 
Figure 4-4. Characterisation of pHEA polymers, and the removal of the PFP group. 
A) 19F-NMR spectra showing depletion of PFP peaks (~1750 cm-1). B) FTIR spectra 
showing depletion of C-F peaks and thus PFP removal. C) Molecular weight 
distributions, by SEC, of PFP- and NTA-pHEA polymers used. A shoulder is visible 
in the NTA-pHEA trace, possibly due to transamination reactions. 
 






















The pHEA polymers were dissolved in 40 nm citrate stabilised gold nanoparticles, 
citrate@Au40 (purchased from BBI solutions), and incubated on a roller at room 
temperature for an hour, then washed 4 times to remove excess free polymer from 
solution. The three PFP-pHEAn@Au40 solutions were initially assessed by DLS to 
observe any instability (evidenced as large aggregate formation), and the NTA-
pHEA45@Au40 was selected as being the most stable, with other chain lengths leading 
to aggregation. 
This sample was functionalised with NiCl2 in HEPES buffer, washed, and again shown 
to be stable by DLS. Finally, the Ni-NTA-pHEA45@Au40 solution was incubated with 
His-tagged protein, in order to capture the protein via the surface Ni2+ atoms, and 
washed to remove excess free protein in solution. The use of Ni-NTA groups 
immobilised on NP surfaces have been used extensively in His-tag protein capture, 
and is routine for protein purification.33 N-terminal His-tagged recombinant protein of 
the LUMT PVC tail fibre segment, from Photorhabdus asymbiotica, was expressed 
from E. coli by Joseph Healey at the University of Warwick and purified by 
immobilised metal affinity chromatography (IMAC). To optimise protein conjugation, 
a dilution series was used to determine which applied protein concentrations were 
stable, and 5 μg.mL-1 was determined to be the highest concentration at which these 
conjugates were stable: the addition of higher protein concentration resulted in AuNP 
precipitation. 
DLS, UV-Vis and TEM measurements were used to assess the stability, shape and 
size of all AuNP samples. The hydrodynamic diameter of the protein conjugates 
increased with each successive conjugation step without the presence of higher 
diameter aggregates (indicative of instability), showing a ~20 nm increase in diameter 
from the citrate to protein conjugates, and a ~10 nm increase in diameter from the 
citrate to pHEA46@Au40 conjugates. Indeed, >8000 g.mol-1 polymers, and proteins, 
on an Au40 surface would be expected to cause an increase in size in solution relative 















Citrate@Au4 42.7 ± 21.7 38.3 ± 3.7 -37.8 ± 0.2 e 525 
pHEA46@Au40 53.6 ± 27.5 41.5 ± 4.7 1.3 ± 7.27 f 528 
NTA-pHEA45@Au40 56.5 ± 32.4 37.1 ± 4.1 -4.8 ± 20.1 f 529 
Ni-NTA-pHEA45@Au40 57.3 ±30.1 36.4 ± 3.4 -3.9 ± 16.5 g 528 
LUMT-Ni-NTA-pHEA45@Au40 63.3  ± 28.5 30.3 ± 3.8 -6.2 ± 19.4 g 520 
a Hydrodynamic diameter determined by DLS distribution by intensity of particles, 
averaged over 3 measurements; b Gold core diameter, average of 100 particles by 
TEM; c Averaged over 3 measurements; d From UV-Vis measurements; e 
commercial AuNP solution, pH 4.88; f pH 7.6; g AuNPs suspended in HEPES buffer, 
pH 7.9. 
Electrons on the surface of AuNPs oscillate collectively at a specific wavelength of 
visible light, and this is termed surface plasmon resonance (SPR), and this SPR alters 
with changes in AuNP size, shape, surface functionality and aggregation. By UV-Vis 
spectroscopy, a change in the peak of maximum SPR absorbance may be measured, 
as an indication of a change in surface functionality or AuNP aggregation. An increase 
in the SPRmax by 3 nm was observed between the citrate@Au40 precursors and the 
pHEA46 and Ni-NTA-pHEA45@Au40 conjugates, but no change >10 nm were 
observed, suggesting that no aggregation occurred with the conjugations. TEM was 
used to determine the size and shape of the AuNP core. These measurements showed 
no change in shape, and no significant changes in size: all changes between successive 





Figure 4-5. Characterisation of LUMT@Au40 samples. A) Size distributions by 
intensity of particles, from DLS measurements. B-C) TEM micrographs of 
citrate@Au4 and LUMT-Ni-NTA-pHEA45@Au40 respectively. D-E) N 1s and O 1s 
peaks respectively from XPS spectra showing change upon conjugation of AFP 
protein. 
XPS and zeta potential measurements demonstrated conjugation of the citrate@Au40 
precursors with polymer and protein. XPS allows determination of the elemental 
composition of the AuNPs, and showed a relative decrease in the Au 4f peak upon 
polymer coating, from 0.96 % to 0.51 % and 0.31 % for the pHEA46 and NTA-pHEA45 
conjugates respectively. A relative increase in the Ni 2p peak from NTA-
pHEA45@Au40 after Nickel (II) conjugation (from 0 to 0.82 %), followed by a 
decrease upon LUMT PVC tail fibre conjugation (back to 0 %), evidenced the 
presence of Ni on the AuNP surface, and its obscuring by protein conjugation. In 
particular the organic character of the samples (the percentage of C, O and N 1s 
character) changed with each conjugation step. For example, the N 1s content 
increased upon pHEA46 and NTA-pHEA45 conjugation by ~1 and 4 % respectively, 
and the C 1s content increase by 7 % upon LUMT protein conjugation to Ni-NTA-
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pHEA45@Au40. These changes support the success of the conjugation of polymer and 
protein to the AuNPs. 
Zeta potential is a measure of AuNP surface charge, resulting from changes in surface 
composition. The conjugation of polymers reduced the negativity relative to the 
citrate@Au40 precursor, from -38 mV to 1 mV and -5 mV for the pHEA46 and NTA-
pHEA45 conjugates respectively. This is indicative of the displacement of negatively 
charged citrate ions on the AuNP surface. The protein conjugates (LUMT-Ni-NTA-
pHEA45@Au40) did not show a large change in zeta potential relative to the NTA-
pHEA45@Au40 conjugates, as this change was less than 2 mV and the values showed 
large standard deviation errors (19 mV for the LUMT conjugate). 
TGA was used to determine the mass of the polymer and protein conjugated to the 
AuNPs. The mass of NTA-pHEA45 was determined to be ~0.2 mg and the mass of 
pHEA46 ~0.4 mg in 1 mL of solution. The TGA data also suggests that all applied 
LUMT PVC tail fibre protein is captured by the Ni-NTA-pHEA45@Au4 conjugates, 
with 5 μg present per mL of solution, which could be the reason for the instability of 
the AuNPs when more protein was applied. As the LUMT PVC tail fibre does not 
pellet at the centrifuge speed used in the washing steps, there is expected to be no free 
protein present in the LUMT-Ni-NTA-pHEA45@Au40 solution. 
4.5.2. Cytotoxicity assays with LUMT/AuNP conjugations 
Incubations with typical human epithelial cells, using A549 lung adenocarcinoma 
cells, serves as a test of whether or not the protein/AuNP conjugates interact with 
mammalian cells. Stability experiments were first performed to ensure that the final 
LUMT@Au40 conjugates were stable in cell medium (necessary for subsequent 
experiments). In these experiments, the Au40 samples were transferred to cell media 
and incubated at 37 °C over a weekend. DLS measurements after incubation showed 
no change in size or dispersity of conjugates in media instead of buffer (showing a 
mean diameter of 66.6 and 61.6 nm before and after incubation respectively), though 




Figure 4-6. DLS measurements for stability tests. LUMT-Ni-NTA-pHEA45@Au40 
pre- and post-incubation for 48 hrs at 37 °C. 
 
Figure 4-7. MTT assay data showing cell viability. Experiments performed in 
triplicate, with 24 hrs of culture. 
The MTT assay determines the metabolic activity of a cell population by assessing the 
cells’ capacity to metabolise the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) dye to an insoluble formazan, to enable viability to be 
probed. The transformation of the yellow MTT to purple formazan is indicative of the 
viability of the cells after incubation with an analyte. A549 cells were incubated in a 
Microplate for 2 hours to allow adhesion, before 24-hour incubation with a serial 
dilution of LUMT-Ni-NTA-pHEA45@Au40 or pHEA46@Au40 control solution (to 
determine non-specific polymer/AuNP activity). Cells were then washed, incubated 
with MTT for 3 hours, and solution was added to solubilise any insoluble formazan 
that had formed. The transformation of MTT to formazan was determined by UV-Vis 
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absorbance readings, and % viability determined relative to control wells of cells 
incubated in cell medium alone. The LUMT-Ni-NTA-pHEA45@Au40 conjugates 
caused a loss of 10 to 30 % cell viability, with no obvious concentration dependence. 
The pHEA46@Au40 control conjugates showed just slightly lower viability, with 70-
85 % cell viability in all dilutions, but with greater deviations between replicates. The 
assay suggested there might be no significant difference in cell viability between the 
LUMT conjugates and pHEA46@Au40 control solutions (see Table 4-11 in appendix 
for statistical test showing no significant difference). 
 
Figure 4-8. Live/dead cell survival assay microscopy images showing (A) live 
control in PBS, (B) dead control in methanol, (C) LUMT-Ni-NTA-pHEA45@Au40 
and (D) pHEA46@Au40 at 0.3 ng/mL AuNP concentration respectively. All scale 




Figure 4-9. Live/dead cell survival assay data. A) Ratio of live cells in samples. B) 
Total number of cells as a percentage of cells present in the live control. Experiments 
performed in triplicate, with 24 hrs of culture. 
However, the MTT assay measures only the metabolic activity of a cell population, 
and not if the cells are alive or dead. Therefore the live/dead membrane integrity assay 
was also used, in which calcein AM and ethidium homodimer-1 (EthD-1) were applied 
to cells incubated with an analyte solution. Calcein AM is transported through the 
membranes of live cells, thereby staining them fluorescent green. EthD-1 is not 
membrane permeable, but it is able to move through the compromised cell membranes 
of dead cells and bind to their DNA, staining them red. In this assay, cells were 
prepared as above, before the MTT assay, then incubated with calcein AM and EthD-
1 for 30 minutes, then washed. The ratio of green-stained to red-stained cells indicates 
the ratio of live to dead cells, and this can be compared to live (incubated in cell media) 
and dead (incubated in ethanol) cell controls. 
Although this live/dead assay was performed qualitatively rather than quantitatively, 
counting the cells in the images produced allowed crude quantitation of the ratio of 
live cells in each sample (the number of live cells divided by the total number of cells). 
Both the images and this data showed no significant change in the ratio of live cells in 
each sample, with the live control and all test samples all having over 90 % live cells 
(see Table 4-11 in appendix for statistical test showing no significant difference 
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between the samples). There was a visible difference, however, with the number of 
cells in each image (see Figure 4-8, C in particular). The data bore out this change in 
total number of cells, with the pHEA/AuNP conjugates showing less than 40 % of the 
cell numbers visible in the live control, though the LUMT/AuNP conjugates showed 
over 80 % at even the undiluted concentration (~0.3 ng/mL Au concentration). This 
change in total cell numbers of the pHEA conjugates could signify that the adherence 
of the A549 cells to the microplate is affected by the presence of the nanoparticles, 
suggesting that the live cell ratios may be overly high due to the loss of an unknown 
quantity of non-adhering dead cells. That there is less change in both the live cell ratio 
and total cell number with the LUMT/AuNP conjugates is promising, however, as it 
suggests that these effects may potentially be due to the structure of the AuNP 
construct rather than the surface protein. 
 
Figure 4-10. Cell lysis from hemolysis assay of ovine erythrocytes. A-B) Assay with 
LUMT-Ni-NTA-pHEA45@Au40 and pHEA46@Au40 respectively. Experiments 
performed in triplicate, with 24 hrs of culture. 
As previous studies have shown PVCs to bind to insect hemocytes, it is possible that 
these constructs may interact specifically with circulating cells.1,9,11,14 Hemolysis 
assays, with ovine erythrocytes, were therefore undertaken to determine if these 
specific Pvc13 subunit proteins could themselves be haemolytic. Ovine erythrocytes 
were washed and incubated with AuNP solutions for 16 hours at 4 °C, 25 °C and 37 
°C. The intensity of hemoglobin present in the cells’ supernatant was used to assess 
hemolysis as % cell recovery relative to incubation with a PBS control. This assay 
showed LUMT-Ni-NTA-pHEA45@Au40 to be lytic, causing approximately 65 % 
hemolysis at 37 °C, which reduced to ~30 % at 64X dilution. Incubations at room 
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temperature and 4 °C were only ~30 % haemolytic, reducing by 5 % with 64X dilution. 
The pHEA46@Au40 control conjugates, to test non-specific polymer/AuNP binding, 
showed slightly less hemolysis than the protein/AuNP conjugates at 37 °C and room 
temperature, with around 80 % for all room temperature incubations. Conversely, the 
pHEA45@Au40 conjugates showed more hemolysis at 4 °C, with 40 % recovery rising 
to ~80 % recovery upon 64X dilution. These data suggests that both the protein and 
polymer/AuNP conjugates are haemolytic, and there are no significant differences 
between the samples (see Table 4-11 in appendix for statistics). That there is a decrease 
in lysis between the protein and polymer conjugates at room temperature and 37 °C 
suggests that part of this hemolysis may be specifically caused due to the presence of 
protein on the AuNP surface. 
From these assays we can therefore conclude that there is no significant change in cell 
viability or the ratio of live cells (by the MTT and live/dead assays) between the 
pHEA/AuNP control and protein/AuNP samples when looking at human epithelial 
cells. Hemolysis assays, however, showed an increase in hemolysis with the protein 
conjugates over the pHEA46@Au4 controls, which suggests that, as suspected, the 
LUMT protein may indeed have more activity with circulating cells (previous studies 
showing interaction with eukaryotic hemocytes) than internal endothelial cells, which 
indicates a possible route to pathogenicity. 
4.5.3. ICP-OES investigations into A549 and SW480 cell 
interactions with LUMT/AuNP conjugates 
Following the synthesis of protein@AuNP conjugates, cytotoxicity and haemolysis 
assays, inductively-coupled plasma optical emission spectroscopy (ICP-OES) was 
used to determine AuNP attachment to cells over a 24 hour incubation period. As 
previously documented clinical cases of Photorhabdus asymbiotica are linked only by 
outdoor activity, it stands to reason that pathogenic targets might be present in those 
cells either on the body surface, or present upon the inhalation or ingestion of 
pathogens present in soil (ie. either the lungs or gastrointestinal cells, though this is 
unlikely).1 In these experiments, therefore A549 cells were used here as a model lung 
epithelial cell, to provide a full cell study data set in combination with previous 
cytotoxicity studies (see section 4.5.2). SW480 colorectal cells were also being 
cultured in the laboratory, so these were used here as a model gastrointestinal epithelial 
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cell for these studies. Alternatively many surface proteins will be common to most cell 
types so it was considered reasonable to test these as representatives of typical human 
cells. 
In ICP-OES, samples are excited using inductively coupled plasma to produce excited 
atoms that emit electromagnetic radiation. The spectrum emitted is characteristic of 
the elements present (such as an Au peak at 268 nm), and the intensity at an element’s 
characteristic wavelength is a measure of its quantity in the analyte. In this experiment 
the intensity of the Au elemental peak relative to a calibration curve was used to 
determine the amount of AuNPs attached to the cells, and is particularly appealing as 
no additional labels, such a fluorophores, are required.  
A549 cells were incubated in a microplate for 2 hours to allow adhesion, before 24-
hour incubation with a serial dilution of LUMT-Ni-NTA-pHEA45@Au40 or 
pHEA46@Au40 control solution. Cells were washed and removed from their well by 
trypsin digestion. These solutions were then digested by aqua regia to atomise AuNPs 
present before being diluted and analysed by ICP-OES. Incubation with increasing 
concentrations of pHEA45@Au40 showed an increase in gold concentration, 
suggesting non-specific adhesion. This was not observed, however, in the LUMT 
conjugates, where it appeared that negligible quantities of AuNPs were attaching to 
the A549 cells. 
A key consideration should be the quantity of AuNP present per cell in these 
experiments, but unfortunately this was not possible here. The live/dead experiments 
suggested a lower cell count in those experiments with LUMT@AuNP incubations. 
This could mean that, rather than free AuNPs (not cell-bound) being lost, the washing 
step of this procedure could have removed unattached cells with or without AuNPs 
bound. Cell counting during the washing steps after incubation would have made it 
possible to calculate the number of AuNPs present per cell, which would be a better 




Figure 4-11. ICP-OES data showing quantity of AuNP adhered to cells upon 
incubation, indirectly through [Au]. A) Experiment with A549 cells. B) Experiment 
with SW480 cells. Experiments performed in triplicate, with 24 hrs of culture. 
Following these data with A549 cells, incubation and ICP-OES was undertaken with 
SW480 cells. These experiments were performed at concentrations guided by A549 
results, and they showed the same results as incubation with A549. This suggests that 
the protein conjugates did not adhere to these two human cell lines. This could be due 
to there not being sufficient protein present on the AuNP surface, a steric effect 
resulting in the protein being unable to interact with its cell surface target, or due to 
the protein simply not interacting with the cell surface moieties that are expressed on 
these cell lines to a significant extent. It is also possible that, because Photorhabdus 
asymbiotica has been proposed to be an intracellular pathogen, it is not well-adapted 
to interact with the mammalian cell surface.28 
4.5.4. Lipid-binding assays to determine LUMT interaction 
Previous results in this chapter showed no cell binding, but in our investigation we 
wanted to look at isolated targets as well. Arrays can be used as a high-throughput 
method to determine the binding of a tagged protein to a library of targets.34–38 Lipids 
are a class of biomolecules that have functions in membranes, the storage of energy 
and a variety of signalling pathways.36,37,39 Their presence in the plasma membrane is 
of particular interest in uncovering the membrane-binding partners for Photorhabdus 
asymbiotica’s PVClumt_Pvc13 construct. His-tagged recombinant tail fibre protein 
was incubated with a library of lipids pre-spotted and dried on nitrocellulose 
membranes.  This was followed by washing, incubation with anti-his antibodies and 
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development to visualise any Pvc13 protein bound to the lipid array. This assay 
showed no binding of the analyte protein to any of the target lipid spots (see Figure 4-
12). This suggests that the LUMT PVC protein may not bind to any of the 15 lipids 
included in this assay. 
 
Figure 4-12. PIP stripsTM experiment to assess protein binding to lipid array. A) 
Experiment with His-tagged LUMT PVC tail fibre protein. B) Schematic showing 
lipid spots on array purchased from Molecular Probes (MP 23748). 
Table 4-3. Legend for Figure 4-10. 
Spot # Lipid Spot # Lipid 
1 Lysophosphatidic acid 9 Sphingosine 1-phosphate 
2 Lysophosphatidylcholine 10 PtdIns(3,4)P2 
3 Phosphatidylinositol (PtdIns) 11 PtdIns(3,5)P2 
4 PtdIns(3)P 12 PtdIns(4,5)P2 
5 PtdIns(4)P 13 PtdIns(3,4,5)P3 
6 PtdIns(5)P 14 Phosphatidic acid 
7 Phosphatidylethanolamine 15 Phosphatidylserine 




4.5.5. Glycan microarray assay to determine LUMT binding 
Glycan microarrays are a valuable tool for assessing the binding of adhesive proteins 
to their glycan targets, especially as glycoproteins serve as the keystone of immune 
cell recognition, and all mammalian cells are covered in a thick glycocalyx, which is 
a primary site for pathogen adhesion.40–46 This is particularly important in 
understanding the interaction of the PVC construct to immune cells such as 
macrophage-like cells, which has been proposed as a possible mechanism of action.1,28 
In addition to this, a recent study found a novel galactose-binding lectin in the 
Photorhabdus luminescens genome suggesting a role in specific glycan binding in this 
bacteria’s attachment to its nematode host or insect host targets.47 
His-tagged PVClumt_Pvc13 protein was pre-incubated with fluorescent anti-His6 dye 
(mouse monoclonal antibody fused to Alexa Fluor 488) before being incubated with 
an array of glycans attached to a glass slide. This slide was then washed to remove 
excess protein or dye, and read using a fluorescence array scanner to determine 
binding to glycan targets. Glycan “hits” were determined as having at least a 1-fold 
increase in fluorescence relative to fluorescence with the control array (incubated with 
dye but not protein), with increase in more than one spot in each set of six replicate 
spots, in more than one array. 
Table 4-4. Glycan-binding “hits”  
Structure Glycan Structure Glycan 
1 Heparin disaccharide III-S (ΔUA→2S-
GlucNS) 
8 α1-3-Mannobiose 
2 Heparin unsaturated disaccharide I-H 9 α1-6-Mannobiose 
3 Heparin unsaturated disaccharide IV-H 10 Galβ1-6Gal 
4 Lacto-N-difucohexaose I 11 Galβ1-3GalNAcβ1-4Galβ1-4Glc 
5 Asialo galactosylated, fucosylated 
biantennary (NA2F) 
12 3'-Sialyllactosamine 
6 Asialo, galactosylated, biantennary (NA2) 13 LS-Tetrasaccharide c (LSTc) 
7 Asialo, galactosylated, tetranatennary, N-






There were a variety of saccharides with which the PVClumt_Pvc13 interacted (see 
Table 4-4). In particular, there were several sialyl, galactose and heparin glycan hits, 
but these are too varied to make any specific conclusions about the glycan binding of 
these proteins. Sialic acids or sialyllactoses have been proposed as cellular receptors 
for adenoviruses with structures closely related to the PVC construct.48 However, 
further glycan arrays, with greater diversity, would be beneficial to unpack what lies 
behind these glycan hits and observe any significant trends. 
 
 




























































Key to glycan symbol nomenclature
Circle - hexoses









4.5.6. PVClumt_Pvc13 pull-down experiments with 
mammalian cell lysates 
Photorhabdus PVC operons are reasonably well conserved, although their precise 
roles, if any, in human infection by P. asymbiotica remains un-investigated. Indeed it 
is not known which, if any, of the specific PVC operons encoded by P. asymbiotica 
could elaborate needle complexes capable of binding to mammalian cells.8,21 However 
due to strong mammalian environment specific expression of the PVClumt operon, its 
Pvc13 binding fibres remain the most likely candidate for mammalian specific cell 
type binding.  
Following the lipid and glycan assays, only a small number of small molecule targets 
were identified (see sections 4.5.4 and 4.5.5). Proteomics analyses of whole cell 
lysates were therefore performed to look at a larger pool of potential binding 
candidates. In these experiments, the recombinant PVClumt_Pvc13 construct was 
used as “bait” in mammalian cell extract “pull-down” experiments. Pull-down 
experiments with cellular lysates allow the determination of any protein targets present 
in the lysate solution with which the “bait” can bind.  
Herein, protein/FeNP conjugates were produced, using His-Ni-NTA technology to 
immobilise His-tagged PVClumt_Pvc13 recombinant tail fibre protein (“bait”) to a Ni-
NTA-coated FeNP, and exposed to cellular lysates. Multiple washes were performed 
by pulling the magnetic FeNPs from solution magnetically before being re-suspended. 
Cellular proteins bound to PVClumt_Pvc13, still attached after the washes, were 
subsequently eluted with imidazole solution (similarly to the IMAC protocol). Eluted 
protein samples were assessed by SDS-PAGE gel to ascertain that the “bait” was still 
present, before being prepared and run through Orbitrap mass spectrometry to identify 
any bound cellular proteins enriched relative to control experiments that had no Pvc13 
“bait” present. Orbitrap mass spectrometry and data acquisition was performed in the 
University of Warwick Proteomics RTP by Cleidi Zampronio. Perseus software was 
used to statistically screen candidate binding partner proteins (see section 4.8.3.20) 
seen in replicate experiments. Where candidates were identifiable by both Perseus and 
Scaffold analysis, they may be considered more significant: but for this study, all 




Figure 4-14. Cartoon of pull-down experiment procedure. 
Protein candidates from pull-down experiments with PVClumt_Pvc13 tail fibre “bait” 
interacting with mammalian lysates are shown in Table 4-5 and Table 4-11 in 
appendix. The mammalian lysates used in these studies were chosen due to being 
readily available in the laboratory; therefore, protein candidates that were identified in 
multiple lysates are highlighted here. The use of multiple lysates allows the ruling out 
of candidates being chosen purely due to overexpression in the cell line lysate used. 
Proteins that were not known to localise to the plasma membrane (using the Uniprot 
database) were also filtered out from analysis. Known contaminants (such as skin 
debris) were also excluded from the analysis by use of the Perseus software. This 
software was also used to statistically screen potential candidates, resulting in 
“volcano” plots to visualise these candidates overrepresented in the pull down 
experiments relative to the controls (see Figures 4-15 and Figures 4-33 and 4-34 in 
appendix). As those clinical cases previously observed are linked only by outdoor 
activity, and the nematode symbiont with which Photorhabdus associates dwells in 
soil, it makes sense that the pathogen’s targets would be present in cells exposed to 
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the outside. The Human Protein Atlas was used to determine the protein expression 
levels in skin, the immune system and the gastrointestinal system.  
 
Figure 4-15. Volcano plots from pull-down experiments with His-tagged 
recombinant PVClumt_Pvc13 tail fibres. A) THP-1 human monocytic cell line. B) 
Caco-2 human epithelial colorectal adenocarcinoma cell line. See section 4.8.3.20 
for full details on the analysis of this data and generation of this plot. 
These data suggest that membrane-bound protein targets for the PVClumt_Pvc13 
protein derived from Photorhabdus asymbiotica do exist, which is promising if the 
pathogen requires these adhesive toxins to bind the outside of host cells and facilitate 
bacterial internalisation. In particular, these assays suggest that P. asymbiotica’s 
PVClumt_Pvc13 tail fibre construct has the capacity to bind to a range of mammalian 
cell surface proteins. A large number of the protein candidates identified also showed 
expression in skin, immune system or gastrointestinal tissue. It is not clear at this point 
if this represents a real range of binding partner protein targets, or if this could 
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represent a general property to bind a common epitope on different cellular proteins, 
such a sugar group, or general “stickiness” of Pvc13 (or the host proteins). 
Several cadherin-related proteins appear in this candidate list, namely: desmocollin, 
desmoglein and desmoplakin, These proteins are involved in the desmosome, a protein 
structure linking together the keratin in two adjacent cells. The filaggrin and hornerin 
candidate proteins are also known to interact with keratin fibres in their function. In 
addition, several membrane channel candidates are present in the list (gene IDs 
CLIC1, SLC12A2 and SLC3A2). 
Looking specifically at what would correlate with previous studies, PVCs exposed to 
hemocyte cell cultures have the capacity to rearrange the actin cytoskeleton.1,11 
Therefore it is of interest that several candidate proteins, such as ezrin and the 
SLC9A3R2, connect to the actin skeleton and the plasma membrane. In particular, 
contactin is related to the cellular periphery and the rearrangement of the actin 
cytoskeleton. It is unclear, however, whether these proteins have extracellular motifs 
with which a pathogen protein such as Pvc13 might interact. Two tight junction 
proteins (TJP1 and 2) were also identified as candidates. These proteins are known to 
connect the actin cytoskeletons of adjacent cells, and are therefore confirmed to 
present on the cellular surface. 
As previous studies have also shown that PVCs interact with eukaryotic immune cells, 
it is of note that there are also several protein candidates involved in the immune 
response: an immunoglobin, and proteins S100A8 and 9, which are involved in 
inflammation in cystic fibrosis.1 These various protein candidates may provide us with 
potential routes to pathogenicity in mammals. 
 
Table 4-5. Candidates identified from LUMT pulled down with more than one 
mammalian lysate 














































































































































































a The Human Protein Atlas was used to obtain this information, b From Perseus 
software, student’s t-test between Sample and Control. c/d/e/f Values from 
experiments with A549/THP-1/CACO2/SW480 respectively.  ✔✔✔ = high. ✔✔ 
= medium. ✔ = low. ✖ = not detected. n/a = protein either not in database, or is not 
annotated with protein expression. */+ Identified by Scaffold software analysis, 
difference in average (over 3 samples and controls) total unique spectra or total 





4.5.7. Pvc13 tail fibre pull-down experiments with Drosophila 
cell lysate to determine protein binding 
Both P. luminescens and P. asymbiotica interact pathogenically with the cells of their 
insect hosts after being regurgitated within the blood by their nematode symbionts. 
Members of this genus conserve serval the PVC gene loci, which produces syringe-
like constructs shown to be toxic to insects.11 The His-tagged versions of 
heterologously produced Pvc13 tail fibre proteins from three different PVC operons; 
PVClumt and PVCpnf, from P. asymbiotica and PVCunit4 from P. luminescens, were 
conjugated to magna beads as described above and used as bait in insect cell pull down 
experiments.  Drosophila menanogaster S2 whole cell lysates were used as a 
convenient source of insect cells as the line was readily available in the laboratory. 
Herein, tail fibres were bound to magnetic FeNP beads, washed and exposed to the S2 
lysate. These beads were washed several times before the “bait” and any proteins from 
the lysate were eluted with imidazole solution from the beads. The elusions were 
assessed by SDS-PAGE gel to confirm the presence of the “bait” before being 
analysed by Orbitrap mass spectrometry to identify any protein candidates enriched in 
the pull-down samples with “bait” present versus controls without any “bait” attached 
to the beads. Orbitrap mass spectrometry and data acquisition was performed in the 
University of Warwick Proteomics RTP by Cleidi Zampronio. Perseus software was 
used to statistically screen candidates (see section 4.8.3.20), as well as produce 
“volcano” plots to visualise the data (see Figure 4-16 and Figure 4-35 in appendix). 
Where candidates were identifiable by both Perseus and Scaffold analysis, they may 
be considered more significant; but for this study, all candidates are shown regardless 
of significance. 
A very short list was produced of candidates pulled down by more than one of the 
candidate proteins various, though it is likely that the fibres will bind to different 
cellular receptors (for reference, all proteins are shown here (Table 4-6) regardless of 
cellular localisation). This is because it is possible that the bait could pull down whole 
cellular protein complexes, binding surface proteins, but pulling down intracellular 
proteins by association in a complex. Protein candidates where several family 
members were identified (Table 4-7) and single protein candidates localised to the 
plasma membrane or cell projections are also shown (Tables 4-12 and 4-13 in 
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appendix). Flybase was used to determine the cellular localisation and molecular 
function of the various protein candidates identified, such that proteins expressed in 
the plasma membrane or cellular projections could be highlighted. Proteins without a 
gene ID, or not present on the Flybase database, were also excluded from analysis. No 
contaminants should be present in this candidates list due to the use of a Drosophila 
cell line as opposed to a human one. 
 
Figure 4-16. Volcano plots from pull-down experiments with His-tagged 
recombinant Pvc13 tail fibres from the PVCpnf construct and Schneider 2 (S2) 
Drosophila melanogaster macrophage-like cell line. 
It is clear that PVCunit4_Pvc13 showed a larger number of protein candidates than 
the other lysates, potentially suggesting that these PVCs show some species 
specificity, and that this Pvc13 fibre is better adapted to interacting with cells of 
Drosophila menanogaster than LUMT or PNF. This fits with PVCunit4_Pvc13 being 
derived from an insect host restricted strain, P. luminescens TT01. 
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Several proteins related to the glycosylphosphatidylinosityl (GPI) lipid cell surface 
anchoring mechanism are implicated in the candidate list (gene IDs PIG-S, PIG-T, 
Cont and Nrx-IV). This GPI anchor is involved in cell-cell adhesion, such as in septate 
junctions present in epithelia. Other miscellaneous protein candidates present in the 
S2 plasma membrane include various receptors and channels (kuzbanian, and gene 
IDs pvr, stim), proteins involved in notch cell-cell communication (gp150), a lectin-
like protein domain (ergic53, similar to ConA’s glycan-binding domain, which 
suggests galactose-binding is possible), various proteins involved in vesicle trafficking 
(rab1, 5 and 11) and various proteins involved in fatty acid trafficking and metabolism 
(spectrin and desaturase 1).  
PVCpnf expressed in E. coli and injected into Galleria mellonella larva caused 
extensive actin cytoskeleton rearrangements in the hemocytes in vivo.1,11 Therefore it 
is of particular interest that a large number of proteins that bind to actin or 
microtubules were presented as candidates in these assays. For example, the actin-
related proteins, hu-li tai shao, lasp, cheerio, profiling, shibire, kinesin and Rho1are 
all involved in modulating the actin cytoskeleton or the crosslinking of f-actin. LanA 
and rap1 GTPase are proteins involved in cell migration and organisation. While the 
cognate Pnf toxin (responsible for actual re-arrangement) is not being “delivered” in 
these pull downs, its possible that the PVCpnf_Pvc13 binding fibre is “pulling down” 
entire complexes involved with the cytoskeleton. For example; the karst and zipper 
proteins involved in cell adhesion and movement respectively, serve as key 
connections between the external cell-surface and the cytoskeleton.  
It is believed that, at least some, PVCs may selectively interact with eukaryotic 
immune cells in order to manipulate the host immune system. Therefore the presence 
of down syndrome cell adhesion molecule 1 (DSCAM1) and TER94 (see Table 4-12 
in appendix), which are an insect immunoglobin-like molecule and a protein involved 
in various other organismal responses, is of note.1 In particular, DSCAM1, which has 






Table 4-6. Candidates identified from S2 lysate pulled down by more than one 
recombinant PVC tail fibre 









alpha-Spec Spectrin α chain PNF, Unit 4 2.19 d 31.3 *e 2.83 d 25.3 +e 
CCT3 a T-complex 
protein 1 subunit 
γ 










2.95 d 2.67 *c 
34.7 *e 
HSC70-4: 
1.61 d 0.67 *c 
22.7 *e 
HSC70-3: 
4.96 d  5.00 +c 
17.0 +e 
HSC70-4: 
4.00 d 1.00 +c 
12.3 +e 
hts Protein hu-li tai 
shao 
PNF, Unit 4 2.46 d 5.00 *e 2.00 e 4.00 +e 
Lam a Lamin 
LUMT, PNF, 
Unit 4 
1.33 *c 3.02 d 
23.7 *c 
1.67 +c 6.81 d 
16.0 +e 
Lasp 
LIM and SH3 
domain protein 
Lasp 






LUMT, Unit 4 0.67 *c 5.00 *c 0.67 +c 4.67 +e 













PNF, Unit 4 2.91 d 3.00 *e 3.91 d 2.00 +e 
a Not known to localise to the plasma membrane or cell projection, b From Perseus 
software, student’s t-test between Sample and Control. c/d/e Values from experiments 
with LUMT/PNF/Unit 4 respectively. */+ Identified by Scaffold software analysis, 
difference in average (over 3 samples and controls) total unique spectra or total 
unique peptides respectively. 
 
Table 4-7. Candidates identified from S2 lysate pulled down by recombinant PVC 
tail fibre, where more than one protein family member candidate was identified. 
















14-3-3 protein ε 
Unit 4 
1.67 *e 1.33 +e 
14-3-3zeta 14-3-3 protein ζ 5.67 *e 4.67 +e 
Actin-related 
proteins 
Arp3 Actin-related protein 3 
Unit 4 
1.33 *e 1.33 +e 
Arpc4 a 
Actin-related protein 2/3 
complex subunit 4 





Heat shock 70-kDa protein 










Heat shock protein cognate 










Heat shock protein cognate 
5, isoform B Unit 4 
1.00 *e 1.00 +e 




Gp93 Glycoprotein 93 
Unit 4 
7.00 *e 6.00 +e 
Hsp83 Heat shock protein 83 11.7 *e 8.33 +e 
LanA Laminin subunit α Unit 4 
 





LanB1 Laminin subunit β-1 8.33 *e 5.67 +e 
LanB2 Laminin subunit γ-1 6.33 *e 4.67 +e 
Mitochondrial 








(Ubiquinone) B15 subunit 
Unit 4 
 
0.67 *e 0.67 +e 
ND-B17 GM23292p 0.67 *e 0.67 +e 
ND-
PDSW 







48 kDa subunit 
Unit 4 
 
10.7 *e 7.00 +e 
OstDelta 
Oligosaccharide transferase 
δ subunit, isoform B 4.67 *
e 2.67 +e 
Ostgamm
a 








anchor biosynthesis, class S 
ortholog Unit 4 
2.67 *e 2.33 +e 




4.00 *e 3..3 +e 
Rab11 Drab11 0.67 *e 0.67 +e 










beta-Spec Spectrin β chain Unit 4 1.00 *e 1.00 +e 
a Not known to localise to the plasma membrane or cell projection, b From Perseus 
software, student’s t-test between Sample and Control. c/d/e Values from experiments 
with LUMT/PNF/Unit 4 respectively. */+ Identified by Scaffold software analysis, 
difference in average (over 3 samples and controls) total unique spectra or total 




4.5.8. PVCunit4_Pvc13 tail fibre pull-down experiments with 
Caenorhabditis elegans lysate to determine cell protein 
binding partner(s) 
Photorhabdus luminescens exists in an obligate symbiosis with Heterhorhabditis 
bacteriophora nematode worm vector in order to gain access to their insect host.5,11,15 
Therefore there are hypothesised to be specific genes and/or operons required for 
symbiosis.  
The PVCunit4 operon is the single variant found in all strain genomes so far examined, 
and furthermore experiments with over-expressed Unit4 needle complex showed a 
very strong phenotype (induced endotokia matricida) in Caenorhabditis elegans 
nematode worms (Addison, M., Hapeshi, A. and Waterfield, N., unpublished data). 
Herein a pull-down experiment was performed between the recombinant 
PVCunit4_Pvc13 tail fibre and C. elegans proteins to attempt to determine the 
potential nematode binding protein partner.  
As with the previous pull-down experiments, PVCunit4_Pvc13 tail fibre “bait” was 
bound to magnetic FeNP beads, washed and exposed to the C. elegans lysate. The 
beads were washed to remove unattached proteins before both bait and candidate 
proteins were eluted with imidazole solution. SDS-PAGE was used to determine the 
presence of bait, before analysis by Orbitrap mass spectrometry to identify proteins 
enriched in the pull-down samples with bait present versus controls without any bait 
attached to the beads. Orbitrap mass spectrometry and data acquisition was performed 
in the University of Warwick Proteomics RTP by Cleidi Zampronio. Candidates were 
screened for significance by Perseus software, as well as produce “volcano” plots to 
visualise the resultant candidates (see Figure 4-36 in appendix). Where candidates 
were identifiable by both Perseus and Scaffold analysis they may be considered more 
significant; but for this study, all candidates are shown regardless of significance. 
A shortlist of candidates for PVCunit4_Pvc13 tail fibre binding, with significantly 
more protein present in the samples versus controls with no Pvc13 present, as 
determined by Perseus and/or Scaffold analysis, was identified (Table 4-8), and 
unknown proteins or proteins not known to localise to the plasma membrane are shown 
in the appendix (Table 4-14). 
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The PVCunit4_Pvc13 tail fibre showed binding to myosin-4, intermediate filament 
protein ifb-1 and tropomyosin isoforms a/b/d/f, all of which are actin-binding proteins. 
Myosins are a superfamily of ATP-dependent proteins that regulate cell movement via 
actin-binding.49,50 Tropomyosins are integral components of the actin filaments, and 
in some forms are essential in the regulation of actin/myosin interactions.51 This is 
potentially significant as the endotokia matricida phenotype is believed to require 
paralysis of the nematode vulva muscle, preventing egg laying and causing the eggs 
to be retained and hatch with the body of the hermaphrodite adult.  
A novel fucose-binding lectin has been identified from Photorhabdus luminescens, 
suggesting that glycan-binding may be an adhesive mechanism for this bacteria.52 Two 
carbohydrate binding proteins, protein irg-7 and probable galaptin (implicated in 
regulating cell-cell adhesion) lec-8, are in the candidate list. Membrane transporters, 
vacuolar H ATPase and anion exchange protein, and two V-type proton ATPases, 
probable V-type proton ATPase subunits B and G, are also in the candidate list. 
It should be noted that, from what is known of the P. luminescens/H. bacteriophora 
symbiotic life cycle, it is expected that bacteria are transferred from maternal to 
infective juvenile nematodes developing in the maternal body cavities, and therefore 
attachment of P. luminescens to their nematode host is expected to occur at this 
stage.1,13 As the function of many proteins, such as tropomyosins, is dependent on the 
organism’s developmental stage, understanding at which development stage the PVCs 
bind to C. elegans would be very useful. 
 
Table 4-8. Candidates identified from Caenorhabditis elegans lysate pulled down by 


















Possible extracellular/secreted protein. 












Localised to membrane. Unknown 
function, but integral component of 
membrane, possible chaperone 
B3WFV9 0.33 * 0.33 + 
Anion exchange 
protein 








Integral component of plasma membrane 
LEC8 0.33 * 0.33 + 
Probable 
galaptin lec-8 
Carbohydrate, glycolipid binding. 
Involved in defense response to gram 














Integral component of plasma membrane, 
involved in motor neuron axon guidance 
Q95X44 1.00 * 1.00 + 
Vacuolar H 
ATPase 
Localised to plasma membrane. Proton-








Potentially cytoplasmic. Provides 
mechanical strength to cells. Essential 
protein involved in attachment structures 









Potentially cytoplasmic. In association 
with troponin complex, which has a 
central role in Ca-dependent striated 
muscle contraction. Muscle actin filament 
organization, muscle arm extension and 










Localised to plasma membrane and 
cytosol. Subunit of V1 complex of 











Catalytic subunit of V1 complex of 
vacuolar ATPase, which acidifies various 
intracellular compartments 
a For Uniprot database (note that those from Caenorhabditis elegans also have 
“CAEEL” after their accession number, b From Perseus software, student’s t-test 
between Sample and Control, c According to Uniprot database (including data from 
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Wormbase database). */+ Identified by Scaffold software analysis, difference in 
average (over 3 samples and controls) total unique spectra or total unique peptides 
respectively. In this table, where samples were only identified by scaffold, no protein 







In this chapter we developed an entirely new method using nanoparticles to probe 
complex protein function, enabling us to determine a large number of potential 
candidate binding targets for the Pvc13 tail fibre proteins from three different PVC 
operons from two different Photorhabdus species. 
The potentially mammalian-active PVClumt_Pvc13 recombinant tail fibre protein 
from the Photorhabdus asymbiotica was attached to a Ni-NTA@AuNP scaffold and 
characterised by a battery of analytical techniques (including TEM, DLS, XPS and 
TGA) to ensure uniformity, stability and successful protein conjugation to the AuNP 
scaffold. This use of the His-tag to attach a protein of unknown function to AuNPs 
could be a useful technique for elemental analysis of cell line incubations. Both 
cytotoxicity and ICP-OES assays performed after 24 hours incubation with human 
A549 lung adenocarcinoma cells exhibited no binding to this cell line. Subsequent 
ICP-OES of human SW480 colorectal cells also showed no binding, which suggests 
that these cell types may not express (or may not express highly) PVClumt_Pvc13 
protein binding partners. 
This PVClumt_Pvc13 tail fibre recombinant protein was then exposed to lipid and 
glycan arrays, which showed no significant affinity for the lipids tested, but potential 
candidates in sialated or heparin-related targets. These are in fact typical targets of 
host interaction factors from diverse pathogens, such a viral binding fibres and 
bacterial toxins.   
Finally, assessment of pull-down assays in a range of human whole cell lysates 
uncovered various candidates such as actin-binding or immunity proteins. Separately, 
the Pvc13 tail fibre recombinant proteins were tested in pull down experiments with 
Drosophila menanogaster S2 whole cell lysate, and the PVCunit4_Pvc13 specifically 
with C. elegans whole lysate. In these assays, various keratin or actin-binding protein 
candidates, as well as several proteins linked to the immune response, were identified, 
which may indicate a potential route to mammalian pathogenicity. 
These data suggest that protein targets for PVC Pvc13 tail fibre protein do exist, as do 
possible human extracellular targets (both proteins and glycans). This is promising in 
considering future application of these constructs in specific drug delivery.  
 
 231 
4.7. Further Work 
The work presented in this chapter may be considered as on going: therefore there are 
a variety of avenues that future investigations may follow. As the number of 
candidates assessed by the PIP strips assay and the glycan array is limited, further 
microarray assays might yield more hits to be further analysed (particularly if 
informed by the glycan hits identified here). 
The development of the ICP-OES and pull-down systems as detailed herein could be 
used in more human cell lines to develop a greater understanding of candidate binding 
proteins for PVC constructs. Namely, skin cells (due to previous clinical cases 
showing skin lesions), immune cells (due to previous hematocyte invasion studies) or 
gastrointestinal cells (as many candidates identified here were found to be expressed 
highly in this system). Analysis of a variety of relevant cell lines would also allow us 
to determine the significance of the identification of certain candidate proteins in 
context. 
Additional insect cell line experiments would also be useful as the presence of few 
protein binding candidates with the PVCpnf and PVClumt recombinant Pvc13 tail 






4.8. Materials and Methods 
4.8.1. Materials 
Ultra-pure water with resistance < 18 Ω, was obtained from a Milli-Q© Integral Water 
Purification System. All chemicals were purchased from Sigma-Aldrich and used as 
supplied unless otherwise stated. 6-((4-(aminomethyl)benzyl)oxy)-7H-purin-2-amine 
was purchased from Carbosynth.. Goat anti-rabbit IgG antibody, HaltTM phosphatase 
inhibitor cocktail, Micrococcal Nuclease Solution (100 U/L), THF, DMF, ethyl acetate 
and 6x-His Tag, Alexa Fluor 488, clone: 4E3D10H2/E3 (by InvitrogenTM) were 
purchased from Fisher. For washing of AuNPs, Amicon Ultra-0.5 centrifugal filter 
units with Ultracel-30 membrane were used. 40 nm citrate-stabilised gold colloid 
solution was purchased from BBI solutions.  
All cell cultures reagents were sourced from either Thermo Fisher Scientific at the 
highest attainable quality and stored at 4 °C or -20 °C as instructed when not in use. 
Complete medium consisted of Ham’s F-12K (Kaighn’s) medium (with phenol red) 
containing 10 % (v/v) FBS plus 100 U/mL Penicillin and 100 μg/mL Streptomycin 
(unless otherwise specified) and all cells were incubated at 37 °C in a 5 % CO2(g) 
humidified atmosphere. PBS was sourced from Thermo Fisher Scientific. All cell 
culture plastic ware was obtained from Greiner Bio-One Ltd, Gloucestershire, UK and 
all cell culture experiments were performed in a class II biosafety cabinet to ensure 
sterility with cells regularly assessed for bacterial and, fungal and yeast contamination. 
Defibrinated sheep blood was purchased from TCS Biosciences and used within 5 
days of delivery. Lysis buffer was prepared as follows, containing no EDTA, ionic 
detergents, DTT or DTE to be compatible with subsequent dynabeads pull-down 
assays: 1 mL of 150 mM NaCl, 1% Triton X-100, 50 mM Tris, pH 8.0. Buffers used 
for PIP strip assay, Glycan microarray and DynabeadTM pulldown experiments were 
prepared as detailed in their respective manuals. Other buffers (PBS, TBS, TS-T) were 
prepared in house by the University of Warwick Life Sciences technicians. PIP 
StripsTM, glycan microarray and DynabeadsTM were all used as described by Molecular 
Probes,  Dextra UK and Invitrogen respectively. A549 and SW480 cells used for lysis 
were prepared in house as described in 4.5.3.9 below. CACO2 cells used for lysis were 
provided in 100 mm plates as provided by Dr Blessing Anonye. THP1 and S2 cells 
were provided in suspension as provided by Dr Alexia Hapeshi of the Waterfield 
 
 233 
group. LUMT and PNF His-tagged proteins were supplied by Joe Healey of the 
Waterfield Group, and Unit4 His-tagged protein was supplied by Dr Alexia Hapeshi 
of the Waterfield group. Reagents used for preparation of proteins for mass 
spectrometry analysis were provided in house at the University of Warwick 
Proteomics Research Technology Platform. 
4.8.2. Analytical Methods 
1H, 13C and 19F-NMR spectra were obtained using a Bruker DPX-400 NMR 
Spectrometer; all chemical shifts are reported in ppm (δ) relative to residual non-
deuterated solvent. Mass spectrometry was carried out in pure methanol or water on 
the Agilent 6130B ESI-Quad instrument using electrospray in positive mode. FTIR 
spectroscopy was carried out on a Bruker Vector 22 FTIR spectrometer with a Golden 
gate diamond attenuated total reflection cell. SEC (GPC) measurements were carried 
out on an Agilent 390-LC MDS instrument equipped with a dual angle light scatter 
(LS), 2 x PLgel Mixed D columns (300 x 7.5 mm) and a PLgel 5 µm guard column. 
The eluent was DMF with 5 mmol NH4BF4 additive. Samples were run at 1ml/min at 
50oC. Poly(methyl methacrylate) standards (Agilent EasyVials) were used for 
calibration between 955,000 – 550 gmol-1. Analyte samples were filtered through a 
nylon membrane with 0.22 μm pore size before injection. Respectively, experimental 
molar mass (Mn,SEC) and dispersity (Đ) values of synthesized polymers were 
determined by conventional calibration and universal calibration using Agilent 
GPC/SEC software. Nanoparticle size was determined using Dynamic Light 
Scattering (DLS), performed on a Malvern Instruments Zetasizer Nano- ZS with 4mW 
HeNe laser 632.8 nm. UV/Vis spectroscopy and fluorescence plate readings were 
performed on a BioTek Synergy HT Microplate Reader. UV-vis spectroscopy was 
used to determine nanoparticle size according to a method developed by Haiss et al.53 
Transmission electron microscopy (TEM) was performed on a JEOL 2100 LaB6 high-
resolution microscope. X-ray photoelectron spectroscopy (XPS) was carried out on 
the Kratos Axis Ultra with a delay-line detector. Mass spectrometry of the pulldown 
experiment elution samples was performed in the University of Warwick Proteomics 
Research Technology Platform using the in-house in-gel trypsin digest protocol. 
Glycan microarrays were scanned using an Agilent Technologies 2 Colour Array 
Scanner with a 50 sample auto chamber. 
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4.8.3. Synthetic Methods 
4.8.3.1. Synthesis	 of	 2-(dodecylthiocarbonothioylthio)-2-
methylpropionic	acid	(DMP/DDMAT)	
 
Dodecane thiol (4.75 mL, 19.8 mmol) was added dropwise to a stirred suspension of 
K3PO4 (4.02g, 18.9 mmol) in acetone (60 mL). The reaction vessel was placed in an 
ice bath. Carbon disulfide (3.20 mL, 53.0 mmol) was added and the solution turned 
bright yellow, but was still cloudy. After stirring for ten minutes, 2-bromo-2-
methylpropionic acid (3.00 g, 18.0 mmol) was added and a precipitation of KBr was 
noted. The ice bath was removed after 10 minutes and the reaction was left stirring at 
room temperature for 16 hours. Solvent was removed in vacuo and the residue was 
extracted into DCM (2 x 50 mL) from 1 M HCl (100 mL). The organic extracts were 
further washed with water (100 mL) and brine (100 mL) and dried over MgSO4. 
Recrystallisation from n-hexane yielded a bright yellow solid (1.80 g, 27.5%). 
 
1H NMR (400 MHz, CDCl3) δppm: 3.28 (2H, t, JHH=7.5, H6); 1.66 (6H, s, H3/4); 
1.10-1.25 (20H, alkyl, H7-16); 0.79 (3H, m, H17). 
13C NMR (400 MHz, CDCl3) δppm: 220.86 (C5); 178.04 (C1); 55.51 (C2); 37.08 
(C7); 31.92 (C6); 29.64, 29.57, 29.46, 29.35, 29.12, 28.98, 27.82 (C8-15); 25.23 
(C3/4); 22.70 (C16); 14.13 (C17). 
FTIR (solid, νmax/cm-1): 2910 (CH2); 1710 (C=O); 1440 (C-C); 1305 (C-O); 1070 
(S-(C=S)-S).  













2) CS2 25 oC, 16 hrs





















2-(Dodecylthiocarbonothioylthio)-2-methylpropionic acid (DMP) (0.500 g, 1.37 
mmol), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) 
(0.390 g, 2.05 mmol), and 4-(dimethylamino)pyridine (DMAP) (0.250 g, 2.05 mmol) 
were dissolved in DCM (50 mL) and stirred for 20 minutes under N2. 
Pentafluorophenol (PFP) (0.780 g, 4.24 mmol) in 5 mL DCM was added. The reaction 
was stirred overnight at room temperature. The reaction was washed with 3 M HCl 
(100 mL), 1 M NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4, filtered 
and then concentrated in vacuo to evolve a yellow solid with melting point close to 
room temperature (0.437 g, 60.2%). 
 
1H NMR (300 MHz, CDCl3) δppm: 3.24 (2H, t, JHH=7.4 x 2, H12); 1.62 (6H, m, 
H9/10); 1.26 (20H, alkyl, H13-22); 0.81 (3H, m, H23). 
19F NMR (300 MHz, CDCl3) δppm: 151.54 (m, F2/6), 157.74 (m, F3/5), 162.3 (m, 
F4). 
FTIR (solid, νmax/cm-1): 2934 (CH2); 1705 (C6F5C=O); 1439 (C-C); 1260 (C-O); 
1080 (S-(C=S)-S).  
This species’ ESI-MS did not show any of the expected peaks, though the above 
















1) EDC, DMAP, N2 atmosphere, 



























The following procedure describes a reaction with a theoretical degree of 
polymerisation (DP) of 50 repeat units. 4,4-azobis(4-cyanovaleric acid) (5 mg, 0.018 
mmol), pentafluorophenyl 2-(dodecylthiocarbonothioylthio)-2-methylpropionic acid 
(CTA) (47 mg, 0.088 mmol, for the polymer without a PFP-end group, DMP was used 
instead of PFP-DMP) and N-hydroxyethyl acrylamide (1 g, 8.8 mmol) were dissolved 
in 1:1 methanol: toluene (4 mL) in a glass vial with a stirrer bar. Mesitylene (200 μL) 
was added and a sample was removed for 1H-NMR analysis in CDCl3. The reaction 
mixture was degassed by N2 for 30 minutes, sealed and placed in a 70°C oil bath. After 
90 minutes, the solution was opened to air and quenched by submerging the flask in 
N2(l). The polymer (pHEA) was precipitated three times from methanol into diethyl 
ether to give a light yellow solid.  
Conversion (NMR): 94.0%; Mn (theoretical): 5664 g.mol-1; Mn (SEC) 8253 g.mol-
1; Mw (SEC) 9231 g.mol-1; Mw/Mn (SEC): 1.1.  
1
H NMR (300 MHz, CDCl3) δppm: 8-8.15 (br s, N-H (H4)); 3.4-3.8 and 3.05-3.2 (2 
x m, H5); 1.9-2.35 and 1.4-1.8 (2 x m, H1/2). 
19F NMR (300 MHz, CDCl3) δppm: 155.29, 161.61, 165.67. 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2854 (alkyl C-H stretch); 1641 
(amide C=O stretch); 1555 (N-H bend); 1443 (alkane); 1225 (C-O stretch); 1060 (C-
O stretch); 950 (C-F peak on shoulder of 1060 peak). 



























PFP-pHEA45 (90.8 mg, 0.018 mmol) and primary amine (6-((4-
(aminomethyl)benzyl)oxy)-7H-purin-2-amine (BG) or Nα,Nα-Bis(carboxymethyl)-
L-lysine hydrate(NTA) ) (0.088 mmol) were dissolved in DMF (5 mL). To the stirred 
mixture, triethylamine (35 μL) was added, and the reaction was moved to a 50 oC oil 
bath for 16 hours. The polymer was precipitated three times from methanol into diethyl 
ether to give a sandy yellow solid. 
 
Mn (SEC) 6101 g.mol-1; Mw (SEC) 8205 g.mol-1; Mw/Mn (SEC): 1.3 (an increase in 
dispersity is observed post-modification). 
1H NMR (300 MHz, D4-MeOH) δppm: 4.8-5 (br s, H6), 3.44-3.85 and 3.05-3.22 (2 x 
br s, H5), 1.94-2.35 and 1.31-1.86 (2 x br s, H1/2). 
19F NMR (300 MHz, CDCl3) δppm: no peaks visible. 
FTIR (solid, νmax/cm-1): 3300 (N-H and O-H stretch); 2944 (alkyl C-H stretch); 1627 
(amide C=O stretch); 1562 (N-H bend); 1390 (C-H alkane); 1060 (C-O stretch) (C-F 
























































1 mg of NTA-pHEA45 polymer was added to 1 mL of Au40 in a 1.5 mL microcentrifuge 
tube. This was left, covered with foil, for 60 minutes. The solution was centrifuged at 
13,200 rpm, for 5 minutes, supernatant removed, and the pellet re- dispersed in 1 mL 
water. The nanoparticles were washed in this manner a further 3 times before being 
re-dispersed in a final volume of 1 mL distilled water and stored in the fridge until 
required. Nanoparticle size and dispersity was measured by TEM, UV-Vis 
spectroscopy and size and zeta potential measurements by DLS. 
Nanoparticle diameter (TEM): 37.1 nm (standard deviation 4.1 nm). 
4.8.3.6. Synthesis	of	pHEA46@Au40		
 
1 mg of pHEA46 polymer was added to 1 mL of gold nanoparticles in a 1.5 mL 
microcentrifuge tube. This was left, covered with foil, for 60 minutes. The solution 
was centrifuged at 13,200 rpm, for 5 minutes, supernatant removed, and the pellet re- 
dispersed in 1 mL water. The nanoparticles were washed in this manner a further 3 

























the fridge until required. Nanoparticle size and dispersity was measured by TEM, UV-
Vis spectroscopy and size and zeta potential measurements by DLS. 
Nanoparticle diameter (TEM): 41.5 nm (standard deviation 4.7 nm). 
4.8.3.7. Ni-NTA-pHEA45@Au40	
 
1 mL of NTA-pHEA45@Au40 solution was centrifuged at 13,200 rpm, for 5 minutes, 
supernatant removed and Nickel(II) Chloride Hexahydrate (1 mL of 500 μM solution 
at pH 8 in 10 mM HEPES, 100 mM NaCl buffer) was added to the pellet. This was 
left, covered with foil, for 60 minutes. The solution was centrifuged at 13,200 rpm, for 
6 minutes, supernatant removed, and the pellet re- dispersed in 1 mL water. The 
nanoparticles were washed in this manner a further 3 times before being re-dispersed 
in a final volume of 1 mL distilled water and stored in the fridge until required. 
Nanoparticle size and dispersity was measured by TEM, UV-Vis spectroscopy and 
size and zeta potential measurements by DLS. 
Nanoparticle diameter (TEM): 36.4 nm (standard deviation 3.4 nm). 
4.8.3.8. Synthesis	of	LUMT-Ni-NTA-pHEA45@Au40	
Recombinant LUMT PVC tail fibre protein with a hexa-histidine tag was provided by 
Joseph Healey of the Waterfield Group, University of Warwick. 1 mL of Ni-NTA-
pHEA45@Au40 solution was centrifuged at 13,200 rpm, for 6 minutes, supernatant 
removed and LUMT protein in HEPES buffer (4.6 μg/mL protein in 10 mM HEPES, 


























































minutes. The solution was centrifuged at 13,200 rpm, for 6 minutes, supernatant 
removed, and the pellet re- dispersed in 1 mL water. The nanoparticles were washed 
in this manner a further 3 times before being re-dispersed in a final volume of 1 mL 
distilled water and stored in the fridge until required. Nanoparticle size and dispersity 
was measured by TEM, UV-Vis spectroscopy and size and zeta potential 
measurements by DLS. 
Nanoparticle diameter (TEM): 30.3 nm (standard deviation 3.8 nm). 
4.8.3.9. Rejuvenation	and	passage	of	cultured	A549	cells	
A single 1 mL cryopreserved aliquot (10 % (v/v) DMSO in complete medium) in a 
1.8 mL cryovials of cells was removed from cryostorage (N2(l)) and immediately 
thawed rapidly in a 37 °C water bath. Thawed cells were then immediately placed in 
a 75 cm3 flask containing 20 mL of pre-warmed medium and incubated overnight. 
Phase-contrast light microscopy (Nikon UK Limited, Surrey, UK) was used to confirm 
the presence of adherent cells and the medium aspirated and cells washed with 10 mL 
of PBS to remove any non-adherent cells, debris and residual DMSO. 20 mL of pre-
warmed medium was added and cells incubated until confluency. 
The following quantities are based on transfer from/to a 175 cm3 flask, and should be 
adjusted according to these volumes for different-sized flasks. Confluence is defined 
as 70-80 % of the total surface area consisting of cultured cells according to light 
microscopy. All cells were incubated at 37 °C in a 5 % CO2(g) humidified atmosphere. 
Medium from confluent cells was removed and the cells were washed with 25 mL 
PBS and replaced with 3.5 mL 0.25 % (w/v) trypsin solution. The flask was incubated 
for 5 minutes to ensure all cells were detached but not allowed to aggregate. The 
trypsin solution was neutralized by the addition of 3.5 mL of media, and the cells 
pelleted and resuspended in 1 mL media. Trypan blue was used, along with a 
hemocytometer, to determine cell concentration by light microscopy. 1 ml was 
removed and transferred into a 175 cm3 flask containing 25 mL of pre-warmed (37 
°C) media. The flask was then replaced in the incubator and cells allowed to adhere 




The following details a MTT reduction assay for cells seeded in a 96-well plate format. 
A549 cells (1 x 104 cells/well) were seeded in phenol-free (otherwise complete) 
medium in a 96-well plate and incubated for 3 hours at 37 °C in a 5 % CO2(g) 
humidified atmosphere. Medium was removed and replaced with 100 μL analyte in 
pre-warmed (37 °C) phenol-free (otherwise complete) medium. Cells were incubated 
for 24 hours. After incubation, medium was removed, cells washed with 100 μL PBS 
and replaced with 100 μL phenol-free (otherwise complete) medium. 10 μL of MTT 
(10 mg/mL) was added in each well and the plate was incubated for 3 hours. After 
incubation, 100 μL DMSO was added to solubilize insoluble formazan, and the plate 
was agitated in a plate shaker for 30 minutes at room temperature to give a uniform 
distribution of product. Absorbance was measured by plate-reader at λ1 = 570 nm and 
λ2 = 630 nm to show the mitochondrial reduction of yellow MTT to purple/blue 
formazan. This assay was repeated three times, with duplicates of each analyte in each 
assay. Results were analysed as the average of viability (% of the untreated control in 
medium) +/- standard deviation. This allowed a calculation of percentage cell recovery 
after treatment with analytes. A single-factor ANOVA test was used to assess whether 
the LUMT@AuNP incubation data were significantly dissimilar from the 
pHEA@AuNP incubation data. 
4.8.3.11. Live/Dead	assay	
The following details a Live/Dead assay for cells seeded in a 96-well plate format. 
A549 cells (1 x 104 cells/well) were seeded in phenol-free (otherwise complete) 
medium in a 96-well plate and incubated for 3 hours at 37 °C in a 5 % CO2(g) 
humidified atmosphere. For visualization assays, black clear-bottomed plates were 
used, whilst for plate-reader assays black plates were used. Medium was removed and 
replaced with 100 μL analyte in pre-warmed (37 °C) phenol-free (otherwise complete) 
medium. Controls (live and dead) were incubated in phenol-free (otherwise complete) 
medium. Cells were incubated for 24 hours. After incubation, medium was removed, 
cells washed twice with 100 μL PBS and replaced with 100 PBS (except for dead 
control, which was replaced with 100 μL methanol). 2 x Live/Dead solution was made 
up as 4 μL EthD-1, 1 μL Calcein AM and 2 ml PBS and vortexed to ensure dissolution. 
100 μL of this solution was added to each well, and the plate was incubated for 30 
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minutes at 37 °C in a 5 % CO2(g) humidified atmosphere. For the visualization assay, 
fluorescence microscopy was performed with red and green filters taken for each 
image. For the plate reader assay, the plate was read at excitation/emission of 485/530 
nm and 530/645 nm for Calcein AM and EthD-1 respectively. Viable cells fluoresce 
green (with Calcein AM uptake) and dead cells fluoresce red (with EthD-1) due to 
membranolysis. A single-factor ANOVA test was used to assess whether the 
LUMT@AuNP incubation data were significantly dissimilar from the pHEA@AuNP 
incubation data. 
4.8.3.12. Haemolysis	assay	
Fresh ovine RBCs as supplied were centrifuged (23 °C, 10 minutes, 1950 g) and the 
top layer containing residual plasma was removed. The RBCs were resuspended to a 
volume of 6.25 mL in PBS and mixed thoroughly. 20 μL of RBCs was added to each 
microcentrifuge, along with 60 μL of analyte, followed by vortexing to mix. For each 
analyte at temperatures of 4 °C, 25 °C and 37 °C, triplicate samples were prepared to 
allow averaging. Samples were incubated overnight in darkness at the specified 
temperature. The next day, 320 μL PBS was added for a 5 x dilution of the RBCs. 
Samples were centrifuged (23 °C, 10 minutes, 1950 g) and three aliquots of 100 μL 
were removed to a clear, flat-bottomed 96-well polystyrene plate. Absorbance at 415 
nm was measured to give an average and standard deviation for each analyte at each 
temperature relative to a PBS control. This allowed the calculation of % cell recovery 
and hemolysis using the following equations. A 100% hemolysis control was 
calculated as samples suspended in 540 μL H2O for 5 minutes (induce 100 % 
hemolysis) before adding 60 μL of 10 x PBS solution. A single-factor ANOVA test 
was used to assess whether the LUMT@AuNP incubation data were significantly 





%	𝐶𝑒𝑙𝑙	𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 = 	100	% − (%)𝐻𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠 




The following details an ICP-OES experiment assay for A549 cells seeded in a 96-
well plate format. The same procedure was used for SW480 cells. This assay was 
performed in triplicate. A549 cells (1 x 104 cells/well) were seeded in medium in a 96-
well plate and incubated for 3 hours at 37 °C in a 5 % CO2(g) humidified atmosphere. 
Medium was removed and replaced with 100 μL analyte in pre-warmed (37 °C) 
phenol-free (otherwise complete) medium. Cells were incubated for 24 hours. After 
incubation, medium was removed, cells washed with 100 μL PBS and replaced with 
50 μL 0.25 % (w/v) trypsin solution. The microplate was incubated for 5 minutes to 
ensure all cells were detached but not allowed to aggregate. The trypsin solution was 
neutralized by the addition of 50 μL of media, and the cells transferred to labeled glass 
vials. Incubation with aqua regia for 30 minutes was used to atomise the AuNP 
samples, with the same quantities of aqua regia, media and trypsin present in all 
samples and calibration controls. All samples were subsequently diluted with distilled 
water to final nitric acid content of 2 %. 
4.8.3.14. General	procedure	for	lysis	of	adherent	mammalian	cells	
Lysates were prepared according to standard procedures such as recommended by 
Bio-Rad and Thermo-fisher manuals. This procedure was utilised for the preparation 
of lysates of A549, CACO2 and SW480 cells. Briefly, cells were washed twice in a 
100 mm dish with ice-cold PBS and gently rocked. Ice-cold lysis buffer (1 mL) was 
added and the dish was tilted in ice for 20 minutes, gently agitating every few minutes. 
Cells were scraped from the surface using a rubber spatula and the solution was 
transferred to a microcentrifuge tube. This was centrifuged down for 10 minutes at 4 
oC, 12 kRPM and the supernatant removed to a fresh tube. Lysates were stored at -20 
oC before use. 
4.8.3.15. General	procedure	for	lysis	of	cells	in	suspension	
Lysates were prepared according to standard procedures such as recommended by 
Bio-Rad and Thermo-fisher manuals. This procedure was utilised for the preparation 
of THP1 (mammalian) and S2 (drosophila) cell lysates. Briefly, cells were pelleted at 
low speed in a 15 mL centrifuge tube and media was removed. Ice-cold PBS was 
added and the tube inverted to wash the cells. Cells were again pelleted and liquid 
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removed. This washing procedure was repeated. Ice-cold lysis buffer (1 mL) was 
added and the tube was placed in ice for 20 minutes, gently agitating every few 
minutes. This was centrifuged for 10 minutes at 4 oC, 12 kRPM and the supernatant 
removed to a fresh tube. Lysates were stored at -20 oC before use. 
4.8.3.16. Lysis	of	C.	elegans	nematode	worms	
The protocol used was based on a protocol by Walhout, A. J. M. and Boulton, S. J..54 
Cultured C. elegans worms were prepared and provided by Dr Alexia Hapeshi of the 
Waterfield Lab. Worms were washed thrice in cold saline solution (0.1 M NaCl) and 
centrifuged (2500 G, 4 minutes, 25 °C) to remove residual bacteria and dead worms 
in the supernatant. The pellet was resuspended in modified CSK lysis buffer (100mM 
Pipes (pH 6.0), 100mM NaCl, 3mM MgCl2, 1mM PMSF, 0.3M sucrose, 0.5% triton 
X 100, complete (Roche) protease inhibitor tablets, and HaltTM phosphatase inhibitor 
cocktail: 2mM β-glycerophosphate, 5mM NaF, 1mM Na3VO4, 0.1 μM okadaic acid). 
The worm solution was twice frozen on dry ice and thawed in a 37 °C water bath. This 
lysate was dounced in a dounce homogenizer 6 times, followed by centrifugation to 
collect the soluble lysate supernatant (5000 G, 5 minutes, 25 °C).The pellet was 
resuspended in half its volume of modified CSK buffer, and micrococcal nuclease 
solution was added to a final concentration of 3U/μl. The suspension was incubated 
for 30 minutes, shaking at 37 °C, and the chromatin lysate supernatant collected by 
centrifugation (5000 G, 5 minutes, 25 °C). The chromatin and soluble lysates were 
combined to give a C. elegans whole lysate. 
4.8.3.17. PIP	strips	fat-binding	assay	
The PIP StripsTM standard experimental protocol as published by Molecular Probes 
(MP 23748, 100 pmoles of lipid present in each array spot) was followed, using the 
manual’s recommended buffer preparations. Briefly, the membrane was blocked with 
blocking buffer (Tris-buffered saline pH 7.5 + 0.1 % Tween (TBS-T) + 3% fatty acid-
free BSA) for one hour at room temperature on a rocker. Buffer was removed and the 
membrane incubated overnight in solution containing recombinant LUMT PVC tail 
fibre protein with a hexa-histidine tag (provided by Joseph Healey of the Waterfield 
Group, University of Warwick) (0.5 μg/mL in blocking buffer) at 4 oC. Following this, 
the membrane was washed 6 times, incubating 10 mins each time in blocking buffer. 
The membrane was then incubated in primary antibody (Rabbit IgG diluted in 
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blocking buffer) for 90 minutes and washed. The membrane was then incubated in 
secondary antibody (Goat anti-rabbit IgG Secondary antibody with HRP, in blocking 
buffer) for 1 hour and washed. Antibodies were diluted as described by the 
manufacturer. Finally the membrane was incubated in developing solution (Pierce 
ECL substrate) or 2 hours and a photo was taken. 
4.8.3.18. Glycan	array	glycan-binding	assay	
The glycan array kit user manual’s standard procedure as published by Dextra (Dextra 
Glycan Array Kit User Manual v6) was followed, using the manual’s recommended 
buffer preparations. Briefly, 1 μg of protein (recombinant LUMT PVC tail fibre 
protein with a hexa-histidine tag provided by Joseph Healey of the Waterfield Group, 
University of Warwick) was prepared in array PBS (62.5 μL) and this was pre-
complexed with alexa fluor 488 His-tag antibody (2.5 μL) for 10 minutes at 4 oC in 
the dark. A control was also prepared with the same concentration antibody in array 
PBS. The slide was pre-blocked with 0.5% BSA in array PBS for 5 minutes, followed 
by two  2 minute washes in just array PBS. Gene frames were applied to the slide and 
protein or control solution (65 μL for each array) was applied to each array, and these 
were incubated 30 minutes at room temperature in the dark. The slide was then 
submerged in 0.5% BSA in array PBS to facilitate gene frame removal, and agitated 
for 2 minutes, followed by two washes in 0.5% BSA in array PBS. The slide was dried 
by centrifugation (200 g) for 10 minutes in an empty 50 mL centrifuge tube prior to 
scanning. 
4.8.3.19. General	procedure	for	DynabeadsTM	pull-down	assay	
The DynabeadsTM His-tag isolation and pulldown standard procedure as published by 
Invitrogen (MAN0017121) was followed, using the manual’s recommended buffer 
preparations. Briefly, lysates were buffer-exchanged into pull-down buffer and 
histidine-tagged bait protein was exchanged into binding/wash buffer prior to starting 
the assay. Recombinant LUMT or PNF PVC tail fibre protein was provided by Joseph 
Healey, whilst recombinant Unit 4 PVC tail fibre protein was provided by Dr Alexia 
Hapeshi, both of the Waterfield Group, University of Warwick. The dynabeads vial 
was vortexed to mix the particles, and 50 μL beads were transferred to a 
microcentrifuge tube. The tube was placed on a magnet for 2 mins to pellet and 
supernatant was removed. The bait protein sample (<700 μL) was added to the tube 
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and incubated on a roller for 15 minutes at room temperature. The beads were pelleted 
by applying to a magnet for 2 minutes, supernatant was removed and the beads were 
washed 4 times by resuspending in bind/wash buffer (300 μL), vortexing, pelleting 
and removing the supernatant. Lysate sample (<700 μL) was added at this point, the 
tube was vortexed and incubated on a roller for 30 minutes at room temperature. The 
beads were pelleted, supernatant was removed and the beads were washed 4 times by 
resuspending in bind/wash buffer (300 μL), vortexing, pelleting and removing the 
supernatant. His-elution buffer (50 μL) was added, the tube was vortexed and 
incubated on a roller for 5 minutes at room temperature. The beads were pelleted and 
supernatant was removed to a fresh tube. The presence of the bait sample in this elution 
was determined using SDS-PAGE gel. 
4.8.3.20. General	 procedure	 for	 Perseus	 and	 Scaffold	 statistical	
analysis	of	Proteomics	data	
In the Perseus software, a paired t-test (assuming equal variance) was utilised. An s0 
value of  2 was selected, to give a greater relative importance on the difference between 
the means of the sample and control datasets relative to the p value. Proteins with a –
logP of greater than 1, and a t-test difference of greater than 0, were selected as 
candidates. Known contaminants (such as skin debris), and proteins with identification 
by site alone, were removed from analysis. Throughout processing, the data was 
assessed visually to determine it was acceptable.   
Scaffold analysis was also utilised to identify certain protein hits. Processed Scaffold 
files were provided by the University of Warwick Proteomics RTP team, and total 
spectrum and peptide count were used as measures for protein enrichment in the 
samples relative to the controls. In order to identify a protein as being significantly 
enriched, the average and total count over the 3 samples had to be higher than the 
average and total counts for the 3 controls, for both total spectrum count and total 
unique peptide count.  







Figure 4-17. Reconstruction of PVC head particle structure from CryoEM. 
Unpublished results, performed in collaboration with Franziska Leidreiter at the Max 
Planck Institute of Molecular Physiology, Dortmund, Germany. The presumed 
Pvc13 binding fibres can be see projecting in 6 fold symmetry from the baseplate 
region.   
 

















Figure 4-21. UV-Vis spectra for stages of synthesis of LUMT-Ni-NTA-
pHEA45@Au40. 
 






Figure 4-23. DLS data showing distribution of particle sizes by intensity, for stages 
of synthesis of pHEA46@Au40.  
 
Figure 4-24. TEM datafor all AuNPs used in this study. A) Citrate@Au40. B) 
pHEA46@Au40. C) NTA-pHEA45@Au40. D) Ni-NTA-pHEA45@Au40. E) LUMT-Ni-
NTA-pHEA45@Au40. F) Distribution of particle sizes by TEM, from an average of 





Figure 4-25. XPS data for TEM data for stages of synthesis of LUMT-Ni-NTA-





Figure 4-26. XPS data for TEM data for stages of synthesis of pHEA46@Au40. A) 
Survey scans. B) Au 4f double peak at 82-88 eV. C) C 1s peak at 284-287 eV. D) O 
1s peak at 530-534 eV. 
 
Table 4-9. AuNP sample elemental composition determined by XPS. 
Particle C a O a N a Ni b Au c 
Citrate@Au4 56.4 42.0 0.69 0 0.96 
pHEA46@Au40 53.8 43.2 1.94 0 0.51 
NTA-pHEA45@Au40 74.9 20.1 4.71 0 0.31 
Ni-NTA-pHEA45@Au40 67.8 23.0 8.28 0.82 0.08 
LUMT-Ni-NTA-pHEA45@Au40 74.8 19.0 6.02 0 0.12 




Figure 4-27. TGA temperature curves data for stages of synthesis of LUMT-Ni-
NTA-pHEA45@Au40. 
 





Table 4-10. Masses of organic substances present in LUMT-Ni-NTA-pHEA45@Au40 
samples determined by TGA. 
Particle 
Mass present in sample 
(mg/mL) a 
NTA-pHEA45  on Au40 0.18 
LUMT on Au40b 0.005 
pHEA46 on Au40 0.39 
a All calculations were taken as the mass difference between 150 and 600, and all 
AuNP samples were determined to be the same concentration of gold by UV-Vis 
spectroscopy; b All protein-containing sample calculations were blanked relative to 
HEPES buffer solution, and were then calculated relative to the known organic 





Figure 4-29. Live/dead cell survival assay microscopy images. A) Live control in 
PBS. B) Dead control in methanol. C/E/G) LUMT-Ni-NTA-pHEA45@Au40 at 0.3, 
0.15 and 0.08 ng/mL AuNP concentration respectively.  D/F/H) pHEA46@Au40 at 
0.3, 0.15 and 0.08 ng/mL AuNP concentration respectively. All scale bars 100 μm. 
Experiments performed with 24 hrs of culture.  
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Table 4-11. Single-factor ANOVA Statistics completed on cell assays. Each 
statistical test simply compared the number groups from the control and test groups. 
The null hypothesis is that the means of these groups are equal (ie. The populations 
are not significantly different). 
Experimenta Fb F critb Null hypothesis 
rejected?c 
MTT assay, % 
viability 
0.0007 4.600 No 
Live-dead assay, total 
live cell number 
0.4 4.3 No 
Hemolysis assay, % 
lysis 
1.4 4.1 No 
aIn each case, data from the LUMT@AuNP incubations was compared to data from 
pHEA@AuNP incubations. bF>F crit results in rejection of the null hypothesis. cNull 
hypothesis rejection suggests there is a significant difference between the test and 




Figure 4-30. SDS-PAGE gels for pull-down experiments using His-tagged 
recombinant LUMT PVC tail fibre protein in human whole cell lysates. A) A549 
human alveolar basal epithelial lysate, B) SW480 human colon adenocarcinoma 
lysate, C) CACO2 human epithelial colorectal adenocarcinoma lysate, D) THP-1 




Figure 4-31. SDS-PAGE gels for pull-down experiments using His-tagged 
recombinant PVC tail fibre protein in whole cell lysates. A-C) Pull-down 
experiments in S2 Drosophila melanogaster macrophage-like cell lysate using bait 
protein from the LUMT PVC, PNF PVC and Unit 4 PVC constructs respectively. D) 
Pull-down experiments in Caenorhabditis elegans lysate using bait protein from the 














Figure 4-33. Volcano plots from pull-down experiments with His-tagged 
recombinant tail fibres from the LUMT PVC construct. Experiments with the A) 
Schneider 2 (S2) Drosophila melanogaster macrophage-like cell line and B) SW480 




Figure 4-34. Volcano plots from pull-down experiments with His-tagged 
recombinant tail fibres from the LUMT PVC construct with the A549 human 






Figure 4-35. Volcano plot from pull-down experiments with His-tagged recombinant 
tail fibres from the Unit4 PVC construct and Schneider 2 (S2) Drosophila 





Figure 4-36. Volcano plot from pull-down experiments with His-tagged recombinant 




Table 4-12. Candidates identified from LUMT pulled down with mammalian lysates: 
identified in only one experiment 























associated protein 1 




channel protein 1 





✔✔✔ ✔✔✔ 2.48 5.69 
CTTN Src substrate 
cortactin 
A549 ✔✔ ✔✔✔ ✔✔✔ 2.10 6.02 




binding protein 1 










A549 n/a n/a n/a 1.83 5.80 
GSDMA Gasdermin-A CACO2 ✔✔
✔ 
✖ ✖ 0.67 * 0.67 + 
PDIA6 Protein disulfide-
isomerase A6 
SW480 ✔✔ ✔✔✔ ✔✔✔ 1.00 * 1.00 + 
PTRF 
Polymerase I and 
transcript release 
factor 
SW480 ✔✔ ✔✔ ✔✔ 0.67 * 0.67 + 
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SLC12A2 Solute carrier 
family 12 member 
2 
A549 ✔ ✔✔✔ ✔✔✔ 2.61 5.89 
SLC3A2 4F2 cell-surface 
antigen heavy chain 







A549 ✖ ✖ ✔✔✔ 2.87 5.87 
SPRR1B Cornifin-B SW480 n/a n/a n/a 0.67 * 0.67 + 
STIM1 Stromal interaction 
molecule 1 
A549 ✔✔ ✔✔ ✔✔✔ 2.67 3.06 
XP32 Skin-specific 
protein 32 
A549 n/a n/a n/a 2.00 * 0.67 + 
CTSG Cathepsin G THP-1 ✖ ✔✔✔ ✖ 7.67 * 4.00 + 
a The Human Protein Atlas was used to obtain this information, b From Perseus 
software, student’s t-test between Sample and Control.  ✔✔✔ = high. ✔✔ = 
medium. ✔ = low. ✖ = not detected. n/a = protein either not in database, or is not 
annotated with protein expression. 
 
Table 4-13. Candidates identified from S2 lysate pulled down by one recombinant 
PVC tail fibre, where cellular localisation is known to include the plasma membrane 
or cell projection  
Gene ID Protein name 








Acsl Acyl-CoA synthetase long-chain, isoform J Unit 4 0.67 * 0.67 + 
alt Aluminum tubes, isoform G Unit 4 4.67 * 4.67 + 
beta-
Spec 
Spectrin β chain Unit 4 1.00 * 1.00 + 
BuGZ 
Bub3 interacting GLEBS and zinc finger 
domain protein, isoform A 
Unit 4 1.33 * 1.33 + 
CD98hc CD98 heavy chain, isoform D Unit 4 0.67 * 0.67 + 
Chc Clathrin heavy chain Unit 4 0.67 * 0.67 + 
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cher Cheerio, isoform I Unit 4 0.67 * 0.67 + 
chic Profilin Unit 4 2.67 * 1.67 + 
Chro Chromator, isoform A Unit 4 2.33 * 2.33 + 
Cnx99A Calnexin 99A, isoform E Unit 4 1.67 * 1.33 + 
Cont Contactin Unit 4 3.67 * 3.33 + 
cpa F-actin-capping protein subunit α Unit 4 2.33 * 2.00 + 
Desat1 Desaturase 1, isoform A Unit 4 0.67 * 0.67 + 
Dhc93A
B 
Dynein heavy chain at 93AB, isoform C PNF 0.67 * 0.67 + 
Dscam1 
Down syndrome cell adhesion molecule 1, 
isoform CA (Fragment 
Unit 4 3.33 * 3.33 + 
Edem1 α-1,2-Mannosidase Unit 4 0.67 * 0.67 + 
EMC1 ER membrane protein complex 1, isoform C Unit 4 0.67 * 3.67 + 
ergic53 Ergic53, isoform A Unit 4   
Fmr1 
Fragile X mental retardation syndrome-
related protein 1 
PNF 2.02 3.29 
Gp150 Gp150, isoform E Unit 4 3.33 * 3.00 + 
Hmu FI18644p1 Unit 4 11.7 * 6.00 + 
Khc Kinesin heavy chain Unit 4 0.67 * 0.67 + 
kst Karst, isoform E Unit 4 0.67 * 0.67 + 
kuk Kugelkern, isoform A Unit 4 0.67 * 0.67 + 
kuz Kuzbanian, isoform F Unit 4 1.67 * 1.33 + 
muc Midline uncoordinated, isoform A Unit 4 5.33 * 4.00 + 
Nap1 LD21576p Unit 4 1.67 * 1.67 + 
Nrx-IV Neurexin-4 Unit 4 1.33 * 1.33 + 
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Phb2 Prohibitin 2, isoform E Unit 4 21.3 * 10.7 + 
Pvr 
PDGF-and VEGF-receptor related, isoform 
G 
Unit 4 0.67 * 0.67 + 
Ran GTP-binding nuclear protein Unit 4 4.67 * 2.67 + 
Rap1 Rap1 GTPase, isoform B Unit 4 0.67 * 0.67 + 
Rho1 Ras-like GTP-binding protein Rho1 Unit 4 1.00 * 1.00 + 
Sc2 Sc2 Unit 4 2.67 * 1.33 + 
sesB Stress-sensitive B, isoform E Unit 4 8.33 * 5.33 + 
SH3PX1 Sorting nexin Unit 4 1.00 * 1.00 + 
shi Shibire, isoform F Unit 4 1.33 * 1.33 + 
SrpRbet
a 
GM04779p Unit 4 1.67 * 1.00 + 
Stim FI18406p1 Unit 4 4.33 * 3.33 + 
Tap42 LD07294p Unit 4 1.33 * 1.33 + 
Tctp 
Translationally controlled tumor protein 
ortholog, isoform B 
Unit 4 0.67 * 0.67 + 
TER94 TER94, isoform E Unit 4 0.67 * 0.67 + 
Tm1 Tropomyosin 1, isoform Q Unit 4 0.67 * 0.67 + 
UQCR-
C2 
AT02348p Unit 4 15.0 * 8.67 + 
Vha68-2 MIP16230p Unit 4 2.00 * 1.33 + 
vnc LD19812p Unit 4 1.67 * 1.33 + 
zip Zipper, isoform F Unit 4 0.67 * 0.67 + 
a From Perseus software, student’s t-test between Sample and Control. */+ Identified 
by Scaffold software analysis, difference in average (over 3 samples and controls) 




Table 4-14. Candidates identified from S2 lysate pulled down by one recombinant 
PVC tail fibre, where cellular localisation is unknown. 










Ahcy Adenosylhomocysteinase Unit 4 1.00 * 0.67 + 
Aldh-III Aldehyde dehydrogenase Unit 4 1.33 * 1.33 + 
BcDNA CG8108, isoform A Unit 4 7.67 * 6.33 + 




Unit 4 1.00 * 0.67 + 
CG11505 La-related protein CG11505 Unit 4 3.00 * 2.33 + 
CG11999 GH21273p Unit 4 4.33 * 3.67 + 
CG12909 CG12909 protein Unit 4 0.67 * 0.67 + 
CG13321 RE03883p Unit 4 0.67 * 0.67 + 
CG1371 CG1371 Unit 4 0.67 * 0.67 + 
CG18259-RA FI13061p Unit 4 0.67 * 0.67 + 
CG31915 Glycosyltransferase 25 family member Unit 4 3.33 * 2.33 + 
CG3224 Zinc finger protein 593 homolog Unit 4 4.67 * 3.00 + 
CG3817 RRP15-like protein Unit 4 1.33 * 1.33 + 
CG5482 Peptidylprolyl isomerase Unit 4 1.00 * 0.67 + 
CG6422 CG6422, isoform A Unit 4 2.00 * 1.67 + 
CG7461 CG7461, isoform B Unit 4 1.00 * 1.00 + 
CG7556 CG7556, isoform A Unit 4 0.67 * 0.67 + 
CG7800-RA CG7800 Unit 4 5.00 * 3.00 + 
CG8326 CG8326 Unit 4 0.67 * 0.67 + 
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CG8507 CG8507 Unit 4 39.7 * 24.0 + 
CG9784 CG9784, isoform C Unit 4 0.67 * 0.67 + 
CG9911 CG9911, isoform A Unit 4 9.00 * 7.67 + 
CNBP CG3800, isoform B Unit 4 0.67 * 0.67 + 
CT23145 CG7565 Unit 4 0.67 * 0.67 + 
fl Female lethal d, isoform C Unit 4 2.33 * 1.67 + 
Gale UDP-glucose 4-epimerase Unit 4 5.33 * 3.67 + 
muc Midline uncoordinated, isoform A Unit 4 5.33 * 4.00 + 




PNF 2.43 5.57 
Pdi Protein disulfide-isomerase Unit 4 3.33 * 3.00 + 
spidey CG1444 Unit 4 1.00 * 1.00 + 
Ubi-p63E Ubiquitin-63E, isoform C LUMT 0.67 * 1.00 + 
Ugt58Fa RE07815p Unit 4 5.67 * 3.67 + 
a From Perseus software, student’s t-test between Sample and Control. */+ Identified 
by Scaffold software analysis, difference in average (over 3 samples and controls) 





Table 4-15. Candidates identified from Caenorhabditis elegans lysate pulled down 
by Unit 4 recombinant PVC tail fibre, where cellular localisation is unknown or not 


















Localised to mitochondria. 
Involved in protein import and 
macromolecular assembly, 
preventing misfolding and 
promoting refolding 














Q19336 0.33 * 0.33 + Unknown, potentially localised 
to nucleus 
Q21889 0.33 * 0.33 + Unknown 
SIP1 0.33 * 0.33 + Stress-induced 
protein 1 
Binds to unfolded proteins, 
localised to cytosol 
Q564R5_CAE
EL-DECOY 




Q95XI9 0.33 * 0.33 + Proton-transporting ATPase 
activity, rotational mechanism 
YQI7 1.00 * 1.00 + Unknown 
a For Uniprot database (note that those from Caenorhabditis elegans also have 
“CAEEL” after their accession number, b From Perseus software, student’s t-test 
between Sample and Control, c According to Uniprot database (including data from 
Wormbase database). */+ Identified by Scaffold software analysis, difference in 
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The development of materials to interact with or capture proteins remains a challenge, 
with current synthetic methods often limited by kinetics, the need for cytotoxic 
reagents and low selectivity/specificity (as described in Chapter 1). Macromolecular 
materials (polymers and nanoparticles) are proposed as excellent biomolecule mimics, 
but also as excellent scaffolds for bioconjugation to probe function. 
In this work, a glycopolymer library with controlled chain length, carbohydrate 
density, side chain length and functionality was synthesised to target a pathogenic 
lectins (CTxB). In chapter 2, these glycopolymers were synthesized using RAFT 
polymerization and “click”-like post-polymerization double modification. These 
polymers were assayed for CTxB binding via both a competitive assay (against the 
native ligand, GM-1) and with bio-layer interferometry. Glycopolymers with a 
hydrophilic glucosamine secondary modification and low carbohydrate density 
showed greater specificity and binding activity towards CTx over another galactose 
specific lectin (RCA120). These results suggest that the implementation of greater 
complexity proximal to the primary glycan binder can further enhance their anti-
adhesive activity via improved selectivity. 
In chapter 3, the impact of multivalent presentation on the ice-binding protein AFP 
type III was investigated by immobilisation onto a ~4 nm AuNP scaffolds. Two 
bioorthogonal linker types were used, with the large, covalent SNAP fusion tag/BG-
AuNP linkage found to retain all AFP activity in several assays, in comparison to His-
tag (non-covalent). This showed that conjugating proteins on NP surfaces is a useful 
tool to evaluate activity, even though the effective molar concentration was lower. Ice 
binding assays suggested the AFPs could span multiple faces, unlike monovalent AFP. 
Poly(vinyl alcohol) was also immobilised onto AuNP scaffolds, via the polymer’s 
thiol end functionality, to form fully-synthetic spherical antifreeze protein mimics. 
The branched spherical structure was found to have no significant impact on ice 
recrystallisation inhibition of longer (DP ~150) PVA relative to linear PVA of the 
same concentration. These experiments showed the potential of using these AuNP 
scaffolds to form branched-type materials with enhanced antifreeze activity, and that 
both synthetic and natural antifreezes have similar design rules. 
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In Chapter 4, ICP-OES was utilised to assess cell binding of recombinant His-tagged 
proteins of Photorhabdus virulence cassette tail fibre immobilised on AuNPs. NTA-
pHEA polymers synthesized by RAFT polymerization, followed by post-
polymerisation modification of the end group, were first conjugated to AuNPs, and 
Ni2+ added to form surface Ni-NTA groups. PVClumt_Pvc13 was then conjugated to 
~40 nm AuNPs using this His-Ni-NTA-pHEA linkage. Cell based assays suggest 
cytotoxicity at high concentrations, but interestingly no significant binding nor uptake. 
Glycan and lipid arrays were also used to assess PVClumt_Pvc13 binding, and some 
glycan candidate hits were identified for the first time. Pull-down assays were then 
conducted in a variety of whole cell lysates using recombinant His-tagged tail fibre 
proteins of three Photorhabdus virulence cassettes (PVClumt_Pvc13, PVCpnf_Pvc13 
and PVCunit4_Pvc13) attached to Ni-NTA-coated magnetic beads. These pull-down 
experiments identified proteins of interest (such as immunogenic proteins and actin-
binding proteins). The identification of actin-binding proteins or glycans/proteins 
present on immune cells may suggest a potential route to pathogenicity for these PVC 
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